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The Severe Acute Respiratory Syndrome, SARS, is a new infectious respiratory 
disease that shocked the world in year 2003. The disease originated from Southern 
China in late 2002. Within months, it spread globally to affect more than 8000 people. 
At the end of the epidemic in early July 2003，SARS had infected 8098 people all 
over the world with 774 deaths. The etiological agent of this deadly disease was 
identified as a previously unknown coronavirus，The Severe Acute Respiratory 
Syndrome-associated coronavirus, the SARS-CoV. 
SARS-CoV is an enveloped positive-sense and single-stranded RNA virus. 
Its genome size is about 30kbp and its genome organization is typical of 
coronaviruses, having the characteristic gene order [5 '-replicase (rep), spike (S), 
envelope (E), membrane (M), and nucleocapsid (N)-3'] and short untranslated 
regions at both termini. Among these proteins, the N protein is found to be highly 
immunogenic and abundantly expressed during infection in many coronaviruses. 
Moreover, studies of other coronaviruses indicate the multifunctional characters of N 
protein including viral replication, nuclear-import signaling, RNA packaging, and 
delay of cell cycle etc. Since the SARS-CoV nucleocapsid (N) protein shares little 
homology with that of other family members, characterization of the SAPS-CoV N 
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protein at the molecular level can help to elucidate the possible pathogenesis of 
SARS. 
In this study, the SARS-CoV N protein demonstrated different intracellular 
compartmentations in HepG2 and VE6 cells. The EGFP-tagged SARS-CoV N 
protein is localized in the cytoplasm only in VE6 cells but a small amount of 
SARS-CoV N protein is translocated into the nucleus of HepG2 cells. The cDNA 
microarray analysis on the differential gene expression patterns induced by the 
over-expression of SARS-CoV N gene altered the transcription levels of over 200 
genes belonging to various functional classes. The RNAi experiment identified three 
putative siRNA target sequences that could inhibit the expression of both SARS-CoV 
nucleocapsid mRNA and protein effectively. In the human fgl2 prothrombinase 
. promoter analysis, the transcriptional activation of the human fgl2 prothrombinase 
gene induced by SARS-CoV N protein may be one of the contributing factors of the 
pulmonary fibrosis in the SARS patients who died. To conclude, this study 
demonstrated a multifunctional character of SARS-CoV N protein and also provided 









沙士冠狀病毒是一種有殼正感單鏈的核糖核酸病毒（RNA virus) °它的基因 
組由大約三萬個核甘酸構成’而它的基因組結構亦帶有冠狀病毒典型獨有的基 
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CHAPTER ONE INTRODUCTION 
1.1. Severe Acute Respiratory Syndrome (SARS) 
1.1.1. Background of SARS 
The Severe Acute Respiratory Syndrome, designated by the World Health 
Organization in March 2003 (World Health Organization 2003a), is one of the novel 
emerging infectious diseases that hit the international community in the century. 
The disease originated in the Guangdong Province of Southern China, where cases of 
a highly contagious, severe atypical pneumonia with unidentified cause were first 
reported in late 2002 (Zhong et al, 2003). By mid-February, it reached Hong Kong i 
•• via an infected medical doctor from Guangdong, who not only transmitted the illness 
to his families and the health care workers in Hong Kong, but also sixteen other 
guests staying on the same floor with him in Hotel M. These, in turn, led to the 
deadly outbreaks of this mysterious infection in Hong Kong, Toronto, Singapore and 
Hanoi (Centers for Disease Control and Prevention 2003a, Tsang et a., 2003, Lee and ； 
Hui et al, 2003, Poutanen et al., 2003). This drew worldwide attention on March 12 ； 
2003, when the World Health Organization (WHO) issued a global alert about this 
1 
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new infection spreading outside China. By the amplification effect of the 
international air travel，SARS spread rapidly to affect over 8,000 people in 29 
countries across 5 continents to achieve the global dimensions within weeks (World 
Health Organization. 2003b). At the end of the epidemic in early July 2003, SARS 
had infected 8098 people all over the world with 774 deaths (Figure 1) (World Health 
Organization. 2003b). 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ Iiidonesi^^ Jf，l^gtoam: 
^ J r ^iiigapoie: 
Figure 1. The global distribution of reported SARS cases (reproduced from the 
World Health Organization, 2003b). The numbers of reported cases of SARS 
infection are denoted. Countries/ regions with substantial local transmissions are 
denoted in red color. 
2 
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1.1.2. Etiology and pathology of SARS 
Biological scientists responded quickly in understanding this new disease. The 
causative agent was soon identified to be a previously unknown coronavirus, which 
was later named as SARS-coronavirus (SARS-CoV) (Peiris et al., 2003a, Ksiazek et 
al, 2003). Although the true origin of the SARS-CoV in nature is still not known, 
scientists believe that the palm civet cats, raccoon dogs and ferret badgers, which are 
regarded as "exotic wild food" in the Southern China cuisine (Guan and Zheng et al, 
2003), are the important animal reservoirs. The viral genome was completely 
sequenced just after a few weeks of its emergence from China (Marra et al, 2003, 
Rota et al, 2003, Ruan et al, 2003). Our laboratory had also sequenced the genome 
of the strains CUHK-SulO (NCBI Accession number: AY282752) and CUHK-Wl 
•(NCBI Accession number: AY278554) (Tsui et al, 2003). 
Major site of attack of SARS coronavirus in humans is the lung and this results 
in atypical pneumonia (Chen and Lee et al, 2005, Hsiao et al, 2005a, Chau, Lee and 
Choi et al, 2004, Tse et al, 2004, Nicholls et al, 2003, Mazzulli et al, 2004, Chow 
and Hon et al, 2003). Other internal organs, such as the liver (Yang and Xu et al, 




and Tsang et al.，2005), are also affected. Abnormal chest radiographs and pulmonary 
infiltrates are the common clinical features of SARS patients (Chen and Lee et al, 
2005, Hui and Hon et al, 2004). Other symptoms including shortness of breath, fever, 
chills, cough, vomiting and diarrhea are also observed. (Chen and Lee et al, 2005, 
Yang and Xu et al, 2005, Srikantiah et al, 2003, Hui and Wong et al, 2004, Liu et 
al, 2005, Morb Mortal Wkly Rep. 2003 Mar, World Health Organization. Consensus 
document on the epidemiology of SARS). The incubation period ranges from 1 to 14 
days with an average of about 4 to 6 days. The case-fatality ratio (CFR) of SARS 
varies from 0 to more than 50% depending age groups of the patients. The overall 
estimated CFR is about 15% (World Health Organization, Consensus document on 
the epidemiology of SARS). The progressive age dependence in mortality and its 
underlying biological basis, however, still remain unclear. The major routes of 
•transmission of SARS include the direct contact, less than 1 meter, with the 
infectious respiratory droplets (Poutanen et al, 2003, Wong and Lee ct al, 2004, 
Seto et al, 2003) or other body fluids, such as tear (Loon et al., 2004, Chan and Yuen 
et al.’ 2004, Tong et al., 2005). Other means, including small aerosols or contact with 
contaminated environmental surfaces, were also observed in some situations (Centers 
for Disease Control and Prevention 2003a,b). But the role of fecal-oral transmission 
is still not well-established. (Lapinsky et al, 2004). The basic reproduction number 
4 
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Ro is about 3, which means that each SARS patient will transmit the disease to 3 
persons on average (Donnelly et al, 2003，Lipsitch et al, 2003). 
1.1.3. Genome organization and expression of SARS-CoV 
The SARS-CoV, which fulfilled the Koch's postulates, is an enveloped positive 
stranded RNA virus belonging to the family Coronavirdae. Six criteria are required 
to establish a virus as the cause of a disease according to Koch's postulates. These 
include isolation of virus from diseased hosts, cultivation in host cells, proof of 
filterability, production of comparable disease in the original host species or a related 
one, re-isolation of the virus, and detection of a specific immune response to the 
virus. These six criteria have been met for SARS-CoV by several research groups 
'(Fouchier et al, 2003，Peiris et al, 2003, Poutanen et al, 2003, Ksiazek et al, 2003, 
Drosten et al, 2003) 
The prefix "Corona" is derived from the "crown"-like appearance of the viral 
Spike (S) protein as seen under electron microscopy. The morphology of the 
SARS-CoV is shown in Figure 2 (Stadler et. al, 2003). CoVs are the largest RNA 
virus with genome size ranging from 27 to 31.5 kb. They usually cause respiratory, 
5 
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hepatic and enteric diseases in avian and mammalian species. So far, 3 groups with 
approximately 15 species have been identified in this family. 
. _ \ I . . . . . , ‘ ^ •» mmmmmmmmmmmrnmrnm 
Figure 2. The morphology of the SARS coronavirus. Electron micrograph of the 
SARS-virus cultivated in Vero cells. The protruding structures showing the 
"crown-like" appearance are the viral Spike proteins (Adapted from Stadler et al., 
2003). 
The genome of SARS-CoV is a polyadenylated RNA with about 29,727 
nucleotides, 37 to 42 % of GC content, and 14 open reading frames of which 12 are 
located in the 3'-proximal one-third of the genome (Marra et al., 2003, Snijder et al 
2003). Its genome organization is typical of coronavirus, having the characteristic 
gene order [5 '-replicase (rep), spike (S), envelope (E), membrane (M), and 
nucleocapsid (N)-3，] and short untranslated regions at both termini. The genome 
structure of SARS-CoV is given in Figure 3. The replicase genes comprise almost 
6 
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two third of the genome and are predicted to encode two polyproteins ORFla and lb. 
Same as all other known coronaviruses, 4 open reading frames (ORFs) downstream 
of rep are predicted to encode the structural proteins S, E, M and N (Marra et al, 
2003，Rota et al, 2003). The structure of the SARS-CoV is given in Figure 4. The S, 
E and M proteins are the viral surface proteins embedded in a lipid bi-layer viral 
envelope derived from the host cell. The viron is about lOOnm in size. The stalk-like 
Spike glycoprotein on the viron envelope is responsible for the receptor binding and 
membrane fusion between the viron and the host cell surface during infection. The 
envelope (E) glycoprotein and the membrane (M) glycoprotein can also been found 
on the viral envelope. The single-stranded positive sense viral RNA is associated 
with the N protein (Stadler et al, 2003). There are 5 predicted ORFs between S & E 
and M & N genes with unknown functions. However, the gene encoding 
hemagglutinin-esterase (HE) present between Orflb and S in Group 2 and some 


















































































































































































































































































































































































































































































































































Nucleocapsid protein (N) 
\ 豹 I 一 j 广 Spike protein (S) 
Envelope protein (E) 
Viral RNA genome C-' Membrane protein (M) 
_ _ 
lOOnm 
Figure 4. The structure of the SARS-CoV. On the viron surface, there are Spike 
protein (S), Envelope protein (E) and Membrane protein (M). Inside the viron, the 
Nucleocapsid protein (N) is associated with the viral RNA genome to form 
ribonucleocapsid core. The size of the viron is about lOOnm (Reproduced from 
Staldereta/., 2003). 
CoV replicates by a unique strategy of discontinuous transcription mechanism 
that is poorly understood. It synthesizes the viral RNA in the cytoplasm of the host 
cell by a negatively-stranded RNA cap followed by a ladder sequence and an 
untranslated region, and acts as an mRNA. An untranslated region followed by a poly 
A tail is found at the 3' end of its genome. Its genome expression starts with the 
9 
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translation of 2 large replicase ORFs, Orf la and lb. The viral transcription and 
translation processes are shown in Figure 5. The replicase proteins are then processed 
by 2 or 3 viral proteinases, for example, the papain-like protease (Plpro-2) and 
3C-like protease (3CLpro) encoding from ORF la. Through the processing, a variety 
ofuncharacterized replicative enzymes, such as an RNA-dependent RNA polymerase 
(RdRp) and an RNA helicase, are obtained. Besides, the replicase complex also 
synthesizes an extensive nested set of subgenomic RNAs (sg RNAs) to express all 
the ORFs downstream of ORF lb, which encode a number of structural proteins. All 
sg RNAs share a common leader sequence at the 5'end, but initiate at different sites 
from the transcription regulatory sequence (TRS) or intergenic sequences in the 
genome and extend toward the 3'end of the genome. Each sg RNAs, except for the 
smallest one, is polycistronic and can only be translated to generate the protein 
product of its most 5, end gene (Lai et aL, 2003, Ziebuhr et al, 2004). So far, ten sg 
RNA species have been identified for the SARS-CoV (Hussain et al, 2005). 
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Figure 5. The transcription and translation processes of SARS-CoV. The viral 
genomic RNA will be first translated to give an RNA dependent RNA polymerase 
(RdRp). With the aid of this RdRp, the positive stranded genomic RNA is transcribed 
into minus stranded RNA that serves as a template for the synthesis of 
positive-stranded genomic RNA. A set of subgenomic RNAs are also synthesized by 
the replication complex. All the transcripts have an identical 5’ non-translated leader 
sequence of 72 nt and a 3’ poly-A tail. Each sub-genomic RNA, except the smallest 
one, is polycistronic. Only the most 5，end gene will be translated. 
The phylogenic analyses of a number of non-structural and structural proteins of 
SARS-CoV, such as the replicase, RdRp, S，E, M and N, clearly show that this virus 
represents a distinct evolutionary lineage from the previously known CoVs (Marra et 
al” 2003，Rota et al, 2003, Snijder et al., 2003). The phylogenetic tree on the 
nucleocapsid protein of different coronaviruses is given in Figure 6. It is roughly 
equidistant from other family members. A more detailed study supported that there 
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are different origins for each viral protein. The analysis supports a mammalian-like 
origin for replicase, and avian-origin for M and N, and a mammalian-avian mosaic 
origin for S (Starvrinides et al, 2003). The phylogenical distribution of SARS-CoV 
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Figure 6 Phylogenetic analysis on the nucleocapsid proteins of different 
coronaviruses. Branch length indicates the number of substitutions per residue. The 
SARS-CoV is roughly equidistant from other coronavirus family members and is 
suggested to be regarded as a new group within the family. MHV: Murine hepatitis 
virus; BCoV: Bovine coronavirus; IBV 1: Infectious bronchitis virus-strain 1, IBV 2: 
Infectious bronchitis virus-strain 2, FCoV: Feline coronavirus, PTGV: Porcine 
transmissible gastroenteritis virus, HCoV-229E: Human coronavirus-229E, 
HCoV-OC43: Human coronavirus-OC43, PHEV: Porcine hemagglutinating 




1.1.4. Current molecular advances of SARS-CoV 
The susceptibility to SARS-CoV infection varies depending on which cell type 
is tested. VeroE6 (VE6), African Green monkey kidney cell line, was first reported to 
be susceptible to SARS infection (Ng and Tan et al” 2003a and b) and is now 
commonly used in many SARS researches. Besides, SARS-CoV infection could also 
be demonstrated in LoVo- the human colorectal adenocarcinoma cell line, Huh-7-
human normal liver cell line, POEK- pig fetal kidney cell line, and PS- pig kidney 
cell line (Chan and To et al, 2004, Hattermann et al, 2005). 
The SARS virus showed tissue tropism for the human respiratory and 
gastrointestinal epithelial cells (Nicholls et al, 2003, Leung et al, 2003). Results 
from immunohistochemical staining for SARS-CoV in the patient tissue sections 
suggested that the type II pneumocytes should be the main target cell of the virus in 
human lungs (Hsiao and Chang et al, 2005). 
The SARS-CoV target cell specificity is determined by its S glycoprotein 
affinity to cellular receptors. Angiotensin-converting enzyme 2 (ACE2) was 
discovered to be a functional receptor of SARS-CoV (Li and Moore et al, 2003) and 
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further studies located the receptor-binding domain of SARS-CoV S protein at a.a. 
318-510 (Wong and Li et al, 2004). Studies using SARS-CoV S glycoprotein 
pseudovirus suggested that acidification of endosomes was required for efficient 
S-mediated viral entry (Simmons et al, 2004). The C-type lectin CD209L, L-SIGN, 
was also proven as an alternative receptor for the virus (Jeffers et al, 2004). These 
virus-receptor interactions would be the potential targets for future therapeutic 
strategies. 
Among the structural proteins, the SARS-CoV S protein was identified as the 
only one that is capable of inducing a detectable serum neutralizing antibody 
response (Buchholz et al, 2004). The monoclonal antibody raised with the S 
recombinant protein of a.a.485-625 region could recognize the native S protein and. 
The attachment of S to its receptor(s) was blocked and finally the anti-S monoclonal 
antibody neutralized the SARS-CoV in cell cultures (Zhou et al, 2004). Furthermore, 
Guo et al identified 11 potential antigenic determinants of SARS-CoV S protein 
recognized by the antibodies in the convalescent sera (Guo et al, 2004). 
‘ I 
When examined by electron microscopy, co-expression of SARS-CoV M, N and 
S proteins in human 293 renal epithelial cells were sufficient for the formation and 
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budding of virus-like particles (VLPs). The M protein might act as a critical bridge 
through its interactions with N and S proteins for the SARS-CoV VLP assembly 
(Huang and Yang et al, 2004). In transfected-insect cells, co-expression of 
SARS-CoV S, E and M proteins also allowed the efficient assembly and release of 
VLPs (Ho et al, 2004, Mortola et al, 2004). These non-pathogenic VLPs could act 
as an effective immunogen to induce protective immunity. Although the probable 
packaging signal of SARS-CoV was predicted to be analogous to that of MHV and 
BCoV by bioinformatics analysis (Qin and Xiong et al, 2003), its defined region 
necessary for packaging has still not been reported. The packaging signal of MHV 
was identified by using the defective interfering viral particles (Kim and Narayanan 
et al, 1998) and the use of VLPs may help in its identification in SARS-CoV. 
• The human leukocyte antigen (HLA) system is often used to search for the 
susceptibility of infectious diseases and autoimmune disorders. A group of Taiwanese 
scientists correlated the HLA-B*4601 allele with SARS susceptibility (Lin and Tseng 
et al, 2003. Lin et al has suggested that people having this particular allele, which 
accounts for about 10% of the Taiwanese population and among other southern 
Asians including people from China's southern coast, Hong Kong, Singapore, and 
part of Vietnam, were most likely to fall victim to SARS. The result may explain 
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why southern China was the most serious region of SARS outbreak. Although the 
HLA-B*4601 allele is seldom seen in Caucasians and in people of African origin, 
Lin's finding could not explain the SARS epidemic in Toronto, Canada, where the 
majority of SARS patient were Caucasians. It is not know if there is any certain 
allele among the Caucasian population in Toronto that made them more susceptible 
to SARS infection because of the lack of data on the HLA studies from other areas 
hit by SARS, such as Toronto. 
The SARS-CoV could induce apoptosis in culture VE6 cells, as shown by DNA 
fragmentation (Yan et al, 2004, Mizutani et al, 2004a). This implicated that the 
virus may have the same effect in vivo that contributed to the severe damage of the 
respiratory system. Further analysis showed that p38 mitogen-activated protein 
kinase (p38 MAPK) was significantly phosphorylated and its downstream targets, 
heat shock protein-27 (HSP-27), cAMP response element-binding protein (CREB) 
and eukaryotic initiation factor 4E (eIF4E), were activated (Mizutani et al, 2004a). 
Other MAPKs, including extracellular signal-regulated kinase 1/2 (ERKl/2) and 
c-Jun N-terminal kinase (JNK) were also phosphorylated (Mizutani et al, 2004c). 
But the low activation level of Akt, the key regulator for cell survival, was not 
sufficient to prevent the SARS-CoV-induced apoptosis (Mizutani et al, 2004b).. 
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STAT 3 at Tyr-705 was dephosphorylated by the activation of p38 MAPK. This 
implicated that the lack of STAT 3 activity during viral infection may further weaken 
the cellular anti-apoptotic activity (Mizutani et al, 2004c). 
The direct actions of the SARS-CoV may not be the only cause for the severe 
damage on lung tissues, but also the secondary effect of the over-exuberant host 
response to the cytokine dysregulation during viral infection. Clinical observation of 
a dramatic cytokine storm was reported (Beijing Group of National Research Project 
for SARS, 2003). The serum levels of pro-inflammatory cytokines, Interleukin (IL)-6, 
IL-8, IL-16 and tumor necrosis factor a (TNFa) and transforming growth factor p 
(TGFp) were highly elevated especially in the recovery phase and this may be 
associated with pulmonary infiltration and proliferation. The increase in IL-8 level 
could also be explained by its induction by the SARS-CoV S protein via activations 
of MAPKs and AP-1 (Chang et al, 2004). The gradual reduction in IL-13, an 
anti-inflammatory cytokine, and persistent decrease in IL-18, a key anti-infection and 
anti-inflammatory cytokine, during the whole clinical course implicated the inability 
to resist the illness progression in the SARS patients. This observation o l dynamic 




As we can see, two conflicting cellular programs, apoptosis to eliminate 
virus-infected cells and survival of cells to alert naive cells by producing antiviral 
cytokines, are triggered in cells during viral infection. It is interesting to ask how cell 
death or survival is determined in SARS-CoV infected cells. However, the control 
mechanisms that balance cell survival against cell death remain to be elucidated. 
1.1.5. Current research advances on SARS-CoV nucleocapsid 
Selective activation of AP-1 signal transduction pathway by SARS-CoV N 
protein had been described. In vitro assay had shown that the components of AP-1 
signal transduction pathway, including transcription factors c-Fos, FosB, CREB-1 
and ATF2, were all activated upon the expression of SARS-CoV N protein. Further 
confirmation by in vivo assay on both VE6 and Huh7 cells had clearly demonstrated 
that the induction of signal transduction pathway by SARS-CoV N protein was 
pathway-selective; i.e. N protein induced AP-1 signal transduction pathway, but not 
the N F k B pathway, (He and Leeson et a/”, 2003). 
The SARS-CoV N protein was also capable of inducing apoptosis in COS-1 
cells under stressed conditions triggered by serum starvation (Surjit et al, 2004b). 
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Surjit M and his colleagues had shown that in the absence of growth factor, the 
expression of SARS-CoV N protein would downregulate pErk, P-Akt and Bcl-2, and 
upregulate the stress-activated protein kinases, Jnk and p38 MAPK pathways. 
Activation of Caspases 3 and 7 were also observed and actin reorganization was 
promoted by the activation of p38 MAPK pathway under serum starvation 
conditions. 
Self-association of SARS-CoV N protein had been reported. The a.a. 184-196 
was identified to be indispensable for the SARS-CoV N protein self-interaction (He 
and Dobie et al, 2004). Meanwhile, He R and his colleagues had proved that the 
same region was also critical for the SARS-CoV N protein and M protein interaction 
(He and Leeson et al, 2004). Another possible region, the C-terminal a-helix-rich 
209 amino-acid region, was also mapped to be responsible for the N-N 
self-multimerization (Surjit et al, 2004a). A recent article has demonstrated that the 
homodimeric SARS-CoV N protein might act as the building block of the oligomers 
and led to the formation of a viral capsid, which in turn, protected the genome from 
extracellular agents as observed in many viruses. In addition, the dimerization region 
was mapped to the C-terminal 139 residues, a.a 285-422 (Yu and Gustafson et cd.’ 
2005). Taken together from these studies, there may be more than one region 
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responsible for the SARS-CoV N protein homodimerization. 
So far, two cellular interacting partners of SARS-CoV N protein have been 
identified. Having the evidence that human cyclophilin A (hCyp A) interacted 
specifically with the capsid domain of HIV-1 gag polyprotein integrated inside the 
viral core, the SARS-CoV N protein was also discovered to have a high binding 
affinity to hCyp A. The putative binding sites have been verified to be the loop 
Trp302-Pro310 of SARS-CoV N protein and the active-site groove of hCyp A (Luo 
and Luo et al, 2004). This finding may provide a hint on understanding the pathways 
associated with the SARS viral infection against host cells. 
In vitro GST-pull down and in vivo yeast two-hybrid assays demonstrated the 
interaction between the SARS-CoV N protein and the human nuclear 
ribonucleoprotein Al (hnRNP Al). The regions involved in such a protein-protein 
interaction were identified to be a.a. 161-210 of SARS-CoV N protein and a.a. 
203-320 of hnRNP Al (Luo and Chen et al, 2005). It is suggested that SARS-CoV N 
, protein and hnRNP Al may be associated with the viral replication/ transcription 




N-terminal structure of SARS-CoV N protein (amino acid residues 45-181) was 
also solved by nuclear magnetic resonance (NMR) spectroscopy. Its N-terminal 
structure consisted of a five-stranded antiparallel p sheet with the topology of 
P4-P2-P3-P1-P5. The RNA-binding site of SARS-CoV N protein was predicted to be 
the exposed loop p2'-p3' with its positively charged lysine and arginine on the 
surface. This positively-charged, exposed loop might assist in clamping the RNA 
against p sheets of the protein (Huang and Yu et al, 2004). The circular dichroism 
(CD) spectra of the soluble full-length SARS-CoV N protein revealed that the 
protein was relatively disordered. Up to 50% of its compositions were turns and coils 
without significant signature of a-helix (Tang and Wu et al, 2005). The analysis also 
showed some p sheets in the SARS-CoV N protein and this is in agreement with 
findings by Huang's group, which revealed a mostly p-sheet structure in its 
N-terminal by NMR. 
A number of epitopes of SARS-CoV N protein have been mapped with both 
SARS patient sera and antibodies isolated from immunized mice. Lin and his 
colleagues first identified an epitope, amino acids residues 21-44 (a.a. 21-44) on the 
N-terminal of the protein (Lin and Zhang et al.’ 2003). Another research group 
demonstrated that a.a. 371-422 at the C-terminal of the protein could also be 
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recognized by the convalescent-phase sera from SARS patients (Liu et al., 2004). Li 
and his colleagues further narrowed down this antigenic region into a.a.371-407 (Li 
and Lin et al, 2004). Some more possible epitopes were identified and they were 
located at a.a. 51-71, 134-208, 249-273 and 349-422 (Chen and Pei et al., 2004). The 
antigenic sites mapped by He Y and his colleagues, a.a. 153-178 and a.a. 362-412 
(He, Zhou and Wu et a!., 2004), overlapped with those identified by Chen's group. 
Moreover, a more recent article reported that a.a. 1-20, 150-170 and 390-410, which 
are similar to those mapped by Chen's group, were identified as having strong 
antigenicity (Tang et al., 2005). 
Phosphorylation of the N protein is well documented in many CoVs. By 
metabolic labeling using P^ ,^ the SARS-CoV N protein was reported to be 
phoSphorylated in 293 cells infected with human adenovirus vector expressing 
SARS-CoV N protein (Zakhartchouk et al, 2005). A recent publication has 
suggested that the SARS-CoV N protein would be phosphorylated at multiple 
different phosphorylation sites by multiple kinases in vivo (Surjit et al, 2005). The 
, SARS-CoV N protein was also demonstrated to undergo post-translational 
modification by covalent attachment to the small ubiquitin-like modifier (SUMO), 
SUMO-1 (Li and Xiao et al, 2005). The major sumoylation site was mapped on the • 
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lysine residue at the amino acid position 62 (K62). Furthermore, the 
homo-oligomerization of SARS-CoV N protein could be greatly promoted by 
sumoylation 
1.1.6. Current diagnostic assays of SARS-CoV infection 
The development of accurate laboratory diagnosis of SARS-CoV infection 
began immediately after the outbreak. Different protocols have been developed. They 
can be classified as 2 major approaches — the PCR-based assays and serologic assays. 
Virus isolation by cell culture, which is a traditional technique extensively used in 
virology study, is not recommended for the routine detection of SARS viral infection 
because of its time-consuming procedure and requirement of skillful technicians 
(CKow and Hon et al, 2003). The low sensitivity and biohazardness also limit its use 
(Hsueh et al, 2003, Parashar et al, 2003). 
The first generation of RT-PCR based assays was developed soon after the 
discovery of the novel SARS-CoV. However, the sensitivity of the assay, which 
largely depended on the type of clinical specimens, the timing of specimen collection 
relative to the onset of symptoms and the targeted viral genomic region to be . 
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amplified (Peiris et al., 2003a), was demonstrated to be as low as 50% (Yam et aL, 
2003). The modified specimen extraction methods in the second generation of 
real-time RT-PCR assays have improved its sensitivity, with a detection limit as low 
as 10 copies of viral RNA, during the first week of illness (Grant et al, 2003, Poon et 
al, 2003). Additional amplification of the viral N gene fragment can also enhance 
the sensitivity of the assay (Ng and Hui et al, 2003), since the N mRNA is the most 
abundant sub-genomic mRNA during infection (Rota et al, 2003). 
The serologic assays of SARS-CoV, which included ELISAs (Guan and Chan et 
al, 2004, Shao et al, 2005, Ohnishi et al.’ 2005, Qiu et al, 2005, Mo et al,’ 2005, 
Saijo et al., 2005,Zhao et al, 2005, Carattoli et al, 2005), immunofluorescent assays 
(Guan and Chen et al, 2004), and western blot assays (Huang and Chiu et al., 2003), 
have also been developed. The N protein is usually chosen as the antigen for 
anti-SARS-CoV antibodies detection in the ELISA assays (Shi et al, 2003, Woo et 
al., 2004, Huang and Chiu et al., 2003, Che et aL, 2004), since it is suggested to be a 
predominant antigen of the SARS-CoV. The antibodies production in human can also 
be elicited by SARS-CoV S protein as the antigen (Huang and Chiu et al.’ 2003). 
However, the titer is much lower than that of the N protein. Since the IgM antibodies 
is detectable only 10 days after onset of symptoms and the mean time of IgG . 
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seroconversion, or the convalescent phase is approximately 21 to 28 days, the result 
of this assay is valid only if the specimens are obtained at Week 3 or even later after 
symptoms onset. Thus, the serologic tests at the present stage may not be applicable 
as a prompt diagnostic system for the detection of SARS-CoV infection. 
Nevertheless, the results of any kinds of the SARS-CoV detection assays should 
always be considered in the context of clinical and epidemiological findings 
1.1.7. Current treatment 
Corticosteroids were extensively used for the SARS therapy. In some 
preliminary studies, corticosteroids treatment, together with Ribavirin, demonstrated 
fever defervescence, improvements in oxygenation rates and chest radiological 
appeiarance (Zhao et al, 2003, Booth et al, 2003, Hsu et al, 2003). However, none 
of these studies were controlled and confounded by other treatments. Reports from 
Hong Kong and China have indicated the adverse outcomes, which included 
immunosuppression, secondary sepsis, aspergillosis and avascular necrosis of bones, 
, associated with prolong and high dose corticosteroids treatment in the patients 
recovered from SARS (Wang and Ding et al, 2003, Chan and Zheng et al, 2003, 
Hong et al, 2004). . 
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The use of Ribavirin, a synthetic nucleoside with broad-spectrum of antiviral 
activity, on the SARS therapy was also a controversial issue. It was widely used in 
the early stage of the epidemic and a number of initial reports have described patients 
treated with it resulted in both clinical and radiological improvements (Tsang et al, 
2003, Lee et al, 2003). However, most patients in these studies were also receiving 
corticosteroids. The lack of a control group makes it impossible to conclude if 
Ribavirin is effective against SARS or not. Moreover, a series of adverse effects, 
such as severe hemolysis, hypocalcaemia and hypomagnesaemia, were identified 
among SARS patients treated with high doses of Ribavirin (Knowles et al, 2003). In 
experiments have shown that Ribavirin is unable to inhibit the SARS-CoV 
replication at clinically attainable concentrations (Cinatl et al, 2003，Stroher et al, 
2004) and high viral loads were also described in the postmortem findings of most 
patients in spite of the Ribavirin treatment (Mazzulli et al, 2004). These suggest that 
Ribavirin may be only beneficial to the SARS patients to a very small extent. 
Lopinavir-ritonavir, which is a combination of 2 protease inhibitors with proven 
efficacy in HIV treatment, was applied to the local SARS patients as the standard 
treatments consisting of corticosteroids and Ravirin in the non-randomized open 
label study. Decreases in overall death rate and intubation rate were noted in the • 
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recipients. As the control group was receiving lower doses of corticosteroids, the 
medical doctors were unable to arrive at a definitive conclusion about its efficacy in 
SARS treatment (Chan and Lai et al” 2003, Chu and Cheng et al, 2004) 
The SARS patients treated with Interferon (IFN) alfacon 1 in the clinical trials 
have shown significant improvement in oxygen saturation levels and rapid resolution 
of radiographic lesions (Loutfy et al, 2003). But similar to other clinical studies, a 
high dose of corticosteroids was also given to the test group. The beneficial effect of 
IFN alfacon 1 remains unanswered. Successful cases of using convalescent-phase 
serum containing high levels of anti-SARS antibodies as passive immunotherapy 
have been described in Hong Kong (Wong and Dai et al, 2003, Wong and Soo et al, 
2005). The development of monoclonal antibodies against SARS may shed some 
light on the ongoing SARS vaccine research studies. 
1.1.8. Vaccine development 
‘ Fundamental studies on the SARS viral genome structure and life cycle can help 
scientists in identifying the possible molecular targets for anti-viral drug design. 
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These targets include the Spike glycoprotein, the RNA-dependent RNA polymerase, 
the helicase and the 3C-like protease. 
The S protein is a good candidate for vaccine development because it presents 
infection of permissive cells through its interaction with the virus specific receptor 
on the host cell surface. Any ligands that block the host cell receptor may prevent the 
viral entry. Monoclonal anti-S antibody and inactivated SARS-CoV vaccine could 
significantly inhibited S protein-mediated viral entry by blocking receptor binding on 
the host cell surface (Sui et al., 2004, He and Zhou et al, 2004b). Recombinant 
proteins (Ni et al, 2005) and peptides (Yuan et al, 2004, Zhu et al, 2004) derived 
from the heptad-repeat regions of the S2 domain of the S protein could serve as the 
potent inhibitors against SARS-CoV entry by suppressing the receptor-induced 
conformational changes in the S protein. 
The RNA-dependent RNA polymerase plays a pivotal role in viral replication 
and thus, it is also a potential target for. antiviral strategy. Nucleoside analog 
inhibitors, which have proven to be active against HCV polymerase and HIV reverse 
transcriptase, may have a similar efficacy on SARS-CoV RNA polymerase (Xu et al, 
2003, Barnard et al, 2004). ‘ 
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Since the polyprotein of the replicase protein is cleaved into functional units by 
the 3C like protease, protease inhibitors may block the viral replication. With the 
help of the crystal structure of 3C-like protease (Yang and Yang et al, 2003), a 
number of small molecules processing this inhibitory effect have been identified (Liu 
et al, 2005, Chen and Lin et al, 2005). 
Small molecules showing inhibitory effect on SARS-CoV replication are also 
considered as anti-SARS drug candidates. Screening of currently available chemical 
libraries and clinically approved antiviral drugs have revealed that Interferon 
a，p and y (Tan et al, 2004，Cinatl et al, 2003, Haagmans al, 2004, Dahl et al, 
2004，Stroher et al, 2004, Hertzig et al, 2004, Chen and Chan et al, 2004, 
Scagnolari et al, 2004, Hensley et al, 2004, Spiegel et al, 2004, Zheng and He et al., 
2004), Nelfinavir (Yamamoto et al, 2004)，Niclosamide (Wu et al, 2004a), 
Glycyrrhizin (Cinatl et al, 2004, Yu and Ohtaki et al, 2005) and its derivatives 
(Hoever et al, 2005, Wu et al, 2004b), Aurintricarboxylic acid (He and Adonov et 
al., 2004), S-nitroso-N-acetylpenicillamine (Keyaerts et al, 2004), 
tetra-O-galloyl-P-D-glucose (TGG)，luteolin, quereetin (Yi and Li et al, 2004), 
Reserpine, Ginseniside-Rbl, Valinomycin, FP-21399, extracts of eucalyptus and 
Lonicera japonica and some saponins (Wu et al, 2004b) exhibit different degrees of , 
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activities against SARS vims in different in vitro model. The synergistic effect on the 
reduction of SARS viral replication in cultured VE6 cells by treatments with 
Interferons p plus y (Sainz et al, 2004) and Interferons p plus Ribavirin 
(Morgenstern et al, 2005) have also been described. 
siRNAs targeting the viral leader sequence and different viral genes, including S 
gene and RdRp gene, have been demonstrated to interrupt the SARS-CoV replication 
by degrading the viral mRNA in a sequence-specific manner (Li and Zhang et al, 
2005，Shi and Yang et al； 2005, Wu et al, 2005, Zheng and Guan et al, 2004，Qin 
and Zhao et al, 2004, Wang and Ren et al, 2004, Zhang and Li et al, 2004, Zhang 
and Guo et al, 2003). 
1.2. Aims of study 
The SARS epidemic has promoted a variety of studies on the viral replication 
cycle, identification of cellular entry mechanism to the host cells, structural and 
functional roles of the SARS-CoV proteins, accurate diagnosis during early infection 
and possible vaccines development. However, the pathogenesis of SARS at the 
molecular level remains unclear. Among the structural proteins of SARS-CoV, the ‘ 
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SARS-CoV nucleocapsid protein is the most immunogenic and abundantly expressed 
protein during SARS infection. Thus, we believe that it may be a good target for 
vaccine development and may play an important role in the pathogenesis of SARS. 
In this study, we aim at characterizing the SARS-CoV nucleocapsid in the 
following aspects: 1) its subcellular localization using enhanced green fluorescent 
protein (EGFP) as the in vivo marker; 2) elucidation of differential human gene 
expression patterns upon the over-expression of SARS-CoV nucleocapsid; 3) 
inhibition on its cellular expression by RNA interference; and 4) investigation at its 
correlation with transcriptional activation of the novel fgl2l fibroleukin 
prothrombinase 
By using the EGFP tag as the in vivo marker, the biological subcellular 
localization of the SARS-CoV N protein could be determined. Thus, we could know 
in which cellular compartment(s) that the viral protein exerts its biological function(s) 
inside the host cells. . 
The cDNA microarray (Affymetrix) analysis could provide a general picture on 
the differential human gene expression patterns induced by SARS-CoV nucleocapsid . 
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and might give us insights on the mechanisms of pathogenesis of SARS. 
RNA interference (RNAi) was applied to examine its potential efficacy to 
inhibit the cellular expression of SARS-CoV nucleocapsid since previous studies on 
HIV and HBV have shown promising results in the reduction of viral infection by 
RNAi. 
Studies on MHV-3 revealed that its viral nucleocapsid protein was critical on 
the transcriptional activation of fgl2l fibroleukin prothrombinase, which in turn 
triggered the fibrin deposition and subsequent thrombosis within the 
microvasculature of the liver during MHV infection (Ning et al, 1999, Marsden PA 
et al, 2003). Similar phenomenon on vascular thrombosis in pulmonary vessels was 
reported from the postmortem examination of SARS patients (Peiris et ul, 2003). 
Taken together, further investigation on the relationship between the human fgl2l 
fibroleukin prothrombinase gene and the SARS-CoV N protein may give us an 
explanation on the development of pulmonary fibrosis in the SARS patients. 
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CHAPTER TWO MATERIALS AND METHODS 
2.1. Subcellular localization study of the SARS-CoV nucleopcapsid protein 
2.1.1. Cloning of SARS-CoV nucleocapsid cDNA into the green fluorescence 
protein (GFP) mammalian expression vector, pEGFP-Cl 
2-1.1.1. Amplification of SARS-CoV nucleopcaisd gene by polymerase chain 
reaction (PGR) 
In order to visualize the subcellular localization patterns of EGFP-tagged 
SARS-CoV nucleocapsid protein in mammalian cells, 
pEGFP-SARS-CoV-nucleocapsid (pEGFP-SARS-CoV-N) construct was made by 
cloning the coding region of SARS-CoV N gene into the C-terminal of EGFP in the 
pEGFP-Cl vector (BD Biosciences Clontech, CA, USA). 
The SARS viral cDNA, strain CUHK-Wl, a generous gift from the Department 
of Microbiology, the Chinese University of Hong Kong, was used as the template for 
the amplification of full-length cDNA of SARS-CoV nucleocapsid gene in this PGR • 
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reaction mixture. The forward primer (5'-TAG GGC AGA TCT ATG TCT GAT AAT 
GGA CCC CAA TCA AAC CAA-3，) and reverse primer (5'-TAG GGC GGA TCC 
TTA TGC CTG AGT TGA ATC AGC AGA AGC TCC-3，）were designed to have 
and BamHl restriction sites at the 5' end, respectively. For the deletion mutant 
encoding a.a. 1-368，the same forward primer and another reverse primer (5'-TAG 
GGC GGA TCC CTC TTA CTC TGT TGG TGG GAA TGT TTT-3') were used. 
The PGR was performed in the presence of 0.2 |Lig SARS viral cDNA template, 
0.5|iM of both forward and reverse primers, 1 unit of Advantage cDNA polymerase 
mix (BD Biosciences Clontech, CA, USA), 2mM of dNTP, IX Advantage cDNA 
polymerase buffer and sterile nano-pure water in 50 [i\ volume. The thermal cycling 
profile was as follows: denaturation at 94°C for 5 minutes, followed by 35 cycles of 
denaturation at 94°C for 36 seconds, annealing at 58°C for 36 seconds and primer 
extension at 68°C for 1 minute and 45 seconds. A final extension was given at 68°C 
for 10 minutes. The thermal cycling was carried out in a PTC-100 Programmable 
Thermal Controller (MJ Research Inc., South San Francisco, CA, USA). The PGR 
product was then electrophoresed on a 1 % TAE agarose gel pre-stained with 
ethidium bromide and visualized under UV. 
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2.1.1.2. Purification of PGR products 
The desired PGR amplified fragment was excised from the 1% TAE agarose gel 
and the purification of the PGR product was carried out using GENECLEAN™ III 
kit (Bio 101 Inc.，La Jolla，CA, U.S.A.). The excised agarose gel slices were 
dissolved in 3 volumes of 6 M sodium iodide (kit component) at 55 °C water bath for 
15 minutes, with occasional shaking until the gel slices were completely melted. 
Then 5 fil of GLASSMILK (kit component) was added into the dissolved agarose 
mixture to allow binding of the DNA to the silica matrix. The suspension was 
incubated at room temperature for 15 minutes with continuous and gentle shaking. 
After incubation, the suspension was centrifuged at 13,000 rpm for 2 minutes. The 
supernatant was discarded and the pellet was washed 3 times with 500 of ice-cold 
NEW WASH solution (kit component). Finally, the pellet was dried by spin vacuum 
for 5 minutes. Elution of DNA was completed by resuspending the GLASSMILK 
pellet in _ of nano-pure water, followed by centrifugation at 13,000 rpm for 3 
minutes and aspiration of the supernatant containing the required and purified DNA. 
� 
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2.1.1.3. Restriction digestion of purified PGR product and the circular 
pEGFP-Cl vector 
10 fil of the purified PGR production was subjected to restriction enzyme 
digestion in a final volume of 20|li1 mixture consisting of 2X One-Phor-All PLUS 
(OPA) buffer (Amersham，Uppsala, Sweden), of both Bg/II and BcmHl 
restriction enzymes and nano-pure water at a 3TC air-bath incubator for 2 hours. 
Meanwhile, l|Lig of pEGFP-Cl vector was digested in parallel with the same 
conditions. The digested PGR product and pEGFP-Cl vector were analyzed on a 1 % 
TAE agarose gel and then purified by using GENECLEAN™ m kit as described in 
Section 2.1.1.2. 
2.1.1:4. Ligation 
Purified digestion product was ligated into the linearised pEGFP-Cl vector with 
compatible ends in a molar ratio of approximately 1:3 of expression vector to insert 
DNA. The ligation reaction mix was composed of 1 unit of T4 DNA ligase (New 
England Biolabs，MA, USA), IX T4 DNA Ligase Reaction Buffer and nano-pure 
water to make up for a final volume of 20|j,l. It was then was incubated at 16°C , 
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overnight. Negative control using nano-pure water instead of insert DNA was 
performed in parallel. 
2.1.1.5. Preparation of chemically competent bacterial cell E.coli strain DH5a 
for transformation 
Preparation of chemically competent bacterial cells was based on the Hanahan 
method. On day one, a single colony of E. coli strain DH5a was inoculated with 10 
ml of LB medium and the culture was incubated at 37�C for overnight (16-20 hours) 
with shaking at 250 rpm. On day two, 7.5 ml of the overnight culture was 
sub-cultured into 250ml of LB medium and further incubated at 37�C for about 2 
hours with shaking at 250 rpm until its absorbance at wavelength 600 run reached 0.3. 
Bacterial cells were harvested by centrifligation at 3,500 rpm at 4 � C for 10 minutes. 
The supernatant was decanted and the cell pellet was re-suspended in 83 ml (1/ 3 
volume of the original culture volume) RFl (100 mM RbCl, 50 mM MnCb^HiO, 30 
mM potassium acetate, 10 mM CaCl2-2H20 and 15% glycerol [w/v], pH 5.8). The 
suspension was incubated on ice for another 15 minutes and the cells were harvested 
by centrifugation at 3,500 rpm at 4°C for 10 minutes. The supernatant was discarded 
and the cell pellet was re-suspended in 20 ml of (1/12.5 volume of the original , 
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culture volume) RF2 (10 mM MOPS, 10 mM RbCl, 75 mM C a C h ^ O and 15% 
glycerol [w/v], pH 6.8). The suspension was incubated on ice for 15 minutes and 
then aliquoted into 200 )li1 fraction. The chemically competent bacterial cells were 
quickly frozen in liquid nitrogen and stored at -80°C. RFl and RP2 were sterilized 
by filtration using a 0.2|i membrane before use. 
2.1.1.6. Transformation of ligation product into chemically competent 
bacterial cells 
Frozen chemically competent bacterial cells were thawed on ice for 10 minutes. 
The ligation mixture was added to the thawed competent bacterial cells (200 [L\) and 
then incubated on ice for 20 minutes. Then the cells were heat shocked at 42°C for 
60 seconds, and immediately chilled on ice for 2 minutes. After the heat shock 
process，800 ).il of LB medium was added and the mixture was incubated at 37°C for 
45minutes with shaking at 250 rpm. Finally, the cells were centrifuged down at 
13，000 rpm for 2 minutes and the supernatant was decanted. The cell pellet was 
suspended in 100 i^l of fresh LB medium. All the cell suspension was spread onto a 
LB agar plate containing selection antibiotic kanamycin (50 |.ig/ml) and incubated at 
37°C for 16 hours for selection. 
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2.1.1.7. Small-scale preparation of bacterial plasmid DNA 
Extraction of bacterial plasmid DNA was accomplished by the Rapid Plasmid 
Miniprep System (Marligen Biosciences, Inc., MD, USA). Briefly, a single 
well-defined bacterial colony was inoculated with 3 ml of LB medium containing the 
appropriate selection antibiotic. The culture was allowed to grow at 37°C for 
overnight with shaking at 250 rpm. Cells were harvested by centrifugation at 13,000 
rpm for 5 minutes. TE buffer (TE) was pre-warmed at 70°C for later use of plasmid 
elution. The supernatant was discarded and the cell pellet was resuspended in 250 yd 
of chilled Cell Suspension Buffer (Gl) by vortexing. 250 |il of Cell Lysis Solution 
(G2) was added into the cell suspension. The contents were mixed by inverting the 
tube five times and incubated at room temperature for exactly 5 minutes. 350 \x\ of 
Neutralization Buffer (M3) was added and mixed immediately by inverting the tube 
five times. The suspension was then centrifuged at 13,000 rpm for 10 minutes. The 
supernatant was loaded into a spin cartridge that was placed in a 2-ml wash tube. The 
composite was centrifuged at 13,000 rpm for 1 minute. The flow-through was 
discarded. 500 [L\ of Optional Wash Buffer (GX) was added to the spin cartridge and 
.. incubated at room temperature for 1 minute, followed by centrifugation at 13,000 for 
1 minute. Thereafter, 700 of Wash Buffer (G4) was added to the spin cauridge and 
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the composite was centrifuged at 13,000 rpm for 1 minute. The flow-through was 
discarded. The composite was further centrifuged at 13,000 rpm for an extra 3 
minutes to remove the residual wash buffer. The spin cartridge was then placed into a 
1.5-ml recovery tube. 100 |il of the pre-warmed TE was added directly to the center 
of the spin cartridge and the composite was incubated at room temperature for 1 min. 
Purified plasmid DNA was eluted and collected by centrifuging the composite at 
13,000 rpm for 3 minutes. 
2.1.1.8. Screening for recombinant clones 
Purified bacterial plasmid DNA was screened for the desired insert by digesting 
the plasmid with the corresponding restriction enzymes used in cloning procedures. 
Each digestion reaction mixture was composed of corresponding restriction enzymes 
used in cloning and One-Phor-All Buffer at the required concentration. 5 }.ig of 
purified bacterial plasmid DNA and appropriate amount of nano-pure water were 
added to make up the final total volume to 20 )il. The digestion reaction mix was 
incubated at 37°C for 2 hours. The digested plasmid was analyzed on a 1% TAE 
- 、 
agarose gel pre-stained with ethidium bromide and visualized under ultraviolet light. 
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2.1.1.9. DNA sequencing of cloned plasmid DNA 
Purified bacterial plasmid DNA containing the insert with expected size was 
verified for the reading frame, the vector and insert identities by using dideoxy DNA 
sequencing with Thermo Sequenase™ Cycle Sequencing Kit (USB, CA, USA). 
Appropriate IRDyeTOO- and IRDye800- fluorescent-labeled sequencing primers were 
used. 
lOOng of the purified plasmid DNA was combined with the master mix 
containing 3 i^l of reaction buffer, 1.5 |il of florescein-labelled primer (either 
pEGFP-Cl forward or reverse primer), 1 of thermo Sequenase and appropriate 
amount of nano-pure water to give a final volume of 25 [il 6 i^l of this final master 
mix solution was added to different reaction tubes, each containing 2 of either 
ddATP, ddCTP, ddGTP or ddTTP Termination mix. The reaction was performed in 
the thermal cycler and the thermal cycling profile was as follows: denaturation at 
96°C for 5 minutes, followed by 40 cycles of denaturation at 95°C for 30 seconds, 
annealing at 50°C for 30 seconds and primer extension at 72�C for 2 minutes. A final 
extension was given at 72°C for 10 minutes, when the reaction was completed, 4 }.il 
of Stop solution was added to each sample. The sample was then revolved on a 
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Standard slab 5.5% acrylamide gel using a LI-COR 4200 DNA Sequencer (LI-COR, 
Lincoln, Nebraska, USA). The sequencing results were checked by BLAST program 
from NCBI and the accuracy of sequencing was over 99.9%. 
2.1.1.10. Midi-scale preparation of recombinant plasmid DNA 
After the DNA sequence was verified, midi-scale preparation of the purified 
bacterial recombinant plasmid DNA was performed using HiSpeecFM Plasmid Midi 
Kit (QIAGEN, CA, USA). Briefly, the purified recombinant plasmid DNA was 
transformed into chemically competent E. coli DH5a as described previously in 
Section 2.1.1.6. A single colony was picked and inoculated with 150 ml of LB 
medium with the appropriate antibiotics. The bacterial culture was allowed to grow 
at 37°C overnight (16-20 hours) with shaking at 250 rpm. The bacterial cells were 
harvested by centrifugation at 6,000 X g for 15 minutes at 4°C. The supernatant was 
discarded and the pellet was resuspended in 6 ml of Buffer PI by vigorous vortexing. 
Then 6 ml of Buffer P2 was added and mixed gently by inverting the 
plasmid-containing vessel 5 times. The mixture was incubated at room temperature 
for 5 minutes. During the incubation, a cap was screwed onto the outlet nozzle of a 
QIAfilter™ Midi Cartridge. After the 5-minute incubation, 6 ml of Buffer P3 was 
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added to the lysate and the contents were mixed immediately but gently by inverting 
the vessel 5 times. The neutralized lysate was then poured into the barrel of the 
QIAfilterTM Midi Cartridge. The QIAfilter^"^ Midi Cartridge was incubated at room 
temperature for 10 minutes. During the incubation time, a Hispeed Midi Tip was 
equilibrated by applying 4 ml of Buffer QBT. After the 10-minute incubation, the cap 
from the QIAfilterTM outlet nozzle was removed and the cell lysate was filtered into 
the equilibrated Hispeed"™ Midi Tip by inserting and pressing the plunger into the 
QIAfilterTM Midi Cartridge. The cell lysate was allowed to enter the resin by gravity 
flow. The Hispeed™ Midi Tip was washed with 20ml of Buffer QC and the bound 
DNA was eluted with 5 ml of Buffer QF. 3.5 ml of analytical grade isopropanol was 
added to precipitate DNA at room temperature and the contents were mixed and 
incubated at room temperature for 10 minutes. During the incubation, the plunger 
from a 20 ml syringe was removed and a Q I A p r e c i p i t a t o r T M Midi Module was 
attached onto the outlet nozzle. After the 20-minutes incubation, eluate/ isopropanol 
mixture was transferred into the 20 ml syringe. The mixture was filtered by inserting 
the plunger into the 20 ml syringe. The Q I A p r e c i p i t a t o r T M was removed from the 20 
ml syringe and the plunger was pulled out. Then the Q I A p r e c i p i t a t o r T M was 
reattached to the 20 ml syringe. The bound DNA was dried by inserting the plunger 
again and pressing air through the Q I A p r e c i p i t a t o r ™ . The plunger was removed 
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from a new 5 ml syringe and the QIAprecipitator^M was transferred from 20 ml 
syringe to the new 5 ml syringe. 200 of Buffer TE was added to the 5 ml syringe 
and the plunger was inserted and pressed to elute the purified recombinant bacterial 
plasmid DNA into a 1.5 ml collection tube. Concentration of the eluted recombinant 
DNA plasmid was measured by spectrophotometer at 260nm. 
2.1.2. Cell culture 
2.1.2.1. Sub-culture of VeroE6 and HepG2 cell lines 
VeroE6 (VE6) cell line was the generous gifts from Prof. W.T. Cheung 
(Department of Biochemistry, The Chinese University of Hong Kong). It was 
maintained in Dulbecco's modified Eagle's medium (DMEM) medium (Gibco BRL 
Life Technologies, Inc, Carlsbad, CA，USA) with 10%; fetal bovine serum (FBS) and 
1% Penicillin-streptomycin (PS) antibiotic mixture. The VE6 cell line was initiated 
from the kidney of a normal adult African green monkey. It is widely used in many 
virus studies including SARS-virus research studies since initial reports showed that 
the SARS-CoV could be cultured in the VE6 cells. 
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HepG2 cell line was purchased from American Type Culture Collection (ATCC, 
Manassas, VA, USA). HepG2 is a human hepatocellular carcinoma cell line, which 
was derived from liver tumor biopsies obtained during extended lobotomies of a 
15-years-old Caucasian male from Argentina. It was maintained in RPMI medium 
(Gibco BRL Life Technologies, Inc, Carlsbad, CA，USA) with 10% FBS and 1% PS 
antibiotic mixture. All cell lines were within the 20th passage throughout 
experiments. 
2.1.2.2. Transient transfection of GFP fusion construct 
VE6 cells were seeded in the 6-well plate containing sterile cover glass with 
complete DMEM medium and maintained in a humidified 5% CO2, 95% air at 37°C 
incubator 24 hours before transfection. When the cells reached 80% confluence， 
transient transfection was performed using the LIPOFECTAMINE™ and 
LIPOFECTAMINE PLUS™ Reagents (Invitrogen Carlsbad, CA, USA). Briefly, for 
each well of transfection reaction, 1 i^g pEGFP-Cl or pEGFP-Cl-SARS-CoV-N 
expression vector was diluted with 100 [i\ of serum-free DMEM medium. Then 6 
of PLUS Reagent was added and incubated at room temperature for 15 minutes. 
Meanwhile, 4 |il o f L i p o f e c t A M I N E Reagent was diluted by 100 of serum-free 
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medium in another tube. After incubation, the pre-complexed DNA and the diluted 
LIPOFECTAMINE Reagent were mixed and allowed for another 15 minutes 
incubation at room temperature. Meanwhile, the growth medium in 6-well plate was 
aspirated. The cells were washed briefly by IX phosphate-buffered saline (PBS) to 
remove trace of antibiotics that might hinder the transfection reaction. It was then 
replaced with 0.8 ml of serum-free medium. After incubation, 
DNA-PLUS-LipofectAMINE Reagent complexes were added into the cells, which 
were then incubated at the humidified 37°C incubator with 5% CO2 for 3 hours. After 
3 hours of incubation, the serum-free medium was replaced with 2 ml of complete 
DMEM medium and the cells were allowed to grow for 24 hours. The transfection 
efficiency was around 20-30%. Similar transfection reaction was performed using 
HepG2 cell line, which was maintained in RPMI medium. 
� 
2.1.3. jEpf-fluorescence microscopy 
After 24 hours of protein expression, the cells were rinsed with IX PBS twice 
and fixed with 1ml of 3.7% para-formaldehyde for 15 minutes at room temperature. 
After the fixation, the cells were washed with IX PBS twice. The cells were then 
stained with 300 of 300nM DAPI at room temperature for 30 minutes in ckikness. 
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Finally, the cells were washed again with IX PBS for 3 times and mounted onto 
glass microscope slides using mowiol for microscopic analysis. Cells expressing 
EGFP or EGFP-SARS-CoV-N protein were imaged using 488nm excitation and 530 
nm emission. Images were captured by the CCD camera (Nikon TE2000 
microscope). 
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2.2. Study on differential gene expression patterns upon SARS-CoV 
nucleocpasid induction by cDNA microarray analysis 
2.2.1. Cloning of SARS-CoV N gene into mammalian expression vector 
pCMV-Tagl 
The pEGFP-SARS-CoV-N mammalian expression vector was used as the 
template for PCR. Forward primer (5'-TAG GGC AAG ATC TAT GTC TGA TAA 
TGG ACC CCA ATC AAA CCA A-3') and reverse primer (5'-TAG GGC GGT ACC 
TTA TGC CTG AGT TGA ATC AGC AGA AGC TCC-3') were designed to have 
BglW and Knp\ restriction sites at their 5，ends respectively. 
The PCR was performed in the presence 0.2|^g of pEGFP-SARS-CoV-N 
template, 0.5|aM of both forward and reverse primers, 1 unit of Advantage cDNA 
polymerase mix (BD Biosciences Clontech, CA, USA), 2mM of dNTP, IX 
Advantage cDNA polymerase buffer and sterile nano-pure water in 50 volume. 
The thermal cycling profile was as follows: denaturation at 94�C for 5 minutes, 
followed by 35 cycles of denaturation at 94°C for 36 seconds, annealing at 55°C for 
36 seconds and primer extension at 68°C for 1 minute and 45 seconds. A final • 
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extension was given at 68°C for 10 minutes. The thermal cycling was carried out in a 
PTC-100 Programmable Thermal Controller (MJ Research Inc., South San Francisco, 
CA，USA). The PGR product was then electrophoresed on a 1 % TAE agarose gel 
pre-stained with ethidium bromide and visualized under UV. The desired PGR 
amplified fragment was excised from the 1% TAE agarose gel and the purification of 
the PGR product was carried out using GENECLEAN™ III kit as described in 
Section 2.1.1.2. 
The purified" PGR product was digested with Bglll and Kpnl in 1.5X 
One-Phor-All PLUS buffer (Amersham, Uppsala Sweden) at 37°C for 2 hours. 
Meanwhile, l|ig of pCMV-Tagl (Stratagene, CA, USA) vector was digested in 
parallel with the same conditions. The digested PGR product and pCMV-Tagl vector 
•  were analyzed on a 1 % TAE agarose gel and then purified by the GENECLEAN"™ 
kit as described in Section 2.1.1.2. The purified digestion product was ligated into the 
linearised pCMV-TagI vector with compatible ends in a molar ratio of approximately 
1:3 of expression vector to insert DNA. The ligation reaction mixture was incubated 
at 16°C overnight. Negative control using sterile distilled water instead of DNA 
insert was performed in parallel. The ligation product was then transformed into 
E.coli. strain DH5a and grown on a LB agar plate containing antibiotic kanamycin 
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(50 i^g/ml) for selection at 37°C overnight. The clones were screened and DNA 
sequencing was carried out to verify the correct insert in the recombinant plasmid. 
Midi-scale of recombinant plasmid DNA was prepared for the transfection later on. 
2.2.2. Cell culture 
2.2.2.1. Sub-culture of VeroE6 cell line 
Identical to Section 2.1.2.1. 
2.2.2.2. Transient transfection of pCMV-Tag-l-SARS-CoV-N construct 
VE6 cells were seeded in 100-mm dish with complete DMEM medium and 
maintained in a humidified 5% CO2, 95% air at a 37C incubator 24 hours before 
transfection. When the cells reached 80% confluence, transient transfection was 
performed using the LIPOFECTAMINE™ and LIPOFECTAMINE PLUS™ 
Reagents (Invitrogen Carlsbad, CA, USA). In general, for each 100-mm dish of 
transfection reaction, 4 fig of pCMV-Tag-1 -SARS-CoV-N expression vector or 
pCMV-Tag-1 empty vector as the control was diluted with 750 of serum-free 
DMEM medium. Then 20 [i\ of PLUS Reagent was added and incubated at room 
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temperature for 15 minutes. Meanwhile, 30 [i\ of LipofectAMINE Reagent was 
diluted by 750 |li1 of serum-free medium in another tube. After incubation, the 
pre-complexed DNA and the diluted LIPOFECTAMINE Reagent were mixed and 
allowed for another 15 minutes incubation at room temperature. Meanwhile, the 
growth medium in the 100-mm dish was aspirated. The cells were washed briefly by 
IX PBS to remove trace of antibiotics in the dish, which might hinder the 
transfection reaction. It was then replaced with 5 ml of serum-free medium. After 
incubation, DNA-PLUS-LipofectAMINE Reagent complexes were added into the 
cells, which were then incubated at 37�C at 5% CO2 for 3 hours. After 3 hours of 
incubation, the serum-free medium was replaced with 10 ml of complete DMEM 
medium and the cells were allowed to grow for 48 hours. 
2.2.3. Total RNA isolation 
2.2.3.1. Total RNA isolation by RNeasy Mini Kit 
The total RNA was extracted from the transfected cells after 2-days incubation. 
RNeasy Mini Kit (QIAGEN, CA, USA) was applied for the total RNA extraction, 
instead of the TRIzol reagent, so as to obtain a better quality and quantity of total 
RNA for cDNA microarray analysis. Since the RNeasy columns exclude certain 
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contaminants that may give rise to a falsely higher spectrophotometric reading, 
including carried-over phenol and transcripts shorter than 200 nucleotides in length, 
which may happens if using TRIzol reagent. By using the RNeasy Mini Kit, the RNA 
molecules with low-molecular weights, such as the 5S rRNA, and tRNA, which 
might make up 15-20% of total cellular RNA, was excluded in the total RNA sample. 
The mRNA transcripts of interest in our samples would be enriched. 
The total RNA was isolated according to the manufacturer's instructions. Briefly, 
the transfected cells were trypsinized with Dnase/Rnase-free Trypsin-EDTA solution 
and pelleted by centrifugation at 3000 rpm for 5 minutes at 4°C. The cells were lysed 
by 600 [d of Buffer RLT (kit component). To ensure efficient lysis, the cell pellet was 
loosened thoroughly and the tube was vortexed. Then, one volume of analytical 
•’ grade of 70% ethanol was mixed well with the lysate by pipetting. The mixture was 
then applied to an RNeasy mini column (kit component) placed in a 2 ml collection 
tube. The composite was centrifuged for 15 seconds at 8000 X g in room temperature. 
Any RNA would be absorbed on the RNeasy silica-gel membrane. The flow-through 
was discarded. The column was then washed by adding 700 …of Buffer RWl. The 
composite was centrifuged at 8000 X g for 15 seconds in room temperature. The 
flow-through and collection tubes were discarded. The column was then transferred 
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to a new 2 ml collection tube and 500 jj.1 of Buffer RPE was pipetted onto it. Again, 
the composite was centrifuged at 8000 X g for 15 seconds in room temperature to 
wash the column and the flow-through was discarded. Another 500 jil of Buffer RPE 
was added to the column and centrifuged at 8000 X g for 2 minutes in room 
temperature to dry the membrane. This step was repeated once to eliminate any 
chance of possible carryover of Buffer RPE. To elute the total RNA, the column was 
transferred to a new 1.5 ml collection tube and a minimum of 30 |il of 
autoclaved-sterile Dnase/Rnase-free DEPC-nano-pure water was added directly onto 
the silica-gel membrane. The composite was centrifuged at 8000 X for 2 minutes. 
The total RNA was eluted. 
2.2.3.2. Checking of RNA integrity 
The total RNA sample (2 }il) was mixed with 2X RNA loading buffer (2 in 
1:1 ratio. It was heated at 65 °C for 5 min and then chilled on ice for 1 minute. The 
RNA sample was then analyzed on a 2 % non-denaturing agarose gel and visualized 
under UV. Two distinct ribosomal RNA bands, 28S and 18S, with the band intensity 
ratio of 2:1 without smear were observed. This indicated that the total RNA samples 
were isolated with good integrity, and free of degradation and genomic DNA 
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contamination. The samples met the quality standard to ensure that the RNA to be 
hybridized to the gene expression arrays was of the highest quality. 
2.2.3.3. Checking of RNA purity 
The purity of the total RNA samples was checked by measuring their 
absorbance at 260nm and 280nm. According to the manufacturer's requirement, an 
acceptable 260/280 ratio fell in the range 1.8 to 2.1. Ratios below 1.8 would indicate 
possible protein contamination. Ratios above 2.1 would represent presence of 
degraded RNA, truncated cRNA or excess free nucleotides. The 260/280 ratios of 
total RNA samples isolated from pCMV-TagI only and pCMV-Tag 1 -SARS-CoV-N 
transfected cells were 1.9 and 2.0 respectively. 
2.2.3.4. Determinations of total RNA concentrations and precipitation 
The concentration of the RNA samples were measured at 280nm and calculated 
to be lower than the Affymetrix total RNA sample concentration requirement, which 
required to be at least l)ag/|Lil. Thus, the samples were then concentrated with Sodium 
Acetate. Briefly, 1 volume of RNA sample was mixed with 1/10 volume of 3M 
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Sodium Acetate (pH 5.2) and 2 volumes of analytical grade of absolute ethanol. The 
mixture was kept at -70°C overnight. The total RNA was precipitated and collected 
by centrifugation at 12,000 rpm for 20 minutes at 4°C. The supernatant was aspirated. 
The RNA pellet was obtained and dried in air until it became semi-transparent. The 
total RNA was eluted in 2 0|il of DEPC-treated water. Finally, the concentrations of 
the RNA samples were measured again at 280nm and found to meet the 
manufacturer's sample quality standard. The amount of total RNA extracted by VE6 
cells transfected with the control pCMV-Tag-1 empty vector and the test 
pCMV-Tag-l-SARS-CoV-N expression vector were 24 i^g (1.2 |ig/|^l) and 22 |ig (1.1 
|ig/ |J,1) respectively. 15 |j,g of each total RNA sample was sent to the manufacturer 
for Affymetrix analysis, while the remaining portion were stored at -70°C for future 
use of cDNA synthesis on the confirmation of Affymetrix results by RT-PCR. 
2.2.4. cDNA microarray (done by Affymetrix Inc.,CA, USA, as a customer 
service) 
2.2.4.1. Precipitation of RNA 
The total RNA sample was mixed with 1/10 volume of 3M Sodium Acetate (pH 
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5.2), 2.5 volume of absolute ethanol, 0.5 |j,l pellet paint and 1 |li1 of 5mg/ml glycogen. 
The mixture was incubated at -20 °C for at least 1 hour. It was then centrifuged at 
12,000 X g for 20 minutes at 4°C. The pellet was washed with 80% ethanol twice. 
After the pellet was dried in air, it was resuspended in DEPC-treated water. 
2.2.4.2. Quantification of RNA. 
The yield of RNA was quantified by spectrophotometric analysis using the 
convention that 1 absorbance unit at 260 nm equaled to 40 |ig RNA per ml. 
2.2.4.3. Synthesis of double-stranded cDNA from total RNA. 
(i) ” First stand cDNA synthesis 
The total RNA sample was mixed with 100 pmol of T7- (dT)24 primer 
(5'-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(dT)24-3') 
,, and incubated at 70°C for 10 minutes for primer hybridization. After incubation, it 
was then centrifuged briefly to bring down condensation on sides of tube and put on 
ice. 4 1^1 of 5X first strand cDNA buffer, 2^1 ofO.lM DTT, 1 i^l of 1 OmM dNTP mix 
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were further added to it and incubated at 42°C for 2 minutes for temperature 
adjustment. Then, 200 units of SuperScript II RT was added to the above mixture and 
further incubated at 42°C for 1 hour to allow for the first stand cDNA synthesis. 
(ii) Second strand cDNA synthesis 
The first strand cDNA synthesis reaction tube was spun quickly and kept on ice. 
It was then mixed with, 30 [d of 5X second strand reaction buffer, 3 |il of 10 mM 
dNTP mix, 10 units of E.coli. DNA ligase, 40 of units E.coli. DNA polymerase I, 2 
units of E.coli. Rnase H and 91 of DEPC-treat H2O to bring up a final volume of 
150 \x\ for the second strand cDNA synthesis and incubated at 16°C for 2 hours in a 
cooling water bath. After 2-hour incubation, 10 units of T4 DNA polymerase was 
added to the above reaction and returned to 16°C for further 5 minutes. Finally, the 
reaction was then terminated by adding 10 |li1 of 0.5 M EDTA. 
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2.2.4.4. Clean-up of double-stranded cDNA 
(i) Phase lock gel (PLG)- phenol/ chloroform extraction 
The phase lock gel (Brinkmann, NY, USA) was first pelleted by centrifugation 
at 12000 X g for 20 to 30 seconds. Phenol: chloroform: isoamyl alcohol (25:24:1), 
which was saturated with 10 mM Tris-HCl pH 8.0, 1 mM EDTA, was mixed with the 
final second strand cDNA preparation reaction in an equal volume. The entire 
cDNA- phenol: chloroform: isoamyl alcohol mixture was transferred to the PLG tube. 
The PLG became a part of the suspension. The cDNA was purified using PLG 
I-Light (Brinkmann, NY, USA) with phenol/chloroform extraction and precipitated 
using ethanol with glycogen as a carrier. The whole composite was centrifuged at 
12000 X g for 2 minutes. The aqueous upper phase was then transferred to a new 1.5 
ml tube. 
(ii) Ethanol precipitation 
0.5 volume of 7.5 M NHUOAc and 2.5 volumes of ice-cold absolute ethanol 
were added to the above sample, vortexed briefly and centrifuged at 12000 X g for 
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20 minutes at room temperature. The pellet was then washed with ice-cold 80 % 
ethanol twice and dried in air. Then, 12 of Rnase free H2O was used to re-suspend 
the pellet. 
2.2.4.5. Synthesis of biotin-labeled cRNA 
cRNA was synthesized by in vitro transcription from 6 |il of double-stranded 
cDNA using the Bio Array High Yield RNA Transcript Labeling Kit (Enzo Life 
Sciences，NY, USA) according to manufacturer's protocol. 
2.2.4.6. Clean-up and quantification of in vitro transcription (IVP) products 
(i) ‘ In vitro transcription clean-up 
The IVP product was pipetted directly onto the silica-gel membrane of the 
QIAGEN RNeasy column and spun for 2 minutes. The flow-through was discarded. 
The IVP product was then eluted with the Rnase-free H2O. 
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(ii) Ethanol precipitation 
0.5 volume of 7.5 M NH4OAC and 2.5 volumes of ice-cold absolute ethanol 
were added to the above sample, vortexed briefly and centrifuged at 12000 X g at 
4°C for 30 minutes. The pellet was then washed with ice-cold 80 % ethanol twice 
and dried in air. The dried pellet was rehydrated in 10 to 20 of Rnase-free H2O. 
(iii) Quantification of cRNA. 
Identical to Section 2.2.3.2. 
(iv) Sample Checking. 
Gel electrophoresis was preformed to ensure the cRNA sample was 
unfragmented. 
2.2.4.7. cRNA fragmentation for target preparation 
.1 
20 \ig of cRNA was composed with 8 of 5X fragmentation buffer and 
appropriate amount of Rnase-free H20 to give a final volume of 40 }il. It was then 
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incubated at 94°C for 35 minutes for cRNA fragmentation by metal-induced 
hydrolysis. After incubation, the reaction mixture was kept on ice. Before proceeding 
to the next step, an aliquot was saved for gel analysis. 
2.2.4.8. Eukaryotic target hybridization 
The probe array was equilibrated to room temperature and subsequently 
pre-hybridized with IX hybridization buffer (60rpm, 45°C) for at least 10 minutes. 
Meanwhile, 100 of hybridization cocktail was prepared by mixing 15 of 
fragmented cRNA，1.7 of 3 nM control oligonucleotide B2, 5 [d of 20X 
eukaryotic hybridization controls (bioB, bioC, bioD and ere), 1 of 10 mg/ ml 
herring sperm DNA, 1 |j,l of 50 mg/ ml bovine serum albumin (BSA), 50 of 2X 
hybridization buffer and distilled H2O. The cocktails were heated to 94°C for 5 
minutes, then 45°C for 5 minutes and subsequently centrifuged at maximum speed 
for 5 minutes to remove any insoluble materials. Sample was then added to the array 
and hybridized at 45°C for 16 hours at 60 rpm in an Affymetrix rotisserie 
hybridization oven. 
61 
Materials & Methods 
2.2.4.9. Probe array washing, staining and scanning 
Streptavidin Phycoerythrin (SAFE) solution mix and antibody solution mix 
were prepared for the array staining. After 16 hours of hybridization, the cocktails 
were removed from the probe array and replaced with non-stringent wash buffer A. 
Washing and staining were performed in an automated fluidics station using the 
EukGEws2v4 fluidics protocol. The probe array was then scanned using an 
Affymetrix scanner (either GCS3000 laser scanner or GeneArray Scanner 2500A). 
2.2.5. Confirmation of results by RT-PCR 
A number of genes was reported to be upregulated or downregulated from the 
results of Affymetrix. In order to confirm the results, the differential expression 
patterns of the affected genes were confirmed by RT-PCR using the same batch of 
total RNA isolated for Affymetrix analysis. 
2.2.5.1. First-strand cDNA synthesis 
> 
Reverse transcription (RT) reactions were performed using 2 [ig of total RNA 
prepared in Section 2.1.3. for a 20 |il reaction mixture using the ThermoScript™ 
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RT-PCR system (Invitrogen Carlsbad, CA, USA). Briefly, template RNA was first 
mixed with 2.5 fil 100 \xM oligo-dT primer and the mixture was denatured at 65°C 
for 5 minutes. Following incubation, 4 \i\ of 5X cDNA synthesis buffer, 2 )il of 10 
mM dNTP mix, 1 )al of 0.1 M DTT, 1 i^l of RNaseOUT, 1 (15 units) 
T h e r m o S c r i p t T M RT and appropriate amount of DEPC-treated water were added to 
the pre-warmed RNA-primer mixture to make up a final volume of 20 fil. The 
reaction was carried out at 55°C for 1 hour. Then it was terminated by incubation at 
85°C for 5 min. After the termination process, 2 units of RNase H was added and 
incubated at 37°C for 20 min. The first-strand cDNA synthesized was stored 
at-20°C until use. 
2.2.5.2. RT-PCR of candidate gene 
The cDNA was first normalized with housekeeping gene GAPDH with forward 
primer (5' -ACC ACA GTC CAT GCC ATC ACT GCC A- 3') and reverse primer 
(5，-TCC ACC ACC CTG TTG CTG TAG CCA A- 3'). The PGR was performed at 
25 cycles of 95�C for 36 seconds, 58�C for 36 seconds and 72°C for 1 minute using 
Taq polymerase. The PGR product was analyzed by 1% TAE agarose gel pre-stained 
with ethidium bromide and visualized under UV. The normalized template was then 
used for the amplification of candidate gene using the gene -specific primer pair 
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(Table 1). Briefly, the PCR was performed at 35 cycles denaturation, annealing and 
primer extension. Again, the PCR product was analyzed on a 1 % TAE agarose gel 
pre-stained with ethidium bromide and visualized under UV. 
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Table 1. Primer sets used in RT-PCR of the candidate gene to confirm the 
differential expression level. (*: The expression of SARS-CoV nucleocapsid mRNA 
was checked to ensure that it was only expressed in the experimental sample. 
GAPDH was used as the housekeeping gene for normalization) 
Genes of Interested Forward Primers (5'--> 3') Reverse Primers (5'-->3') 
SARS-CoV CTT CCC TAG GGC GCT AAC GGC CTT GTT GTT GTT GGC 
nucleocapsid* AAA GAA CTT TAG 
TCG ACC GTT CCG TCA GGT AGC GGT TGA AGT 
H0XA7 GGC TTA TAG AAT GGA ACT 
ACC ACA GTC CAT GCC ATC TCC ACC ACC CTG TTG CTG 
GAPDrf ACT GCC A TAG CCA A 
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2.3. In vitro RNA interference of SARS-CoV nucleocapsid 
2.3.1. siRNA target site selection 
The siRNA target sites were selected using the online "siRNA Target Finder" 
from Ambion. Generally, the transcript of interest was scanned for AA dinucleotide 
sequence. The 3, adjacent 19 nucleotides of each AA were recorded as the potential 
siRNA target sites. This strategy for selecting siRNA target sites was based on the 
experimental observations that the siRNA with 3，overhanging UU dinucleotide were 
the most effective (Elbashir et al, 2001). After scanning the full-length of 
SARS-CoV nucleocapsid gene sequence, it was noted that more than a hundred of 
such target sequences existed. First, stretches of T or A with 4 repe:its or more in t!ic 
target sequence was excluded because a 4-6 nucleotide polyT tract would act as a 
terminal signal for RNA polymerase III. Then, others with lower GC contents 
(30-50%) were selected for further screening. As some regions of mRNA. may be 
either highly structured or bound by regulatory proteins, generally the siRNA target 
*. ‘ 
sites at different positions along the length of the gene sequence and those located in 
the open-loop regions of mRNA structure were selected. Those selected potential 
siRNA target sequences were then compared to human genome database by the 
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BLAST search at NCBI server. In order to create the gene-specific siRNA, target 
sequences with more than 16-17 contiguous base pairs of homology to other coding 
sequences were eliminated from consideration. Finally, 4 siRNA target sites were 
selected (Table 2). A sequence that targeted the SARS-CoV spike gene was selected 
as the negative control for the experiment. A sequence provided by Ambion Inc., TX, 
USA, which specifically targeted the green fluorescent protein was employed as the 
positive control. The complementary oligonucleotides of the target siRNA sequences, 
and the negative and positive controls were synthesized by Invitrogen for annealing 
to give the shRNA inserts (Table 3). 
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Table 2. Selected target sequences for examination of their RNAi effects on 
SARS-CoV nucleocapsid gene. The SARS-CoV nucleocapsid gene sequence was 
scanned for AA dinucleotide sequence. The 3' adjacent 19 nucleotides of each AA 
were recorded as the potential siRNA target sites. An siRNA sequence that targets the 
SARS-CoV spike gene was selected as the negative control and a sequence provided 
by Ambion Inc that specifically targeted the green fluorescent protein was employed 
as the positive control. The A A dinucleotide sequence was underlined and the 
starting nucleotide in each target sequence (except the AA dinucleotide) was bold. 
The GC contents of the target sequences are also indicated. 
Gene Targets Position in 
SARS-CoV Target sequence (5，--> 3') GC 
N gene sequence (sense strand) Content 
SARS-CoV 
nucleocapsid 79 AA TAA CCA GAA TGG AGG ACG C 47.6% 
SARS-CoV 
’ nucleocapsid 734 AA ACT GTC ACT AAG AAATCT G 33.3% 
SARS-CoV 
nucleocapsid 1027 AA AG A TCC AC A ATT C AA AG A C 33.3% 
SARS-CoV 
nucleocapsid 1066 AA GC A CAT TGA CGC ATA CAA A 38.1% 
SARS-CoV 
spike -- M TGT t a g AGG GTT TCA TAG T 33.3% 
Green fluorescent 
protein -- M GGT TAT GTA CAG GAA CGC A 42.9% 
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Table 3. Sequences of oligonucleotide pairs for generation of shRNA inserts 
shRNA inserts Top strands (5--> 3') Bottom strands (5,--> 3') 
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Table 3 (continued) 
shRNA inserts Top strands (5-> 3') Bottom strands (5,--> 3') 
S-siRNA GATCCG TGTTACAGGGTTTCATACT AGCTTTTCCAAAA 
TTCAAGAGA AATGTTACAGGGTTTCATACT 
AGTATGAAACCCTGTAACATT TCTCTTGAA 
TTTTGGAAA AGTATGAAACCCTGTAACA CG 
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2.3.2. Cloning of target siRNA sequences into ^Silencer 3.1-Hl vector 
To clone the hairpin siRNA insert into TpSilencer 3.1-H-hydro vector (Ambion, 
TX, USA), the hairpin siRNA template oligonucleotide was dissolved in 
nuclease-free H2O to give the concentration of about 1 \igl Then, the annealing 
reaction was assembled with 2 of both the sense and anti-sense oligonucleotides 
and 46 of IX DNA annealing to give a final volume of 50 \i\. The mixture was 
heated to 90�C for 3 minutes, followed by cooling to 37�C and incubation at 37°C 
for 1 hour. The annealing siRNA template insert was then ligated into the pSilencer 
3.1-HI vector. The ligation product was then transformed in E.coli. strain DH5a and 
grown on a LB agar plate containing selection antibiotic ampicillin (100 |Lig/ml) 
overnight for selection. The clones were screened and DNA sequencing was carried 
out to verify the correct insert in the recombinant plasmid. Midi-scale of recombinant 
plasmid was prepared for the transfection later on. 
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2.3.3. Cell culture 
2.3.3.1. Sub-culture of VeroE6 cells 
Identical to Section 2.1.2.1. 
2.3.3.2. Transient co-transfection 
VE6 cells were seeded in 60-mm^ dish with complete DMEM medium and 
maintained a day before transfection. When the cells reached 80% confluence， 
transient transfection was performed using the LIPOFECTAMINE™ and 
LIPOFECTAMINE PLUS™ Reagents (Invitrogen Carlsbad, CA, USA) according to 
the manufacturer's instructions. Cells were co-transfected with 1.5 |ag of the 
SARS-CoV nucleocapsid protein expression plasmid pCMV-TagI -SARS-CoV-N and 
the siRNA- ^Silencer 3.0-Hl vectors. 0.5}ag of pEGFPCl vector was also 
co-transfected with each reaction to monitor the transfection efficiency in each 
reaction. After transfection, the cells were maintained in serum-supplemented 
DMEM medium for 48 hours before harvesting. 
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2.3.4. Detection of SARS-CoV nucleocapsid mRNA expression level by 
RT-PCR 
2.3.4.1. Total RNA isolation by TRIzol reagent 
After 2 days of incubation, the cells were washed twice by DEPC-treated IX 
PBS. Then 1 ml TRIzol Reagent was added into each 60mm^ dish and incubated at 
room temperature for 3 minutes. The TRIzol mixture was centrifuged at 12,000 x g 
for 15 minutes at 4°C. After centrifugation, the supernatant was transferred into a 
new tube and avoided to touch the pellet. 0.3 ml of chloroform was then added and 
vortexed for 15 seconds and incubated at room temperature for 2 minutes. The 
mixture was centrifuged at 12,000 x g for 15 minutes at 4°C. The upper aqueous 
’layer was saved and 0.75 ml 1 of 00% isopropanol was added into the aqueous 
solution for RNA precipitation. The mixture was incubated at room temperature for 
10 minutes and centrifuged at 12,000 x g for 10 minutes at 4°C. Following 
centrifugation, the supernatant was discarded and the pellet was washed with 2 ml of 
75% ethanol. Then the sample was centrifuged at 7,500 x g for 5 minutes iX 4�C and 
the pellet was dried in 70°C oven for 10 minutes. Finally, the RNA pellet was 
dissolved in 22 i^l DEPC-dHiO. 2 [il of the RNA sample was mixed with 2X RNA 
73 
Materials & Methods 
loading buffer in 1:1 ratio. It was heated at 65 °C for 5 min and then chilled on ice 
for 1 minute. The RNA sample was then analyzed on a 1 % TAE agarose gel and 
visualized under UV to check for its integrity. The RNA sample was stored at -70°C. 
2.3.4.2. First-strand cDNA synthesis 
Identical to section 2.2.5.1. 
2.3.4.3. RT-PCR assays 
Normalization of cDNA template by housekeeping gene GAPDH was carried 
out. The normalized template was then used for the amplification of SARS-CoV 
”nucleocapsid using its specific primer pair (Forward primer: 5'- CTT CCC TAC 
GGC GCT AAC AAA GAA-3' and reverse primer: 5'- GGC CTT GTT GTT GTT 
GGC CTT TAC-3'). The PGR was performed at 30 cycles of denaturation at 95°C 
for 36 seconds, annealing at 58�C for 36 seconds and primer extension at 72°C for 45 
seconds. The PGR product was analyzed on a 1 % TAE agarose gel pre-stained with 
ethidium bromide and visualized under UV. 
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2.3.5. Detection of SARS-CoV nucleocapsid protein expression level by 
Western blotting 
2.3.5.1. Total protein extraction 
The transfected cells were washed twice with PBS and trypsinized. The cells 
were collected by centrifugation at 3,000 rpm for 5 minutes at 4�C. Cell pellets were 
washed with IX PBS twice and collected by centrifugation. Cell pellets were then 
lysed in 100 |il of lysis buffer on ice for 30 minutes. The cell debris was spun down 
at 15,000 rpm for 20 minutes at 4C. Supernatant was collected and stored at -70°C 
for further assays. 
2.3.5.2. Protein quantification 
The protein content in the cell lysate was determined by the Bio-Rad Protein 
Assay from Bio-Rad Laboratories (Hercules, CA, USA) with BSA (Sigma, St. Louis, 
MO, USA) as the protein standard. IX Bradford solution was prepared by diluting 
one part of Bradford dye reagent concentrate (5X) (Bio-Rad Laboratories, Hercules, 
CA, USA) with four parts of double distilled water. BSA solutions at 0.2 mg/ml, 
75 
Materials & Methods 
0.4mg/ml, 0.6mg/ml and 0.8mg/ml were prepared with sterilized distilled water in 
duplicate from 1 mg/ml BSA stock solution by serial dilution. Cell lysate samples 
were diluted in 50-fold with sterilized distilled water. Diluted BSA standards or cell 
lysate samples (20 |li1) were mixed with 1ml of IX Bradford solutions in a plastic 
cuvette. Both standards and samples were measured in duplicate. The reaction 
mixtures were allowed to stand at room temperature for 15 minutes before the 
absorbance at 595 nm was recorded. The concentrations of protein samples were 
determined spectrophotometrically. Equal amount (50 |Lig) of protein samples were 
subjected to SDS-PAGE analysis. 
2.3.5.3. Protein separation by SDS-PAGE and Western blot 
SDS-PAGE was earned out to resolve cellular proteins according to their 
molecular weights. Samples containing the same amount of protein (50 |ig) were 
mixed with 6X SDS gel loading buffer and boiled for 10 minutes before loading onto 
SDS-polyacrylamide gel with a 5 % stacking gel (0.625 ml of 40% Acrylamide，0.63 
ml of 0.8M Tris buffer pH 6.8，50 i^l of 10% SDS, 50 [i\ of 10% APS, 5^1 ofTEMED 
and 3.605 ml of sterile distilled water). The protein samples were electrophoresed on 
12% SDS-polyacrylamide gel (3 ml of 40% Acrylamide, 2.5 ml of 1.5M Tris buffer 
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pH8.8, 100 [il of 10% SDS, 100 of 10% APS, 4 of TEMED and 4.3 ml of 
sterile distilled water) in IX Tris-Glycine buffer (25mM Tris-HCl, 250mM Glycine, 
0.1% SDS). 2 1^1 of the Full-range rainbow markers (Amersham, Uppsala, Sweden) 
were loaded as molecular weight marker and the gel was run at constant a voltage of 
180V for 1.5 hours. 
The stacking gel was removed after electrophoresis. In order to remove residual 
SDS, which could hinder protein transfer, the running gel was rinsed briefly with 
distilled water and then equilibrated in transfer buffer (25mM Tris-HCl, 192mM 
Glycine, 20% v/v methanol) for 10 minutes. Thereafter, protein transfer apparatus, 
OWI Panther Semi-dry Electroblotter (20 cm x 20 cm) (Bio-Gene Technology, West 
Perth, Western Australia), was set up. The gel and one piece of I m m o b i l o n ™ - p 
Transfer Membrane were placed in between two sets of 2 pieces of 3 MM Whatmann 
chromatography papers (Kent, UK). The chromatography papers and transfer 
membrane were soaked with transfer buffer before assembled into the electroblotter. 
Air bubbles were excluded by rolling a glass test tube on the membrane. The proteins 
on the gel were then electroblotted onto the I m m o b i l o n T M - P Transfer Membrane at 
20 volts for 1 hour. After the transfer, the membrane was incubated with 5% 
skimmed milk in IX TEST washing buffer (20mM Tris-HCl, 137mM NaCl, 0.05% 
7 7 
Materials & Methods 
Tween-20) with constant shaking for 45 minutes to block the non-specific sites prior 
to antibody binding. 
The membrane was then hybridized with the mouse monoclona' anti-flag 
primary antibodies (Stratagene, CA, USA) at a ratio of 1:1000 (v/v) in 10% non-fat 
milk in IX TEST at 4°C for overnight. After binding with primary antibody, the 
membrane was briefly rinsed with washing buffer once and then washed with 
washing buffer for three times, 10 minutes for each time. After washing, the 
membrane was incubated with horseradish peroxidase-linked secondary antibody in 
blocking buffer (1:2000) for 1 hour at room temperature with rotation. Followed by 
three washes with IX TEST washing buffer for a total of 30 min, the membrane was 
subjected to western blot detection. 
2.3.5.4. Western blot analysis 
The signal was detected by the Enhanced Chemluminescence Plus (ECL-Plus) 
dectection kit (Perkin Elmer, MA, USA). Equal volumes of western blotting luminol 
detection solution A was freshly mixed with solution B and then pipetted onto the 
membrane. About 20 |il of the detection reagent was required for each cm of 
membrane. The membrane was tilted back and forth to ensure that the entire surface 
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of the membrane was evenly covered with the detection reagent and was allowed to 
stand for about 1 minute. Excessive reagent was removed by holding the membrane 
vertically and touching the edge of the membrane against a piece of tissue paper. The 
membrane was covered by a transparent screen and placed in the film cassette with a 
piece of X-ray film inside. The X-ray film was allowed to expose in a cassette for 1 
to 5 minutes. Finally, the film was developed and fixed. 
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2.4. Humanprothrombinase promoter analyses 
2.4.1. Cloning of the full-length human fgl2 prothrombinase promoter 
construct into a promoterless mammalian expression reporter vector-
pGL3-Basic 
The primer pair flanking the region of the full-length humanyg/2prothrombinase 
promoter was designed according to its DNA sequence on NCBI (NCBI Accession 
number: AH007300). The 5'-flanking region was amplified from the human genomic 
DNA. The forward primer: 5’-TAG GGC GGT ACC GAT CTA GGG TTG GAA 
GCC-3'and reverse primer: 5'-TAG GGC AGA TCT GCT CCT CAC CCC AGC -3 ' 
were designed with Kpn/ and Bgl// restriction enzyme cutting sites at their 5' ends 
respectively. The PGR was performed under the following conditions: denaturation at 
94�C for 5 minutes, followed by 35 cycles of denaturation at 94�C for 36 seconds, 
annealing at 53°C for 36 seconds and primer extension at 68�C for 2 minutes, with a 
final extension at 68°C for 10 minutes. The PGR product was electrophoresed on 1% 
TEA agarose gel pre-stained with edithium bromide. The desired PGR amplified 
fragment was excised from the 1% TAE agarose gel and the purification of the PGR 
product was carried out using GENECLEANTm j j j kit as described in Section 2.1.1.2. 
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The purified PGR product was digested with Kpnl and BglW in 1.5 X One-Phor-All 
PLUS buffer (Amersham, Uppsala, Sweden) at 37°C for 2 hours. Meanwhile, of 
pGL3-Basic vector was digested in parallel with the same conditions. The digested 
PCR product and pGL3-Basic vector were analyzed on a 1 % TAE agarose gel and 
then purified by the GENECLEAN™ kit as described in Section 2.1.1.2. The 
purified digestion product was ligated into the promoterless pGL3-Basic reporter 
vector (Promega，Madison, USA) containing the coding region for the firefly 
{Photinus pyralis) luciferase as the reporter gene. They were ligated with compatible 
ends in a molar ratio of approximately 1:3 of expression vector to DNA insert. The 
ligation reaction was incubated at 16°C overnight. Negative control using sterile 
distilled water instead of DNA insert was performed in parallel. The ligation product 
was then transformed into E.coli. strain DH5a and grown on a LB agar plate 
containing selection antibiotic ampicllin (lOO^g/ml) overnight for selection. The 
clones were screened and DNA sequencing was carried out to verify the correct 
insert in the recombinant plasmid. Midi-scale of recombinant plasmid DNA was 
prepared for the transfection later on. 
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2.4.2. Cloning of SARS-CoV Membrane gene into the mammalian 
expression vector pCMV-TagI 
The SARS viral cDNA, strain CUHK-Wl was used as the template for the 
amplification of full-length cDNA of SARS-CoV Membrane (M) gene in this PGR 
reaction mixture. Forward primer 5'-TAG GGC AAG ATC TAT GGC AGA CAA 
CGG TAC TAT TAC CGT TGA G -3，and reverse primer 5'-TAG GGC GGT ACC 
TTA CTG TAC TAG CAA AGC AAT ATT GTC GTT-3' were designed to have Bglll 
and Knpl restriction sites at their 5' ends respectively. 
The PGR was performed in the presence 0.2|^g of SARS viral cDNA, 0 . 5 | l i M of 
both forward and reverse primers, 1 unit of Advantage cDNA polymerase mix (BD 
‘Biosciences Clontech, CA, USA), 2mM of dNTP, IX Advantage cDNA polymerase 
buffer and sterile nano-pure water in 50 |al volume. The thermal cycling profile was 
as follows: denaturation at 94°C for 5 minutes, followed by 35 cycles of denaturation 
at 94�C for 36 seconds, annealing at 58°C for 36 seconds and primer extension at 
68°C for 1 minute and 45 seconds. A final extension was given at 68°C for 10 
minutes. The thermal cycling was carried out in a PTC-100 Programmable Thermal 
Controller (MJ Research Inc., South San Francisco, CA, USA). The PGR product 
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was then electrophoresed on a 1 % TAE agarose gel pre-stained with ethidium 
bromide and visualized under UV. The desired PCR amplified fragment was excised 
from the 1% TAE agarose gel and the purification of the PCR product was carried 
out using GENECLEANTM m kit as described in Section 2.1.1.2. 
The purified PCR product was digested with Bglll and Kpnl in 1.5X 
One-Phor-All PLUS buffer (Amersham, Uppsala, Sweden) at 37°C for 2 hours. 
Meanwhile, l^g of pCMV-TagI (Stratagene，CA, USA) vector was digested in 
parallel with the same conditions. The digested PCR product and pCMV-TagI vector 
were analyzed on a 1 % TAE agarose gel and then purified by the GENECLEAN™ 
kit as described in Section 2.1.1.2. The purified digestion product was ligated into the 
linearised pCMV-TagI vector with compatible ends in a molar ratio of approximately 
1:3 of expression vector to insert DNA. The ligation reaction mixture was incubated 
at 16°C overnight. Negative control using sterile distilled water instead of DNA 
insert was performed in parallel. The ligation product was then transformed into 
E.coli. strain DH5a and grown on a LB agar plate containing antibiotic kanamycin 
(50 i^g/ml) for selection at 37°C overnight . The clones were screened and DNA 
sequencing was carried out to verify the correct insert in the recombinant plasmid. 
Midi-scale of recombinant plasmid DNA was prepared for the transfection later on. 
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2.4.3. Cell culture 
2.4.3.1. Sub-culture of HepG2 and VeroE6 cell lines 
Identical to Section 2.1.2.1. 
2.4.3.2. Transient co-transfection of the full-length humin fgl2 
prothrombinase promoter construct with the pCMV-TagI empty vector, 
pCMV-Tagl-SARS-CoV M expression vector, or pCMV-Tagl-SARS-CoV N 
expression vector 
50,000 of VE6 cells were seeded on a 24-well plate with complete DMEM 
medium a day before transfection. Cells were co-transfected with either 0.4)ig of 
pGL3-Basic plasmid or the recombinant pGL3-basic-7^/2 contruct and the empty 
vector pCMV-TagI (as negative control 1)，pCMV-Tag 1 -SARS-CoV Membrane 
protein expression vector (as negative control 2) or pCMV-TagI-SARS-CoV 
Nucleocapsid protein expression vector (as the test group) at different concentrations 
(0.01 jig, 0.05 [ig, 0.1 |Lig) according to the manufacturer's instructions. 0.04fag (1/10 
concentration of firefly luciferase reporter plasmid) of Renilla {Renilla reniformis) 
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luciferase construct, pRL-CMV (Promega，Madison, USA), was co-transfected in 
each reaction as an internal control for normalizing the transfection efficiency. After 
transfection, the cells were maintained in serum-supplemented DMEM medium for 
48 hours before harvesting. 
2.4.4. Dual-Luciferase Reporter Assay 
At the end of incubation, the activity of the human fgl2 prothrombinase 
promoter under the expression of different concentrations of SARS-CoV membrane 
protein or nucleocapsid protein was assayed using the Dual-Luciferase Reporter 
Assay System (Promega, Madison, WI, USA). The growth medium was removed 
and the cultured cells were washed twice with IX PBS to remove detached dead cells 
and residual growth medium, which might interfere the dual-luciferase assay. After 
complete removal of rinse solution, per well, the transfected cells were lysed in 100 
|Lil of IX freshly prepared Passive Lysis Buffer (PLB) at room temperature for 15 
minutes. The measurement of Firefly luciferase activity and Renilla luciferase 
activity ..were performed sequentially in a siliconized polypropylene tube by the 
Single-Sample Luminometer (Turner Designs Model TD-20/20). Briefly, 20 of the 
cell lysate was added into the tube containing 100 [i\ of Luciferase Assay Reagent II 
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(LAR II). The firefly luciferase activity was measured. Then 100 \i\ of IX freshly 
prepared Stop and Glo Reagent was added to the same tube for measuring the Renilla 
luciferase activity. The firefly luciferase activity was normalized by the Renilla 
luciferase activity and the relative activity was arbitrarily calculated by defining the 
activity of pGL3-Basic vector as one. All transfection groups were done in triplicate. 
2.4.5. Detection of fgl2 mRNA expression level under the induction of 
SARS-CoV nucleocapsid protein by RT-PCR 
2.4.5.1. Total RNA isolation by TRIzol reagent 
Identical to Section 2.3.4.1. 
2.4.5.2. First strand cDNA synthesis 
Identical to Section 2.2.5.1. • 
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2.4.5.3. RT-PCR oifgl2 gene 
The cDNA was first normalized with housekeeping gene GAPDH with forward 
primer 5' -ACC AC A GTC CAT GCC ATC ACT GCC A- 3' and reverse primer 
5, -TCC ACC ACC CTG TTG CTG TAG CCA A-3'. The PGR was performed at 25 
cycles of 95C for 36 seconds, 58C for 36 seconds and 72C for 1 minute using Taq 
polymerase. The PGR product was analyzed by 1% TAE agarose gel pre-stained with 
ethidium bromide and visualized under UV. Normalization of cDNA template by 
housekeeping gene GAPDH was carried out. The normalized template was then used 
for the amplification of a fragment of 448 bp from the exon 1 of the fgl2 mRNA 
using its gene-specific primer pair (Forward primer: 5'-CAG CTG TTC TTG CCA 
CTT ACG GTT-3' and reverse primer: 5'-TTC TCC AGG CGA CCA TGA AGT 
ACA-3，). The PGR was performed at 30 cycles of denaturation at 95°C for 36 
seconds, annealing at 60°C for 36 seconds and primer extension at 72°C for 45 
seconds. The PGR product was analyzed on a 1 % TAE agarose gel pre-st-ined with 




CHAPTER THREE RESULTS 
3.1. Computer analysis of SARS-CoV Nucleocapsid 
The coding region of SARS-CoV nucleocapsid gene is 1269bp in length, which 
encodes a protein with 422 amino acids (Figure 7). According to the DNA 
sequencing result, the nucleotide 28253 was found to have a point mutation from 
'cytosine'(c) to 'thymidine (t) (Figure 7，indicated in green color). This is a single 
nucleotide polymorphism (SNP) that occurs in the nucleocapsid gene sequence 
among different strains of SARS-CoVs, such as Frankfurt 1 (NCBI Accession 
number: AY291315) and FRA (NCBI Accession number: AY310120). This led to a 
change of amino acid residue from Threonine (T) to Isoleucine (I) (Figure 7， 
‘ ind ica ted in blue color) at a.a. 50 of the SARS-CoV N protein sequence. The amino 
acid property at a.a. 50 changed from small hydrophobic group (Threonine) to 
aliphatic hydrophobic group (Isoleucine). This change does not affect the theoretical 
pi value of the SARS-CoV N protein, which is still predicted to be 10.11 (Table 4). 
Although this SNP led to change in amino acid residue at a.a. 50, the folding of the 
SARS-CoV N protein should not be affected since there was no change on the total 
number of charged amino acid residues on the SARS-CoV N protein sequence. The 
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predicted RNA-binding domain at the N-terminal (a.a. residue 45—181) (Huang et 
al, 2004) should also not be affected since the predicted RNA-binding domain (a.a. 
residue 45一181) involved the positively-charged a.a. residues at the N-terminal of 
the SARS-CoV N protein. Though there was a change on a.a. residue 50 from 
Threonine to Isoleucine, both Threonine and Isoleucine a.a. residues are not charged. 
The positively charged loops of p2'-p3' at the N-terminal of the SARS-CoV N 
protein, which were suggested to clamp the RNA against these positively-charged 
P-sheets, was not affected by the change on a.a. residue at 50 from Threonine to 
Isoleucine. Thus, the property of the SARS-CoV N protein should not be affected by 
this SNP that has also been found in other strains of SARS-CoV, such as Frankfurt 1 
(NCBI Accession number: AY291315) and FRA (NCBI Accession number: 
AY310120). 
The predicted molecular size of the SARS-CoV N protein is approximately 
46.025kDa (Table 4), which is similar to the N proteins of other coronavirus 
members ranging from 30 to 50 kDa. The theoretical pi of this viral protein is about 
10.11 (Table 4) and the basic nature of this protein well suits its putative function as 
an RNA-binding protein that interacts with the viral RNA genome to form 
ribonucleocapsid core. ‘ 
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As observed from its amino acid composition analysis by ProtParam (Table 4)，a 
unique feature is found in the SARS-CoV N protein among other coronaviruses. The 
SARS-CoV N protein does not contain any cysteine residues. This implies that any 
self-association of this protein is not mediated by formation of disulfide bridge(s) 
through cysteine residues, which occurs in many coronaviruses. The SARS-CoV 
adopts an alternative conformational strategy to overcome the problem of missing 
cysteine residues. As mentioned in Chapter one Introduction, regions that are 
responsible for the SARS N protein multimerization have been mapped and these 
mutlimerization domains help this viral protein to solve the problem of missing 
cysteine. 
Besides, glycine constitutes more than 10% of the total amino acid composition 
and is the most abundant amino acid residue in the SARS-CoV N protein (Table 4). 




� ^ J . Although it is formally non-polar, its very small side chain, which is only 
an H atom, makes no real contribution to hydrophobic interactions. The gylcine-rich 
feature of the SARS-CoV N protein might allow the protein to adopt multiple 
conformations as a structural protein. And such structural flexibility ehables the 




A good example to illustrate the structural flexibility of a glycine-rich viral 
structural protein would be the HIV-1 Gag protein (Liang et al, 2003). Similar to 
SARS-CoV N protein, the HIV-1 Gag protein would also undergo 
self-polymerization and such self-assembly, which, in turn, would drive the 
production of virus-like particles. A glycine-rich sequence 353-GVGGP-357 of the 
HIV-1 Gag protein was determined to be crucial for the multimerization of the Gag 
protein and production of HIV-1 particles. Liang's group has demonstrated that 
mutations of glycine residues on the 353-GVGGP-357 motif restricted the Gag 
protein self-assembly and this led to the impaired association of Gag protein with the 
cellular membranes. When compared with the wild-type Gag molecules, which were 
able to aggregate and to actively assemble virus particles, the mutant Gag proteins 
were less well organized in COS-7 cells and this led to a low yield of viral 
production. Moreover, the viral-like structures detected in the COS-7 cells 
transfected with mutant Gag constructs were heterogeneous in size. The COS-7 cells 
that were transfected with the mutant Gag constructs displayed irregular morphology 
and were larger than the wild-type particles. Thus, mutation on the glycine residue in 
the 53-GVGGP-357 motif not only resulted in severely reduced yield of virus . 
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particles but also caused aberrant virus morphology. Since glycine only has an H 
atom as its side chain, this leaves sufficient space for adjacent residues to rotate. Due 
to this property, glycine might represent a common turning point in the protein 
structures. Similar to the HIV-1 Gag protein, we suggest that the glycine-rich feature 
might be responsible for the structural flexibility of the SARS-CoV N protein. 
From the domain search of SARS-CoV N protein by Proscan (Figure 8), there 
are three clusters of nuclear location signals (NLSs) in the protein located on both N 
and C-terminals. Two overlapping nucleolar localization signals (NoLSs) are also 
predicted in the C-terminal of the protein. In the N-terminal, one pat7 NLS was 
mapped from a.a. 38-44. One pat4 and one pat7 NLSs were found from a.a.257-265 
in the C-terminal. At the C terminals, NLSs including pat4, pat7 and NoLS including 
bipartite are predicated at a.a. 373-390. This bipartite NoLS is unique to SARS-CoV. 
A stretch of SR residues in a.a 177-207 was predicted to be a potential RNA binding 
domain. According to the result from the hydrophobicity plot of SARS-CoV 
nucleocapsid protein by Kyte-Doolittle (Figure 9), the SARS-CoV N protein is 
predicted to be hydrophilic and should be highly soluble. 
The multiple amino acids sequence alignment of SARS-CoV nucleocapsid . 
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protein to some other coronavirus nucleocapsid members shows that the SARS-CoV 
N protein has a relatively low sequence homology ranging from 23-33% with other 
members of coronavirus (Figure 10). The nucleocapsid protein of Murine hepatitis 
virus is found to have the highest amino acid sequence homology with that of 




28105. atg tct gat aat gga ccc caa tea aac caa cgt agt gcc ccc cgc att 
M S ^D N G. P Q S N Q R S A P R I 
28153 aca ttt ggt gga ccc aca gat tea act gac aat aac cag aat gga gga 
T . . .F G G P T D S T D N N Q N G G 
28201 cgc aat ggg gca agg cca aaa cag cgc cga ccc caa ggt tta ccc aat 
R . N G A R P K Q R R P Q G L P N 
28249 aat att gcg tct tgg ttc aca get ctc act cag cat ggc aag gag gaa 
N . I A S W F T A L T Q H G K E E | 
28297 ctt aga ttc cct cga ggc cag ggc gtt cca ate aac acc aat agt ggt 
L R F P R G Q G V P I N T N S G 
28345 cca gat gac caa att ggc tac tac cga aga get acc cga cga gtt cgt 
P . D D Q I G Y Y R R A T R R V R 
28393 ggt ggt gac ggc aaa atg aaa gag ctc age ccc aga tgg tac ttc tat 
G G D G K M K E L S P R W Y F Y | 
28441 tac eta gga act ggc cca gaa get tea ctt ccc tac ggc get aac aaa 
X L G T G P E A S L P Y G A N K 
28489 gaa ggc ate gta tgg gtt gca act gag gga gcc ttg aat aca ccc aaa 
.E G I V W V A T E G A L N T P K 
28537 gac cac att ggc acc cgc aat cct aat aac aat get gcc acc gtg eta 
P H I G T R .N P N N N A A T V L 
• 28585 caa ctt cct caa gga aca aca ttg cca aaa ggc ttc tac gca gag gga 
•Q L P Q G T T L P K G F Y A E G 
.1 — --.-.. "J 
28633 age aga ggc ggc agt caa gcc tct tct cgc tcc tea tea cgt agt cgc 
S R G G S Q A S. S R S S S R S R 
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28681 ggt aat tea aga aat tea act cct ggc age agt agg gga aat tct cct 
騰 置 蔓 f T • • 贊 ‘ G S ^ S ^ c N S， P 
28729 get cga atg get age gga ggt ggt gaa act gcc ctc gcg eta ttg ctg 
^ ^ ^ ^ ^ ^ ^ � . A T T - A L L L 
28777 eta gac aga ttg aac cag ctt gag age aaa gtt tct ggt aaa ggc caa 
S : K. V ' � G K G Q 
28825 caa caa caa ggc caa act gtc act aag aaa tct get get gag gca tct 
讓 _ 隱 , : 0 靜 麵 ^ i T ^ S A - A E A " 1 3 
28873 aaa aag cct cgc caa aaa cgt act gcc aca aaa cag tac aac gtc act 
議 薩 職 肺 、 ， K . : Y N V T 
28921 caa gca ttt ggg aga cgt ggt cca gaa caa acc caa gga aat ttc ggg 
{ 纖 i i , . 華 藍 : Q H F G 
28969 gac caa qac eta ate aga caa gga act gat tac aaa cat tgg ccg caa 
� — Y 梦 JC 
29017 att gca caa ttt get cca agt gcc tct gca ttc ttt gga atg tea cgc 
G ‘ M ... S — R : 
•• 29065 att ggc atq qaa gtc aca cct teg gga aca tgg ctg act tat cat gga 
29113 gcc att aaa ttg gat gac aaa gat cca caa ttc aaa gac aac gtc ata 
29161 ctg ctg aac aag cac att gac gca tac aaa aca ttc cca cca aca gag 
[ ^ ^ ^ ^ g l ^ ^ K : : : � � ^ ? ^ : : . : . P ;::、中::::T ^ 
29209 cct "aaa aag gac aaa aag aaa aag act gat gaa get cag cct ttg ccg 
29257 cag aga caa aag aag cag ccc act gtg act ctt ctt cct gcg get gac 
mmm^^m:4^m-�;_ 上 : [ i s . � 
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29305 atg gat gat ttc tcc aga caa ctt caa aat tcc atg agt gga get tct 
M D D F S R Q L Q N S M S G A S 
29353 get gat tea act cag gca taa 29374 
A D S T Q A * 
Figure 7. The cDNA and predicted amino acid sequences of SARS-CoV 
nucleocapsid gene. The nucleotide 28253 was found to have a point mutation from 
cytosine (c) to thymidine (t) (indicated in green color). This is a single nucleotide 
polymorphism (SNP) that occurs in the nucleocapsid gene among different strains of 
SARS-CoVs, such as Frankfurk 1 (NCBI Accession number: AY291315) and FRA 
(NCBI Accession number: AY310120). This led to a change of amino acid residue at 
a.a. 50 of the SARS-CoV N protein sequence from Threonine (T) to Isoleucine (I) 




Table 4. In silico analysis of SARS-CoV Nucleocapsid protein. Molecular 
weight, theoretical pi and amino acid composition were calculated using 
ProtParam. (http://us.expasv.org/tools/protparam.html) 
Number of amino acids: 422 
Molecular weight: 46.025kDa 
Theoretical pi: 10.11 
Amino acid composition (in descending order of % composition): 
— — ^ ― 圓 ― 
Gly(G) 45 10.7 Asp(D) 22 5.2 
Ser(S) 35 8.3 Glu (E) 14 3.3 
Ala (A) 34 8.1 Phe(F) 13 3.1 
Gln(Q) 34 8.1 lie (I) 11 2.6 
Thr(T) 33 7,8 Tyr(Y) 11 2.6 
丨 Arg(R) 31 7.3 Val (V) 11 2.6 
I P r o ( P ) 3 1 7 . 3 Met(M) 7 1.7 
i Lys (K) 29 6.9 His (H) 5 1.2 
Leu(L) 26 6.2 Trp(W) 5 1.2 
:Asn(N) 25 5.9 
Total number of negatively charged residues (Asp + Glu): 36 




1 MSDNGPQSNQ RSAPRITFGG PTDSTDNNQN GGRNGARPKQ RRPQGLPNNT ASWFTALTQH 60 
61 GKEELRFPRG QGVPINTNSG PDDQIGYYRR ATRRVRGGDG KMKELSPRWY FYYLGTGPEA 120 
121 SLPYGANKEG IVWVATEGAL NTPKDHIGTR NPNNNAATVL QLPQGTTLPK GFYAEGSRGG 180 
181 SQASSRSSSR SRGNSRNSTP GSSRGNSPAR MASGGGETAL ALLLLDRLNQ LESKVSGKGQ 240 
241 QQQGQTVTKK SAAEASKKPR QKRTATKQYN VTQAFGRRGP EQTQGNFGDQ DLIRQGTDYK 300 
301 HWPQIAQFAP SASAFFGMSR IGMEVTPSGT WLTYHGAIKL DDKDPQFKDN VILLNKHIDA 360 




• H H B B H H H O B I 
pat? P K Q R R P Q 3 8 - 4 4 
pat4 K K P R 2 5 7 - 2 6 0 
pat7 P R Q K R T A 2 5 9 - 2 6 5 
pat7 P K K D K K K 3 6 9 - 3 7 6 
pat4 K K K K 3 7 3 - 3 7 6 
bipartite K K K K T D E A Q P L P Q R Q K K 3 7 3 - 3 8 9 
bipartite K K K T D E A Q P L P Q R Q K K Q 3 7 4 - 3 9 0 
pat7 P Q R Q K K Q 3 8 4 - 3 9 0 
Figure 8. The domain search of SARS-CoV nucleopcasid protein predicted 
by ProScan. (A) The amino acids in blue color represent the serine/arginine-rich 
region (SR region), which is a potential RNA binding domain. The amino acids in 
red color represent the putative nuclear localization signals (NLSs). (B) The types of 
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Figure 9. The hydrophobicity plot of SARS-CoV nucleocapsid protein. 
(Kyte-Doolittle). The SARS-CoV N protein is predicted to be hydrophilic and 
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3.2. Subcellular localization of SARS-CoV Nucleopcasid protein in VeroE6 cells 
and HepG2 cells 
With the computer analysis on the amino acid sequence of the SARS-CoV 
nucleocapsid protein, it was found to contain potential nuclear localization signals 
(NLSs) and nucleolar localization signals (NoLSs). In order to verify the roles of 
these potential domains in targeting the protein localization, a subcellular localization 
study using the Enhanced Green Fluorescence Protein (EGFP) expression vector, 
pEGFP-Cl (BD Biosciences, Clontech, CA, USA), was performed. The 
EGFP-tagged SARS-CoV nucleocapsid protein was expressed in VE6 cells for 24 
hours. The transfectants were then fixed by para-formaldehyde. Cell nuclei were 
counterstained with a commonly used nucleus marker DAPI that binds to the minor 
groove of DNA, preferably to a cluster of dinucleotides AT. As examined using the 
^/^/-fluorescence microscopy, green fluorescent signals was observed from the VE6 
cells expressing the viral fusion protein. 
Western blotting was carried out by using the anti-EGFP antibody (1:1000 ratio) 
to probe for the presence of the EGFP-tagged SARS N protein (Figure 11). This was 
performed to further ensure that the fusion protein was expressed properly with 
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predicted size around 73kDa in the VE6 cells. Full-range rainbow molecular weight 
markers (Amersham, Uppsala, Sweden) were used (Figure 11, lane 1). Since the 
full-range rainbow molecular weight markers were not fluorescent markers, the 
bands of proteins with corresponding sizes in the full-range markers were drawn by 
overlapping the immimoblot on the developed film (Lane 1 of Figure 11, Figure 12, 
and Figure 1). In Figure 11，the control experiment with pEGFP-C 1 -transfected VE6 
cells (Figure 11，lane 2) only showed the expression of the green fluorescence protein 
with molecular weight closed to 25 kDa when compared with the full-range markers 
in Figure 11 lane 1. When the pEGFP-SARS-CoV-N expression vector was 
transfected into VE6 cells, the expression of both pEGFP-SARS-CoV-N fusion 
protein, which showed a band with size closed to the corresponding marker at 75kDa, 
and EGFP, which showed a band with size closed to the corresponding marker at 
25kDa, were detected in the pEGFP-SARS-CoV-N transfected VE6 cells (Figure 11， 
lane 3). 
Under the epZ-fluorescent microscope, the pEGFP-SARS-CoV-N-transfected 
VE6 cells showed fluorescent signal from the cytoplasm only (Figure 14). Five 
hundred VE6 cells showing fluorescent signals were quantitated and 95% of these 
cells expressing the fusion protein gave fluorescent signal from the cytoplasm only. 
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The experiments were repeated six times and representative fluorescent photo were 
given in Figure 14. According to the western blotting on Figure 11 lane 3, the 
expression of both the pEGFP-SARS-CoV-N protein (with predicted molecular 
weight about 73kDa) and the enhanced green fluorescent protein (with predicted 
molecular weight about 27kDa) were detected in the 
pEGFP-SARS-CoV-N-transfected VE6 cells. Taken together, the fluorescent signal 
detected from the cytoplasm of the pEGFP-SARS-CoV-N-transfected VE6 cells 
might be due to the presence of both pEGFP-SARS-CoV-N fusion protein and the 
EGFP. For the control experiment with pEGFP-C 1-transfected VE6 cells, fluorescent 
signals were detected diffusely in the VE6 cells in both cytoplasm and nucleus 
(Figure 14). According to the Western blot in Figure 11 lane 2，there was only the 
expression of the EGFP in pEGFP-C 1 -transfected VE6 cells with a band closed to 
the corresponding marker at 25kDa when compared with Figure 11 lane 1. Thus, the 
fluorescent signals detected in the pEGFP-C 1 -transfected control in VE6 cells 
(Figure 14) should be due to the expression of EGFP only in VE6 cells. 
HepG2, a human hepatocarcinoma cell line, was also used in the subcellular 
localization study of pEGFP-SARS-CoV-N fusion protein. The EGFP-tagged 
SARS-CoV nucleocapsid protein was expressed in HepG2 cells for 24 hours. The 
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transfectants were then fixed. The cell nuclei were counterstained with a commonly 
used nucleus marker DAPI. As examined using the epZ-fluorescence microscopy, 
green fluorescent signals were observed from the HepG2 cells expressing the viral 
fusion protein. Western blottings were performed by using the anti-EGFP antibody 
(1:1000 ratio) to probe for the presence of the EGFP-tagged SARS-CoV N protein in 
the pEGFP-SARS-CoV-N transfected HepG2 cells. This was performed to further 
ensure that the fusion protein was expressed properly with expected size around 
73kDa in HepG2 cells (Figure 12). In the western blotting on Figure 12, the 
pEGFPCl-transfected control experiment (Figure 12, lane 2) only showed the 
expression of the EGFP with molecular size around 25kDa. Both 
pEGFP-SARS-CoV-N fusion protein (Figure 12, lane 3), whose size was closed to 
the corresponding band of 75kDa in the markers in Figure 12, lane 1, and EGFP 
(Figure 12, lane 3), whose size was closed to the corresponding band of 25kDa in the 
markers in Figure 12, lane 1，were expressed in the HepG2 cells transfeced with 
pEGFP-SARS-CoV-N expression vector. Under the ep/-fluorescent microscope, 
fluorescent signal were observed in the cytoplasm of HepG2 cells transfected with 
pEGFP-SARS-CoV-N expression vector. Weak fluorescent signal was also observed 
in the nuclear region of the HepG2 cells transfected with pEGFP-SARS-CoV-N 
expression vector. Five hundred HepG2 cells transfected with this recombinant 
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vector were quantitated and 95% of these cells expressing this fusion protein gave 
strong fluorescent signal from the cytoplasm and weak fluorescent signal from the 
nucleus. The experiments were repeated six times and representative fluorescent 
photos were given in Figure 15. According to the Western blotting on Figure 12 lane 
3，both EGFP-tagged SARS-CoV-N protein and EGFP were expressed in HepG2 
cells transfected with pEGFP-SARS-CoV N expression vector. The observation of 
the weak fluorescent signal from the nucleus in the 
pEGFP-SARS-CoV-N-transfected HepG2 might be due to the entry of the minute 
amount(s) of either or both the pEGFP-SARS-CoV-N fusion protein and EGFP into 
the nucleus. 
The nucleolar translocation of N proteins has been reported in many other CoVs, 
such as TGEV, MHV and IBV (Wurm et al, 2001, Chen and Wurm et al, 2002), and 
a bipartite nucleolar localization signal (NoLS) has been predicted in the C-terminal 
a.a. 373-390 of the SARS-CoV nucleocapsid amino acid sequence (Figure 8). Two 
recent reports in the literature have demonstrated the nucleolar localization of 
SARS-CoV-N protein in insect cell line BTl Tn 5B1-4 (Ren and Xie et al, 2004) 
and mammalian cell line HeLa (Li and Xiao et al, 2005). We were interested to 
know if this NoLS would be responsible for the nuclear localization of the 
106 
： Results 
EGFP-tagged SARS-CoV N protein in the pEGFP-SARS-CoV-N -transfected 
HepG2 cells in our observation (Figure 15). Thus, a mutant of SARS-CoV N protein 
that encoded a.a. 1-368 with the bipartite NoLS deleted was generated. It was named 
as pEGFP-SARS-CoV- A N. This deletion mutant was transfected into HepG2 cells 
again. The truncated viral protein was expressed for 24 hours in hepG2 cells. Under 
L 
the ep/-fluorescent microscope, the pEGFP-SARS-CoV- AN-transfected HepG2 cells 
showed strong fluorescent signals from the cytoplasm and weak fluorescent signals 
from the nuclear region (Figure 15). According to the Western blotting in Figure 
13,lane 3，both EGFP-tagged SARS-CoV-AN protein and EGFP were expressed in 
HepG2 cells transfected with pEGFP-SARS-CoV A N expression vector. The 
observation of the weak fluorescent signal from the nucleus in the HepG2 transfected 
with pEGFP-SARS-CoV- A N expression vector might be due to the entry of the 
minute amount(s) of either or both the pEGFP-SARS-CoV-N fusion protein and 
EGFP into the nucleus. 
« 
The fluorescent signals from pEGFP-C 1 -transfected control experiment were 
detected diffusely in both cytoplasm and nucleus (Figure 15) in HepG2 cells. The 
experiments were repeated with 6 times. According to the Western blot in Figure 12 
lane 2, there was only the expression of the EGFP in pEGFP-C 1 -transfected HepG2 
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cells with a band closed to the corresponding marker at 25kDa when compared with 
Figure 12 lane 1. Thus, the fluorescent signal detected in the pEGFP-C 1 -transfected 





Lane 1 2 3 
M C T 
^ l l ^ ' I ^ ^ S t - • - / " - t m . J ^ _ pEGFP-SARS-CoV-Nprotdn 
S B B 线 ( p r e d i c t e d m o d c u l a r siz&-73kDa) 
50k p i ^ f f i H . - .f 
\ ‘ 巧 ^ ^ ^ Enhanced green fluorescent protein 
二t ‘ (EGEPXpredictedmodcular size-27ld:>a) 
Figure 11. Detection of EGFP-SARS-CoV nucleocapsid protein (SARS-CoV-N) 
in VE6 cells by western blot analysis using anti-GFP antibody. Lane 1，M: 
Full-range molecular weight markers (Amersham); Lane 2, C: pEGFP-Cl vector 
transfected control sample; Lane 3, T: pEGFP-SARS-CoV-N expression 
vector-transfected test sample. Proteins isolated from pEGFP-Cl-transfected control 
sample and pEGFP-SARS-CoV-N expression vector-transfected test sample were 
separated by 12% SDS-PAGE and subjected to western blot analyses. Anti-EGFP 
antibody (1:1000 ratio) was used to verify the expression of GFP fusion proteins and 
to ensure that the transfected plasmids were successfully expressed and correctly 





Lane 1 2 3 
M C T 
� 会 黑 ^ m f t i PEG?P-SARS-C0V-Nprotein 
I ^ ^ P U m i l l l i m ^ H ^ I I ^ ! ^ ‘ Enhanced green fluorescent protein 
^ ^ ^ m H ^ ^ � ^ ： ： ( E G F P X F e d i c t e d modcular siz^27kDa) 
Figure 12. Detection of EGFP-SARS-CoV nucleocapsid protein (SARS-CoV-N) 
in HepG2 cells by western blot analysis using anti-GFP antibody. Lane 1，M: 
Full-range molecular weight markers (Amersham); Lane 2, C: pEGFP-Cl vector 
transfected control sample; Lane 3， T: pEGFP-SARS-CoV-N expression 
vector-transfected test sample. Proteins isolated from pEGFP-C 1 -transfected control 
sample and pEGFP-SARS-CoV-N expression vector-transfected test sample were 
separated by 12% SDS-PAGE and subjected to western blot analyses. Anti-EGFP 
antibody (1:1000 ratio) was used to verify the expression of GFP fusion proteins and 
to ensure that the transfected plasmids were successfully expressed and correctly 




Lane 1 2 3 
M C T 
105k 一 
视 � — ^ PEGFP-SARS-Cov-an protein 
^ ^ p i r ; ; — (pr.dictedmodaiarsize^61d3a) 
- ‘ ‘ < J Enhanced green fluonescent protein 
： ^ “ (EGFPXpredictedmDelcularsiz^271d:)a) 
Figure 13. Detection of the deletion mutant of the EGFP-SARS-CoV 
nucleocapsid protein (SARS-CoV-A N) in HepG2 cells by western blot analysis 
using anti-GFP antibody. Lane 1, M: Full-range molecular weight markers 
(Amersham); Lane 2, C: pEGFP-Cl vector transfected control sample; Lane 3, T: 
pEGFP-SARS-CoV- AN expression vector-transfected test sample. Proteins isolated 
from pEGFP-C 1 -transfected control sample and pEGFP-SARS-CoV-N expression 
vector-transfected test sample were separated by 12% SDS-PAGE and subjected to 
western blot analyses. Anti-EGFP antibody (1:1000 ratio) was used to verify the 
expression of GFP fusion proteins and to ensure that the transfected plasnids were 
successfully expressed and correctly translated. Full-range molecular weight markers 





GFP Channel DAPI Channel Overlay 
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Figure 14. The subcellular localization patterns of SARS-CoV nucleocapsid 
protein in VE6 cells. VE6 Cells were grown on coverlids and then transfected with 
pEGFP-SARS-CoV-N expression vector and pEGFP-Cl vector. The proteins were 
expressed for 24 hours. The cells were then fixed with para-formaldehyde and 
stained for nucleus with DAPI. Merged images demonstrate that the localization of 
EGFP-tagged SARS-CoV-N protein. The EGFP-tagged SARS-CoV nucleocapsid 
protein is localized in cytoplasm in VE6 cells. The expression of EGFP also 
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Figure 15. The subcellular localization patterns of SARS-CoV nucleocapsid 
protein in HepG2 cells. Cells were grown on coverlids and then transfected with 
pEGFP-SARS-CoV-N expression vector, pEGFP-SARS-CoV- AN expression vector 
and pEGFP-Cl vector. The proteins were expressed for 24 hours. The cells were then 
fixed with para-formaldehyde and stained for nucleus with DAPI. Merged images 
demonstrate the localization of EGFP-SARS-CoV-N protein and EGFP-SARS-CoV-
AN protein. The SARS-CoV nucleocapsid protein and its deletion mutant (a.a. 
1-368) are localized predominantly in the cytoplasm with weak fluorescent signals 
from the nucleus. The red arrows indicate the fluorescent signals from the nucleus. 113 
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3.3. cDNA microarray analysis on differential gene expression pattern 
upon the over-expression of SARS-CoV nucleocapsid gene 
The human genome-wide differential gene expression pattern induced by the 
expression of SARS-CoV nucleocapsid in VE6 cells was determined by using the 
Affymetrix HG-U133 Plus2.0 array. About 23,000 human genes with 14,500 
well-characterized human genes were included in this GeneChip. VE6 cells were 
transfected with pCMV-TagI-SARS-CoV N protein mammalian expression vector as 
the experimental sample (Figure 18B) and the control sample was VE6 cells that 
were transfected with pCMV-TagI empty vector only (Figure 18A). Both the 
pCMV-TagI-SARS-CoV N expression vector-transfected and empty vector 
pCMV-Tag 1 -transfected VE6 cells were collected for total RNA extraction by 
TRIZol reagent 48 hours after the transient transfections. The amounts of total RNA 
extracted in the control and the experimental samples were 24 |ig (1.2 jig/^l) and 22 
|ig (1.1 |ig/1^1) respectively. Their qualities were analyzed with a 2% non-denaturing 
agarose gel under UV to ensure their integrity (Figure. 16). 4 jig of each total RNA 
was transcribed into cDNA. Semi-quantitative RT-PCRs were performed with the 
SARS-CoV nucleocapsid gene specific primer sets to verify that the viral mRNA was 
properly expressed in the experimental sample (Figure. 17, lane 2). ‘ 
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Synthesis of probes, array hybridization, array scanning, quality control, data 
acquisition and analysis were performed by Affymetrix Inc. as a customer service. 
Since our experiment involved the comparison between the control and experimental 
arrays, the data for each array was normalized. The control array was designated as 
the baseline and the other was designated as the experimental data. The experimental 
signals were analyzed in comparison to the baseline signal. The resultant fold change 
in expression between each of the experimental samples in comparison to that of the 
control was calculated, log2 transformed, and further classified as no change, 
increased (signal log ratio change P value of <0.005), decreased (signal log ratio 
change P value of > 0.995) or marginally increased or decreased with 
Affymetrix-defined comparison mathematical algorithms. 
I 
The transcriptional profile revealed that the expression levels of 109 human 
homologous gene transcripts were upregulated upon the over-expression of 
SARS-CoV nucleocapsid in VE6 cells when compared with the VE6 cells transfected 
with the empty vector pCMV-TagI only. Out of these 109 upregulated genes, 19 
genes were found to give signals exclusively from the experimental array only but 
not the control one. These 19 upregulated genes were regarded as the exclusively 
upregulated genes. These 19 exclusively upregulated mRNA transcripts belong to 
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various functional categories related to transcription (6 out of 19 genes), 
proinflammatory (2 out of 19 genes), signal transduction (2 out of 19 genes), 
glycerolipid metabolism (1 out of 19 genes), purine metabolism (1 out of 19 genes), 
phospholipid metabolism (1 out of 19 genes), phospholipid transporting (1 out of 19 
genes), neutral activity (1 out of 19 genes), autosomal recessive disease (1 out of 19 
genes), phosphorylation of nucleoside diphosphate (1 out of 19 genes) and DNA 
mismatch-repair (1 out of 19 genes). A novel mRNA transcript (1 out of 19 genes) 
was also identified to be upregulted upon SARS-CoV nucleocapsid induction in VE6 
cells. The name of the gene, the gene symbol, the fold induction in signal log signal 
upon SARS-CoV nucleocapsid induction and the NCBI Accession number of each 
exclusively upregulated gene transcript is given in Table 5. 
159 human homologous gene transcripts were found to be downregulated upon 
the over-expression of SARS-CoV nucleocapsid in VE6 cells when compared with 
the VE6 cells that were transfected with the empty vector pCMV-TagI only. Out of 
these 159 downregulated genes, 27 genes were found to give signals exclusively 
from the control array only but not the experimental array. These 27 downregulated 
genes were regarded as the exclusively downregulated genes. These 27 exclusively 
downregulated gene transcripts were classified to a variety of functional categories 
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related to ion/ small molecule transport (5 out of 27 genes), transcription (5 out of 27 
genes), signal transduction (2 out of 27 genes), calmodulin binding (1 out of 27 
genes), cell-cell adhesion (1 out of 27 genes), lysosomal cysteine proteinase (1 out of 
27 genes), iron absorption (1 out of 27 genes), neuronal excitability (1 out of 27 
genes)，GTP binding (1 out of 27 genes), and oxidative phosphorylation (1 out of 27 
genes). Eight novel mRNA transcripts were also identified to be exclusively 
downregulted upon SARS-CoV nucleocapsid induction in VE6 cells. The name of 
the gene, the gene symbol, the fold reduction in signal log signal upon SARS-CoV 
nucleocapsid induction and the NCBI Accession number of each e'lclusively 
downregulated gene transcript is given in Table 6. 
The cDNA templates were first normalized by the housekeeping gene GAPDH 
(Figure 19B). Semi-quantitative RT-PCRs showed that homeobox Al (H0XA7) was 
differentially expressed upon the over-expression SARS-CoV nucleocapsid (Figure 
19A). The H0XA7 gene belongs to the class of transcription factor called homeobox 
gene. The H0XA7 is found in cluster A on chromosome 7 and its mRNA level was 
increased by around 3 fold upon the over-expression of SARS-CoV N gene (Figure 
19A，lane 2) when compared with the control sample that was transfecteJ with the 
empty vector pCMV-Tagl only (Figure 19A, lane 1). ‘ 
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Figure 16. Total RNAs extracted by experimental and control samples. The 
RNA samples were analyzed on a 2 % non-denaturing agarose gel and visualized 
under UV. C: control; E: experimental. Lane 1，C: the total RNA sample extracted 
from VE6 cells that were transfected with the empty vector pCMV-Tagl only as the 
control sample; Lane 2, E : the total RNA sample extracted from VE6 cells that were 
transfected with the pCMV-TagI-SARS-CoV N protein expression vector as the 
experimental sample Two distinct ribosomal RNA bands, 28S and 18S, with the band 
intensity ratio of 2:1 without smear were observed. This indicated that the total RNA 
samples were isolated with a good integrity, and free of degradation and genomic 
DNA contamination. � 
Lane 1 2 
C E 
0> 
Figure 17. Expression of SARS-CoV nucleocapsid mRNA in VE6 cells. 
Semi-quantitative RT-PCRs were carried out with SARS-CoV nuclecoapsid gene 
specific primer set and its viral mRNA was only detected in the experimental sample 





Figure 18. The Images of the GeneChips HG-U133 Plus 2.0 array in the 
microarray analysis on differential expression pattern of human homologous 
gene induced by SARS-CoV nucleocapsid. (A) Gene chip with the control sample 
from VE6 cells that were transfected with the empty vector pCMV-TagI 
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Figure 18B (continued) 
w 
• 
Figure 18. The Images of the GeneChips HG-U133 Plus 2.0 array in the 
microarray analysis on differential expression pattern of human homologous 
gene induced by SARS-CoV nucleocapsid. (B) Gene chip with experimental 




Table 5. Results from Affymetrix on the exclusively upregulated genes upon the 
over-expression of SARS-CoV Nucleocapsid in VE6 cells (in descending order). 
Signal log 
Gene ratio NCBI 
Gene Title Symbol (log2 scale)" Category Accession No. 
chemokine (C-X-C 
motif) ligand 11 CXCL11 5 Proinflammatiory NM_005409 
Glycerolipid 
glycerol kinase GK 4.6 metabolism NM_203391 
Purine 
adenosine kinase ADK 4.5 metabolism NM_001123 
ATPase, Class II, type Phospholipid 
9A ATP9A 4.2 -transporting NM_006045 
A kinase (PRKA) Signal 
anchor protein 13 AKAP13 3.9 transduction NM_006738 
• hypothetical protein 
FLJ20211 FLJ20211 3.7 Unknown NM_017713 
homeo boxA7 H0XA7 3.5 Transcription NM_006896 
phospholipase A2 Phospholipid 
receptor 1, 180kDa PLA2R1 3.3 metabolism NM_007366 
msh homeo box 
homolog 2(Drosophila) MSX2 3.2 Transcription NM_002449 
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Table 5 (continued) 
Signal log 
Gene ratio NCBI 
Gene Title Symbol (log2 scale)" Category Accession No. 
ELK4, ETS-domain 
protein (SRF accessory 
protein 1) ELK4 3.1 Transcription NM_001973 
Homo sapiens proline 
rich 7 (synaptic) PRR7 3 Neural activity NM_030567 
“ Autosomal 
Alstrom syndrome 1 ALMSl 2.7 recessive disease NM—015120 
insulin-like growth 
factor binding protein, Signal 
acid labile subunit IGFALS 2.2 transduction NM_004970 
non-metastatic cells 6, 
protein expressed in Phosphorylation 
(nucleoside- of nucleoside 
diphosphate kinase) NME6 1.3 diphosphates NM—005793 
interleukin 18 
receptor 1 IL18R1 • 1.3 Proinflammatiory NM—003855 
Meisl, myeloid 
ecotropic viral 
integration site 1 
homolog 2 (mouse) MEIS2 1.3 Transcription NM_020149 
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Table 5 (continued) 
Signal log 
Gene ratio NCBI 




Drosophila) MLLT3 1.2 Transcription NM—004529 
bobby SOX homolog 
(Drosophila) ’ BBX 1.1 Transcription NM^020235. 
mutL homolog 3 (E. DNA 
coli) MLH3 1.1 mismatch-repair NM—014381 
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Table 6. Results from Affymetrix on the exclusively downregulated genes upon 
the over-expression of SARS-CoV Nucleocapsid in VE6 cells (in descending 
order). 
Signal log 
Gene ratio Category NCBI 
Gene Title Symbol (log2 scale)" Accession No. 
zinc finger, CCHC 
domain containing 4 ZCCHC4 -4.8 Unknown NM_024936 
potassium channel 
tetramerisation domain ‘ Potassium ion 
containing 12 KCTD12 -4.7 transport NM—138444 
solute carrier family 16 
(monocarboxylic acid Monocarboxylic acid 
transporters), member 1 SLC16A1 -3.3 transporter NM—003051 
Calmodulin binding 
Striatin STRN -2.9 protein NM_003162 
zinc finger protein 652 ZNF652 -2.9 Transcription NM—014897 
sialic acid binding 
Ig-like lectin 8 SIGLEC8 -2.8 Signal transduction NM—014442 
pleckstrin and Sec7 
domain containing 3 PSD3 -2.6 Unknown NM_015310 
Calcium-
cadherin 12，type 2 dependent cell 
(N-cadherin 2) CDH12 -2.1 adhesion NM—004061 
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Table 6 (continued) 
Signal log 
Gene ratio Category NCBI 
Gene Title Symbol (log2 scale)" Accession No. 
transmembrane protein 
39A TMEM39A -1.9 Unknown >TV[_018266 
Lysosomal cysteine 
cathepsin Z CTSZ -1.8 proteinase NM_001336 
solute carrier family 7 
(cationic amino acid 
transporter, y+ system), Cationic amino acid 
member 8 SLC7A8 -1.4 transporter NM一012244 
Regulation of iron 
hemochromatosis HFE -1.3 absorption NM—00410 




calcium-activated Regulation of 
channel, subfamily N， neuronal 
member 2 KCNN2 -1.3 excitability NM 021614 
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Table 6 (continued) 
Signal log 
Gene ratio Category NCBI 
Gene Title Symbol (log2 scale)" Accession No. 
guanylate binding protein 
1, . 
interferon-inducible, 
67kDa GBPl -1.2 GTP binding NM_002053 
ATPase, H+ transporting, 
lysosomal 70kDa, ” Oxidative 
VI subunitA ATP6V lA -1.1 phosporylation NM—001690 
AT rich interactive 
domain 4 A (RBPl-like) ARID4A -1.1 Transcription NM_002892 
transient receptor 
potential cation channel, 
subfamily C, member 1 TRPCl -1.1 Ion transporter NM_003304 
ALLl fused gene from 
5q31 AF5Q31 -1,1 Transcription NM—014423 
transmembrane emp24 
protein transport domain 
containing 5 TMED5 -1 Unknown NM_016040 
Interleukin 6 signal 
transducer (gp, Signal 
oncostatin M receptor) IL6ST -1 transduction NM_002184 
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Table 6 (continued) 
Signal log 
Gene ratio Category NCBI 
Gene Title Symbol (log! scale)" Accession No. 




member 9 ABCC9 -1 Transporter NM_020297 
E74-like factor 1 (ets 
domain transcription 
factor) ELFl -1 Transcription NM_172373 
suppressor of zeste 12 
homolog 
(Drosophila) SUZ12 -1 Transcription NM 一015355 
hypothetical protein 
FLJ22332 FLJ22332 -1 Unknown NM_024724 
PTD016 protein LOC51136 -1 Unknown NM 016125 
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( A ) Lane 1 2 
C E 
Band Intensity 1 3.16 
(HOXA7/ GAPDH) 
( B ) Lane 1 2 
C E 
Figure 19. Verifications of differential gene expression patterns by 
semi-quantitative RT-PCR. E: experimental; C: control. (A) H0XA7 demonstrated 
a increase in its mRNA expression level upon the induction by the SARS-CoV 
nucleocapsid in the experimental cDNA sample. (B) The cDNA templates were first 
‘normalized with the housekeeping gene GAPDH. The band intensity was measured 
by gel-dot densitometry. These experiments were repeated three times and the results 




3.4. In vitro RNA interference of SARS-CoV nucleocapsid 
Previous studies on HBV and HIV from other research groups with RNAi 
technology have demonstrated promising results in decreasing viral mRNA and 
protein expression level, which, in turn, reduced the viral infection. Therefore in this 
study, we applied RNAi to examine its potential efficacy to inhibit the cellular 
mRNA and protein expression of SARS-CoV nucleocapsid. Four target sites, which 
were positioned at nucleotide 79，734，1027，and 1066 downstream of the start codon 
of the SARS-CoV nucleocapsid gene DNA sequence, were selected using the online 
"siRNA Target Finder" from Ambion Inc. The DNA sequence of the nucleocapsid 
gene of SARS-CoV strain CUHK-Wl was scanned for A A dinucleotide sequence 
and each A A and the 3，adjacent 19 nucleotides were recorded as the potential siRNA 
target sites. The sequence should not contain any repeats of more than four A or T 
and the GC content should be around 30-50%. Four target sequences were selected 
and they were all analyzed by BLAST search of the GenBank database to avoid 
similar sequences found in the human genome. A total of four pairs of 
oligonucleotides with shRNA (small hairpin RNA) sequences were synthesized 
{Invitrogen) and inserted into the linearized ^Silencer2>.\-m {Ambion Inc). The 
shRNA expression vectors that expressed these shRNAs were generated according to 
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the manufacturer's instructions. A sequence that targeted the SARS-CoV spike 
glycoprotein was applied as a negative control. A sequence that targeted the Green 
Fluorescent Protein (GFP) provided by Ambion Inc, which could specifically degrade 
GFP mRNA in a sequence-specific manner, was used as a positive control. These two 
shRNA expression vectors were also generated in a similar way. The VE6 cells were 
co-transfected with the pCMV-Tag 1 -SARS-CoV N expression vector and different 
shRNA expression vectors. The transfected cells were collected 48 hours after 
transient transfection for RT-PCR and Western blotting analysis. 
From the results on RT-PCR, the effect of the shRNA on the SARS-CoV 
nucleocapsid gene was observed in all samples co-transfected with the four 
shRNA-expression vectors, N-siRNAl，N-siRNA2, N-siRNA3 and N-siRNA4 
(Figure 20A, lane 3, 4，5，and 6 respectively) compared with sample transfected with 
pCMVTag 1 -SARS-CoV Nucleocapsid protein expression vector alone (Figure 20A, 
lane 1). N-siRNA3 was found to have the most potent inhibitory effect for which 
only 15% of the viral mRNA transcript remained (Figure 20A，lane 5). N-siRNAl 
and N-siRNA2 gave similar suppression with about 80% of reduction on the viral 
transcript expression level (Figure 20A, lane 3 and 4 respectively). N-siRNA4 was 
the least effective as it could only suppress the expression of SARS-CoV 
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nucleocapsid gene viral transcript with around 30%(Figure 20A, lane 6). The 
negative control, S-siRNA, only altered the viral mRNA expression in a small extent 
with about 10% inhibition (Figure 20A, lane 2)，and this might be explained by its 
off-target effect. All shRNA expression constructs had no effect on G3PDH 
expression at mRNA level (Figure 20B). The RT-PCR results were quantified and 
shown in Figure 21. 
The viral protein expression was also analyzed by Western blotting. Since we 
did not have anti-SARS-CoV nucleocapsid antibody，we used anti-flag antibody, 
which recognized the flag-tag of the viral fusion protein expressed from the 
pCMV-TagI, as primary antibody. Results from the Western blots were consistent 
with that of the RT-PCR with similar degrees of inhibitory effect by different shRNA 
,expression vectors. In the Western blots, when compared with the sample that was 
transfected with pCMVTagl-SARS-CoV nucleocapsid protein expression vector 
only (Figure 22A, lane 1)，an expression of approximately 90% of the viral protein 
was suppressed by N-siRNA3 (Figure 22A, lane 6)，which was the most effective. 
N-siRNAl and N-siRNA2 also had high potencies in inhibiting the SARS-CoV N 
protein expression and approximately 70-80% on viral protein expression was 
suppressed by these two shRNA expression vectors (Figure 22A, lane 4 and 5 
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respectively). The least potent shRNA vector was N-siRNA4 and it could only 
reduce about 30% of the viral protein expression (Figure 22A, lane 7). To avoid the 
effect due to differences on transfection efficiencies between the different 
transfection groups, the EGFP was employed as an indicator. The results from 
Western blotting showed that the EGFP expressions in different sets of reaction 
samples were even. The GFP-siRNA expression vector was applied as a positive 
control that degraded the GFP efficiently. It also indicated that our shRNA expression 
vectors were all transfected and transcribed successfully in cultured VE6 cells 
(Figure 22.A, lane 3). The Western blot results were quantified and shown in Figure 
23. 
The results from RT-PCR and Western blotting were consistent. This indicated 
‘ that the siRNAs generated in vivo from shRNA expression vectors silenced 
SARS-CoV nucleocapsid protein expression through blocking the accumulation of 
SASR-CoV nucleocapsid mRNA. The potency of the four tested shRNA expression 
vectors are as follows (in descending order): N-siRNA3> N-siRNA1 ~N-siRNA2> 
N-siRNA4. 
Although these four tested shRNA expression vectors targeting different regions 
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of the SARS-CoV nucleocapsid gene were proven to be efficient in suppressing the 
expression of both the SARS-CoV nucleocapsid mRNA and protein with different 
potencies, another five siRNA target sequences were found to be ineffective in this 
RNAi study. The sequences of these five ineffective siRNAs were given in the 
Appendix 6. The results of the RT-PCRs and the Western blottings showing the 
incapability of these five siRNA target sequences in suppressing the SARS-CoV 
nucleocapsid mRNA and protein expressions are given in the Appendix 7 and 
Appendix 8 respectively. Together with the four effective siRNA target sequences, 
those five ineffective siRNA target sequences would also be discussed in Chapter 
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Figure 20 (A) and (B). Effects of siRNAs on SARS-CoV nucleocapsid gene 
expression in VE6 cells. The mRNA expression levels of SARS-CoV nucleocapsid 
gene in VE6 cells transfected with different tested shRNA-expression vectors were 
determined by semi-quantitative RT-PCRs. Different degrees of inhibitory effects on 
the mRNA expression levels of SARS-CoV nucleocapsid gene that were transfected 
with each of the four tested shRNA expression vectors were observed. (A) VE6 cells 
were transfected with pCMVTagl-SARS-CoV N only (lane 1), 
pCMVTagl-SARS-CoV N plus S-siRNA (lane 2), pCMVTagl-SARS-CoV N plus 
N-siRNAl (lane 3)，pCMVTagl-SARS-CoV N plus N-siRNA2 (lane 4), 
pCMVTagl-SARS-CoV N plus N-siRNA3 (lane 5), pCMVTagl-SARS-CoV N plus 
N-siRNA4 (lane 6). (B) The cDNA templates were normalized with the 
housekeeping gene GAPDH. The band intensity was measured by gel-dot 
densitometry. These experiments were repeated five times and the results shown here 
are from a single experiment representative of similar experiments. ‘ 
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Figure 21. Quantification of the RT-PCR results on the inhibitory effects of the 
SARS-CoV nucleocapsid mRNA expression by different shRNA-expression 
vectors in VE6 cells. The band intensity was measured by gel-dot densitometry. The 
housekeeping gene GAPDH was employed for normalization. The band intensities 
on different transfection groups are indicated in blue color. These experiments were 
. . repeated five times. Values represent the mean 士 SD (standard derivation) of five 
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Figure 22 (A), (B) and (C). Effects of siRNAs on SARS-CoV nucleocapsid 
protein expression in VE6 cells. The protein expression levels of SARS-CoV 
nucleocapsid VE6 cells that were transfected with different tested shRNA-expression 
.vec to r s were determined by Western blotting. (A) VE6 cells were transfected with 
pCMVTagl-SARS-CoV N only (lane 1), pCMVTagl-SARS-CoV N plus S-siRNA 
(lane 2), pCMVTagl-SARS-CoV N plus GFP-siRNA (lane 3), 
pCMVTagl-SARS-CoV N plus N-siRNAl (lane 4), pCMVTagl-SARS-CoV N plus 
N-siRNA2 (lane 5), pCMVTagl ^ SARS-CoV N plus N-siRNA3 (lane 6), 
pCMVTagl-SARS-CoV N plus N-siRNA4 (lane 7). (B) Housekeeping protein 
GAPDH was probed as a loading control. (C) EGFP was served as the positive 
control in lane 3. The band intensity was measured by Image J. These experiments 
were repeated five times and the results shown here are from a single experiment 
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Figure 23. Quantification of the Western blotting results on the inhibitory 
effects of the SARS-CoV nucleocapsid mRNA expression by different 
shRNA-expression vectors in VE6 cells. The band intensity was measured by 
gel-dot densitometry. The housekeeping gene GAPDH was employed for 
normalization. The band intensities on different transfection groups are indicated in 
“purp le color. These experiments were repeated five times. Values represent the mean 
士 SD (standard derivation) of five separate experiments. The statistical significance 
is determined at a/? < 0.01 by Student's /-test. 
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3.5. Transactivation of fgl2 prothrombinase promoter by SARS-CoV 
nucleocapsid protein in HepG2 and VE6 cells 
The promoter region of fgl2 gene (NCBI Accession number: AH007300) was 
cloned into pGL3-basic mammalian expression vector that made use of firefly 
luciferase gene as the reporter gene. Different amounts of SARS-CoV N protein 
expression vector, pCMVTag 1 -SARS-CoV-N, were co-transfected together with the 
7^/2-pGL3 construct. The pGL3-basic vector did not contain any eukaryotic promoter 
and enhancer sequences. Therefore, the expression level of the firefly luciferase gene 
depended on the activity of the promoter fragment inserted. An internal control 
vector, the pRL-CMV which expressed the renilla luciferase gene as the reporter 
gene, was also co-transfected in each transfection reaction to normalize the 
‘transfection efficiencies between different transfection reactions. The 
pCMV-TagI -SARS-CoV-Membrane (M) protein expression vector was employed as 
the negative control to indicate that the fold transactivation of XhtfgU promoter was 
dependent on the expression of SARS-CoV N protein but not other SARS viral 
proteins, such as the SARS-CoV M protein. The pCMV-TagI empty vector was 
employed as another negative control to indicate that the fold transactivation of the 
fgl2 promoter was dependent on the expression of SARS-CoV N protein but not the 
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artifact of transfection reaction. Dual-luciferase reporter assay was employed to 
assay for any changes on the promoter activity of fgl2 gene induced by the 
expression of SARS-CoV N protein. The relative activity was arbitrarily calculated 
by defining the activity of pGL3-Basic vector as one. The fold transactivation was 
calculated by comparison of the relative luciferase activity (RLU) of each 
transfection group with the promoterless pGL3-Basic vector, whose RLU was 
assigned as one. The fold enhancements were calculated by dividing the RLU of the 
7g/2-pGL3 construct co-transfected with SARS-CoV N protein expression vector by 
that of theyg/2-pGL3 construct transfected only. All transfection groups were done in 
triplicate. Each transfection group gave 3 data points. The measurement of firefly 
luciferase and renilla luciferase activity might not be successful every time because 
of the physiological state of the cells, giving sometimes fluctuations of the 
’ independent transfection results. Thus, only the experiments with whole sets of data 
on the luciferase activities that could be successfully and consistently measured by 
the Single-Sample Luminometer were selected for the calculation of the relatively 
luciferase activity and the fold transactivation. To fulfill this criterion, eight sets of 
data were selected for the calculation of the relatively luciferase activity and the fold 
transactivation for both HepG2 and VE6 cells. 
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The equation for standard deviation is Y ，where x is the data 
value,"x is the arithmetic mean of the data items, and n is the number of data items 
(http://www.bimath.com/bimath/Stats/sd.htm). The standard deviation can be 
calculated in the following steps: 1) the arithmetic mean of the set of data is first 
calculated; 2) all the deviations from the arithmetic mean of the set of numbers are 
calculated; 3) all the deviations are squared; 4) the sum of the squares of all these 
deviations are calculated; 5) the arithmetic mean of these squares is then 
calculated; and finally 6) the square root of the mean is the standard deviation. The 
SD value of each transfection group was calculated with 24 data points obtained 
from eight sets of separate experiments done in triplicate. For example, the 24 data 
points from eight sets of separate experiments for the transfection group with 
• 'pGL3-fgl2 only in HepG2 cells' (Figure 24, the second bar in pink color) are 7.09， 
7.11, 7.29，7.37，7.46, 7.49，7.58，7.61, 7.83，7.85, 8.03’ 8.16, 8.39, 8.49, 8.51，8.51, 
8.65, 8.72, 8.81, 9.12，9.17, 9.22, 9.36 and 9.71. The above equation was applied 
for the calculation of SD value. Microsoft Excel was employed for the calculation 
of the mean and SD values. The mean and the SD values for this set of data were 
calculated to be about 8.23 and 0.769 respectively. 
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In both HepG2 and VE6, the firefly luciferase reporter gene showed an increase 
in the transcription level of the fgl2 gene in a dose-dependent manner upon the 
expression on SARS-CoV N protein. The maximum degree of transactivation oifgll 
gene induced by 0.10 fag of SARS-CoV N protein expression vector in HepG2 cells 
was 13.77 fold (Figure 24) compared with that of the promoterless pGL3-basic 
vector, and the fold enhancement of the fgl2 gene expression by SARS-CoV N 
protein in HepG2 cells was calculated to be 1.67 (Figure 25). The SARS-CoV N 
protein demonstrated a higher level in both fold transactivation and fold 
enhancement on fgl2 gene in a different cell line -VE6 cells. The maximum fold 
transactivation offgl2 gene induced by 0.1 [ig of SARS-CoV N protein expression 
plasmid in VE6 cells was 31.53 fold (Figure 26) and the fold enhancement was 2,59 
fold (Figure 27) on transfection of 0.1 ^g of SARS-CoV N protein expression vector. 
Both HepG2 and VE6 cells showed no significant increase in the fgl2 promoter 
activity when pCMV-TagI -S ARS-CoV-M protein expression vector was 
co-transfected with the pGL3-fgl2 promoter construct (Figures 24 and 26 
V 
respectively). The fold transactivation on fgl2 promoter activity caused by the 
transfection of pCMV-TagI -SARS-CoV-M protein expression vector was similar to 
that of the transfection of the pGL3-fgl2 promoter construct only (Figure 25 and 27 
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respectively). This indicated the induction on fgl2 promoter activity was specific to 
SARS-CoV N protein expression but not other SARS viral proteins. 
There was also no significant increase in the fgl2 promoter activity when the 
pCMV-TagI empty vector was co-transfected with the pGL3-7g/2 promoter construct 
in both HepG2 and VE6 cells (Figures 24 and 26 respectively). The fold 
transactivation on fgl2 promoter activity caused by the transfection of pCMV-TagI 
empty vector was similar to that of the transfection of the pGL3-fgl2 promoter 
construct only (Figure 25 and 27 respectively). This indicated the induction on fgl2 
promoter activity was specific to SARS-CoV N protein expression but the artifact of 
transfection reaction in both HepG2 and VE6 cells. 
‘ By using the fgl2 gene-specific primer set, semi-quantitative RT-PCRs on the 
fgI2 mRNA expression were performed on cDNA templates prepared from the 
HepG2 cells that were transfected with pCMV-TagI empty vector 
pCMV-TagI-SARS-CoV M expression vector and pCMV-TagI-SARS-CoV N 
expression vector. The cDNA templates were first normalized by the housekeeping 
gene GAPDH (Figure 28B). From the RT-PCR results, when compared with the 
pCMV-TagI empty vector-transfected HepG2 cells (Figure 28A, lane 1), there -was a 
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1.51-fold induction on the fgl2 mRNA expression level when 0.10 |ig of 
pCMV-TagI-SARS-CoV N expression vector was transfected in HepG2 cells (Figure 
28A, lane 3). There was almost no increase on \hQfgl2 mRNA expression when 0.10 
fig of pCMV-TagI-SARS-CoV M expression vector was transfected in HepG2 cells 
(Figure 28A, lane 2) when compared with the pCMV-TagI empty vector-transfected 
HepG2 cells (Figure 28A，lane 1). This indicated the fgl2 mRNA expression was 
specifically induced by SARS-CoV N protein but not other SARS viral proteins, 
such as the SARS-CoV Membrane protein, in HepG2 cells. There was no change on 
the mRNA expression level of the housekeeping gene, GAPDH, (Figure 28B) and 
this indicated the SARS-CoV N protein specifically induced ih&fgl2 gene expression 
but not other genes. The induction by SARS-CoV N protein was gene-specific iofgl2. 
All RT-PCRs were repeated for four times. The RT-PCR results on they^/2 induction 
‘ by SARS-CoV N protein in HepG2 cells were consistent with the results obtained 
from the dual-luciferase reporter assay in HepG2 cells. 
Similarly, semi-quantitative RT-PCRs on the fgl2 mRNA expression were also 
carried out on cDNA templates prepared from the VE6 cells that were transfected 
with pCMV-TagI empty vector, pCMV-TagI-SARS-CoV M expression vector and 
pCMV-TagI-SARS-CoV N expression vector. The cDNA templates were first 
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normalized by the housekeeping gene GAPDH (Figure 29B). According to the 
RT-PCR result (Figure 29A, lane 3)，when compared with the pCMV-Tagl empty 
vector-transfected VE6 cells (Figure 29A, lane 1), there was a 2.11-fold induction on 
the fgl2 mRNA expression level when 0.10 i^g of pCMV-TagI-SARS-CoV N 
expression vector was transfected in VE6 cells. There was almost no increase on the 
fgl2 mRNA expression when 0.10 |ig of pCMV-TagI-SARS-CoV M expression 
vector was transfected in VE6 cells (Figure 29A, lane 2) when compared with the 
pCMV-TagI empty vector-transfected VE6 cells (Figure 29A, lane 1). This indicated 
the7^/2 mRNA expression was specifically induced by SARS-CoV N protein but not 
other SARS viral proteins, such as the SARS-CoV Membrane protein, in VE6 cells. 
There was no change on the housekeeping gene, GAPDH, mRNA expression level 
(Figure 29B). This indicated the SARS-CoV N protein induced the fgl2 gene 
‘ expression in a gene-specific manner. All RT-PCRs were repeated for four times. The 
RT-PCR results on the fgl2 induction by SARS-CoV N protein in VE6 cells were 
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Figure 24. Effect of pCMV-TagI empty vector, SARS-CoV M protein and 
SARS-CoV N protein onfgU promoter activity in HepG2 cells. Different amounts 
of the pCMV-TagI empty vector, pCMV-TagI -SARS-CoV-M protein expression 
vector or pCMV-TagI -SARS-CoV N protein expression vector were co-transfected 
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with^/2-pGL3 construct. pRL-CMV, which encoded a renilla luciferase protein, was 
employed as the internal control to normalize the transfection efficiency. The relative 
luciferase activity was determined with the dual luciferase reporter assay system 
(Promega). Values represent the mean 士S.D. (standard derivation) of eight sets of 
separate experiments done in triplicate. The statistical significance is determined at a 
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Figure 25. Comparison on the fold enhancement on fgl2 promoter activity by 
different amounts of pCMV-Tagl empty vector, pCMV-Tagl-SARS-CoV M 
protein expression vector and pCMV-Tagl-SARS-CoV N protein expression 
vector in HepG2 cells. Values represent the mean 士S.D. (standard derivation) of 
eight sets of separate experiments done in triplicate. The statistical significance is 
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Figure 26. Effect of pCMV-TagI empty vector, SARS-CoV M protein and 
SARS-CoV N protein onfgl2 promoter activity in VE6 cells. Different amounts of 
the pCMV-TagI empty vector, pCMV-TagI -SARS-CoV M protein expression vector 
or pCMV-TagI-SARS-CoV N protein expression vector were co-transfected with 
fgl2-pGL3 construct. pRL-CMV, which encoded a renilla luciferase protein, was 
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employed as the internal control to normalize the transfection efficiency. The relative 
luciferase activity was determined with the dual luciferase reporter assay system 
(Promega). Values represent the mean 士S.D. (standard derivation) of eight sets of 
separate experiments done in triplicate. The statistical significance is determined at a 
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Figure 27. Comparison on the fold enhancement on fgl2 promoter activity by 
different amounts of pCMV-TagI empty vector, pCMV-Tagl-SARS-CoV M 
protein expression vector and pCMV-Tagl-SARS-CoV N protein expression 
vector in VE6 cells. Values represent the mean 士S.D. (standard derivation) of eight 
sets of separate experiments done in triplicate. The statistical significance is 
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Figure 28. Expression of fgl2 mRNA in HepG2 cells under induction by 
pCMV-Tagl-SARS-CoV-N expression vector. Semi-quantitative RT-PCRs were 
carried out with the fgl2 gene-specific primer set. Lane 1，CI: Control sample 
transfected with 0,10 of pCMV-Tag 1 empty vector; Lane 2, C2: Control sample 
• transfected with 0.10 |ag of pCMV-Tag 1 -SARS-CoV M expression vector Lane 3, T: 
Test, sample transfected with 0.10 |ig of pCMV-TagI -SARS-CoV-N expression 
vector (A) An increase in the mRNA expression of fgl 2 gene was observed under the 
induction of SARS-CoV-N protein expression in HepG2 cells. The band intensity of 
CI: Control sample transfected with 0.10 jig of pCMV-Tag 1 empty vector in Lane 1 
was regarded as 1. The relative fold inductions on band intensity of C2 and T were 
calculated. (B) The cDNA templates from HepG2 cells were first normalized with the 
housekeeping gene GAPDH. The band intensities were measured by gel-dot 
densitometry. These experiments were repeated four times and the results shown here 
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Figure 29. Expression of fgl2 mRNA in VE6 cells under induction by 
pCMV-Tagl-SARS-CoV-N expression vector. Semi-quantitative RT-PCRs were 
carried out with the fgl2 gene-specific primer set. . Lane 1, CI: Control sample 
transfected with 0.10 |ig of pCMV-TagI empty vector; Lane 2, C2: Control sample 
transfected with 0.10 )ig of pCMV-TagI-SARS-CoV M expression vector Lane 3, T: 
Test, sample transfected with 0.10 [ig of pCMV-Tagl-SARS-CoV-N expression 
vector (A) An increase in the mRNA expression offgl2 gene was observed under the 
induction of SARS-CoV-N protein expression in VE6 cells. The band intensity of CI: 
Control sample transfected with 0.10 [ig of pCMV-TagI empty vector in Lane 1 was 
regarded as 1. The relative fold inductions on band intensity of C2 and T were 
calculated. (B) The cDNA templates from VE6 cells were first normalized with the 
housekeeping gene GAPDH. The band intensities were measured by gel-dot 
densitometry. These experiments were repeated four times and the results shown here 
are from a single experiment representative of similar experiments. 
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CHAPTER FOUR DISCUSSION 
4.1. The EGFP-tagged SARS-CoV N protein was localized in the cytoplasm 
only in VE6 cells, but translocated into both cytoplasm and nucleus in HepG2 
cells in the £?/7/-fluorescence microscopy study 
The subcellular localization of the SARS-CoV N protein is one of our aims of 
study. Thus, the SARS-CoV N protein was cloned into pEGFP-Cl mammalian 
expression vector that gave an Enhanced Green Fluorescent Protein (EGFP) tag to 
the N-terminal of the SARS-CoV N protein. This gave us an opportunity to explore 
the biological intracellular location of the SARS-CoV N protein. The EGFP-tagged 
SAR-CoV N protein was expressed for 24 hours in VeroE6 and HepG2 cells 
separately. Any green fluorescent signals were then observed under the epi-
fluorescent microscope. 
In our study, when the VE6 transfectants were subjected to epi- fluorescence 
microscopy, the EGPP-tagged SARS-CoV N protein was found to be localized in the 
cytoplasm only (Figure. 14). According to the Western blotting in Figure 11，lane 3, 




pEGFP-S ARS-CoV-N-transfected VE6 cells should be due to the expression of both 
EGFP-tagged SARS-CoV-N protein and EGFP. The cytoplasmic localization of the 
SARS-CoV N protein is unique in the CoVs family since previous studies on other 
CoVs have shown that translocation to the nucleolus of the host cells is a common 
feature of CoVs N proteins. Reports on Group 1 transmissible gastroenteritis virus 
(TGEV), Group 2 murine hepatitis virus (MHV) and Group 3 infectious bronchitis 
virus (IB V) all described that their N proteins were localized in the cytoplasm as well 
as the nucleolus (Wurm et al, 2001, Chen and Wurm et al, 2002). The N proteins of 
these CoVs would interact with some nucleolar antigens, such as importin, nucleolin 
and fibrillarin, in order to control the host cell processes. Although several NLSs and 
NoLSs were predicted in the SARS-CoV nucleocapsid amino acid sequence analysis 
(Figure 8)，no nuclear signals were observed in the pEGFP-SARS-CoV-N-transfected 
VE6 cells. The NLSs and NoLSs in the SARS-CoV N protein are not functional in 
VE6 cells in our study. 
Our result on VE6 cells was in accordance with the work by Chang's group. His 
group made use of the affinity-purified anti-nucleocapsid antibodies to perform 
indirect immunofluorescence staining on the SARS-CoV infected VE6 cells. Their 
result showed that while no nuclear or nucleolar signals were observed, florescent 
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signals were predominantly distributed in the cytoplasm (Chang et al, 2004). Taken 
together with our results in pEGFP-SARS-CoV N-transfected VE6 cells, this 
indicates that the EGFP tag in the SARS-CoV N protein in our study should not 
affect its subcellular localization. 
HepG2 cells were also used in the localization study of SARS-CoV N protein in 
our study. According to Figure 15, HepG2 cells transfected with 
pEGFP-SARS-CoV-N expression vector showed strong fluorescent signals in the 
cytoplasm and weak fluorescent signals in the nuclear region. In the Western blotting 
in Figure 12, lane 3，there were expressions of both EGFP-tagged SARS-CoV N 
protein and EGFP in the pEGFP-SARS-CoV-N-transfected HepG2 cells. The strong 
fluorescent signals detected in the cytoplasm in HepG2 cells might be due to the 
presence of both EGFP-tagged SARS-CoV N protein and EGFP protein. The weak 
fluorescent signal observed in the nuclear region of 
pEGFP-SARS-CoV-N-transfected HepG2 cells might be due to the entry of the 
minute amount(s) of either or both 'EGFP-tagged SARS-CoV N protein and EGFP 
into the nucleus of HepG2 cells. Confocal microscopy should be performed in the 
future to verify if there is presence of any fluorescent signal in the nucleus of the 
HepG2 cells that were transfected with pEGFP-SARS-CoV N expression vector.' 
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For the HepG2 cells that were transfected with the pEGFP-SARS-CoV-AN 
expression vector, these cells also showed strong fluorescent signal from the 
cytoplasm and weak fluorescent signal from the nucleus (Figure 15). Although there 
was a deletion on the bipartite NoLS at a.a 373-390 in the mutant of EGFP-tagged 
SARS-CoV-AN protein, its subcellular localization was similar to the full-length of 
the EGFP-tagged SARS-CoV N protein (Figure 15). This indicates that the 
fluorescent signal observed in the nuclear compartment of SARS-CoV N protein is 
independent of the bipartite signal predicted on a.a. 373-390 on the viral protein 
sequence. According to the Western blotting in Figure 13, lane 3, both EGFP-tagged 
SARS-CoV N protein and EGFP were expressed in the pEGFP-SARS-CoV-A 
N-transfected HepG2 cells. Thus, the strong fluorescent signals detected in the 
cytoplasm in pEGFP-S ARS-CoV- A N-transfected HepG2 cells might be due to the 
presence of both EGFP-tagged SARS-CoV AN protein and EGFP protein. The weak 
fluorescent signals observed in the nuclear region of pEGFP-SARS-CoV- A 
N-transfected HepG2 cells might be due to the entry of the minute amount(s) of 
either or both EGFP-tagged SARS-CoV AN protein and EGFP into the nucleus of 
HepG2 cells. However, since EGFP gave a uniform fluorescent signal in the nucleus 
under normal circumstances (Figure 15), the nuclear signal observed should be 
unlikely due to that of EGFP. Again, confocal microscopy should be performed in the 
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future to verify if there is presence of any fluorescent signal in the nucleus of the 
HepG2 cells transfected with pEGFP-SARS-CoV AN expression vector. 
It is an interesting phenomenon that the SARS-CoV N protein would be 
localized in different cellular compartments in different cell type - only in cytoplasm 
in VE6 cells, but in both cytoplasm and nucleus in HepG2 cells. Such differences in 
these two mammalian cell lines may be related to the species and tissue specificity 
between VE6, which is derived from African Green monkey kidney cells, and HepG2, 
which is a human hepatocellular carcinoma cell line. The differences in the 
subcellular localization of SARS-CoV N protein might be related to the species 
specificity between human and the African Green monkey in their response to SARS 
infection. While SARS-CoV infection could cause severe illness and casualties in 
human beings, studies on anti-SARS vaccine development has showed that the 
African Green monkeys were relatively tolerated to SARS infection (Gao et al, 2003, 
Bukreyev et al, 2004). This is similar to the species specificity between human and 
the African green monkey during HIV infection. While HIV results in AIDS and 




The intracellular cellular localization of SARS-CoV N protein has been reported 
by other research groups in different cell lines recently. A research group in Mainland 
China has demonstrated that the SARS-CoV N protein was localized in cytoplasm 
and nucleolus in insect cells Trichoplusia BTl Tn 5B1-4 (Ren and Xie et al, 2004). 
A more recent publication from a research group in Singapore has revealed that the 
SARS-CoV N protein was localized in the cytoplasm as well as the nucleolus in the 
HeLa cells by the confocal microscopy (Li and Xiao et al, 2005). Li and his 
colleagues have also demonstrated that the nucleolar translocation of SARS-CoV N 
protein is dependent on its post-translational modification by sumoylation. They 
mutated the sumoylation site at lysine 62 a.a. residue to alaine residue to create a 
K62A mutant of SARS-CoV N protein. They found that much less nucleolar 
localization was seen in HeLa cells expressing this mutant. This indicates that the 
subcellular localization SARS N protein would be regulated by sumoylation rather 
than the NLSs. Sumoylation is a post-translational modification by the conjugation 
of the target protein to the small ubiquitin like modifier (SUMO). The consensus 
sequence for a sumoylation site is ‘中KXE’，where中 represents a hydrophobic 
residue, K represents a lysine residue, X represents any amino acid residue, and E 
represents a glutamate residue. The effect of SUMO modification plays a number of 
crucial roles on the target proteins and these include altering the protein activity, 
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protein-protein interactions, nucleocytoplasmic signalling and transport, and the 
regulation of gene expression (Seeler et al, 2003, Watts et al, 2004) 
Li et al. observed that there were apparently a large number of mulitnucleated 
when the SARS-CoV N protein was overexpressed in HeLa cells. These 
multinucleated cells were quantitated. Li's group discovered that over 25% of HeLa 
cells expressing the SARS-CoV-N protein were undergoing cell division. The 
percentage of HeLa cells undergoing cell division even increased to 31-36% when 
there were over-expression of both sumo-1 and SARS-CoV N protein. But when 
sumo-1 was over-expressed with the K62A mutant of SARS-CoV N protein, whose 
sumoyolation site was mutated to be non-functional, the percentage of HeLa cells 
undergoing cell division markedly reduced to 11 to 15%. Thus, Li's group has 
• proposed that post-translational modification of SARS-CoV N protein by SUMO 
may play an important role to affect the host cell division. 
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4.2. cDNA microarray demonstrated alternations of mRNA transcript level on a 
number of genes belonging to various functional classes upon over-expression of 
SARS-CoV nucleocapsid gene 
In our study, we employed cDNA microarray analysis to characterize the 
cellular transcriptional response of homologous human genes upon the 
over-expression of SARS-CoV N protein. Data obtained from Affymetrix analysis 
showed that 109 human homologous genes were upregulated and 159 human genes 
were downregulated in their mRNA transcriptional levels. 2. Since it was difficult to 
deal with such a large number of genes to confirm their differential expression 
patterns by the semi-quantitative RT-PCR, we first studied the 19 exclusively 
upregulated genes, which gave signals exclusively from the experimental array only 
* but not the control, and the 27 exclusively downregulated gene, which gave signals 
exclusively from the control array only but not the experimental one, as suggested by 
the product specialists from Affymetrix Inc. 
For the 19 exclusively upregulated genes, they belong to 12 different functional 
categories related to transcription, glycerolipid metabolism, purine metabolism, 
phospholipid metabolism, phospholipid transporting, proinflammatory, signal 
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transduction, phosphorylation of nucleoside diphosphate, neutral activity, autosomal 
recessive disease, DNA mistach-repair and novel genes (Table 5). The 6 
transcriptional related genes include homeobox A7 (H0XA7), msh homeobox 
homolog 2 (Drosophila) (MSX2), ETS-domain protein (SRP accessory protein 1) 
(ELK4), myeloid ecotropic viral integration site 1 homolog 2 (mouse) (MEIS2), 
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila) 
(MLLT3), and bobby sox homolog (Drosophila) (BBX). Since 6 out of the 19 
exclusively upregulated genes are related to transcription, it is suggested that the 
SARS-CoV nucleocapsid might have novel functions to affect the host cell process 
by interfering the normal transcriptional levels to disrupt the host cell transcriptional 
machinery. 
* The genes that are related to glycerolipid metabolism, purine metabolism, 
phospholipid metabolism and phospholipid transporting include glycerol kinase 
(GK), adenosine kinase (ADK) phospholipase A2 receptor 1 (PLA2R1) and ATPase, 
Class II，type 9A (ATP9A). The upregulation of these genes imply that the 
SARS-CoV nucleocapsid could also interfere the host cell process through its action 
on the basal cellular metabolism. The two exclusively upregulated proinflammatory 
genes in response to SARS-CoV nucleocapsid induction are the chemokine (C-X-C 
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motif) ligand 11 (CXCLll) and interleukin 18 receptor 1 (IL18R1). This indicates 
that the SARS-CoV nucleocapsid might be one of the causes for the inflammatory 
response that occur during SARS infection. The signal transduction process is also 
affected in response to SARS-CoV nucleocapsid induction as the mRNA transcripts 
of two novel signal transduction molecules, the A kinase (PRKA) anchor protein 13 
(AKAP13) and insulin-like growth factor binding protein, are exclusively 
upregulated. Since the gene transcript of the non-metastatic cells 6 (NME6) is also 
exclusively upregulated, this implies that the SARS-CoV nucleocapsid protein would 
not only be phosphorylated but this viral gene would also affect the phosphorylation 
of other biomolecules, such as the nucleoside diphosphate. However, the reasons for 
the SARS-CoV nucleocapsid to induce the mRNA transcripts of a few genes that are 
related to neutral activity, autosomal recessive disease and DNA mistach-repair still 
• remain unidentified. 
( 
For the 27 exclusively downregulated genes, they are classified into 11 
functional categories related to ion/ small molecule transport, transcription, signal 
transduction, calmodulin binding, calcium-dependent cell-cell adhesion, lysosomal 
cysteine proteinase, iron absorption, neuronal excitability, GTP binding, oxidation 
phosphorylation and novel genes (Table 6). The five gene transcripts relaied to ion/ 
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small molecule transport, which include the potassium channel tetramerisation 
domain containing 12 (KCTD12), solute carrier family 16 (monocarboxylic acid 
transporters), member 1 (SLC16A1), solute carrier family 7 (cationic amino acid 
transporter, y+ system) member 8 (SLC7A8), transient receptor potential cation 
channel subfamily C, member 1 (TRPCl) and ATP-binding cassette, sub-family C 
(CFTR/MRP) member 9 (ABCC9) and one gene related to iron absorption, which is 
the hemochromatosis (HFE), are downregulated in response to the over-expression 
SARS-CoV nucleocapsid. This may imply that the SARS-CoV nucleocapsid may 
develop novel strategies to control the host cellular process or to facilitate the viral 
replication by shutting down the transport of a number of necessary ions and 
molecule into the host cells that might, in turn, interfere the host cells to evoke 
certain cellular response by these necessary ions and molecules to act against the 
, S A R S virus during infection. 
The expression levels of certain mRNA transcripts related to transcriptional 
regulation, such as zinc finger protein 652 (ZNF652), AT rich interactive domain 4A 
(ARID4A)，ALU fused gene from 5q31 (AF5Q31), E74-like factor 1 (ELFl) and 
suppressor of zeste 12 homolog (SUZ12), and signal transduction, such as, sialic acid 
binding Ig-like lectin 8 (SIGLEC8) and Interleukin 6 signal transducer (IL6ST), are 
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found to be downregulated in response to SARS-CoV nucleocapsid expression. As 
mentioned in the previous paragraph, the SARS-CoV nucleocapsid would also 
upregulate the expression of a number of transcriptionally related genes and signal 
transduction molecules (Table 5). Taken together, this indicates the SARS-CoV 
nucleocapsid would alter the host cell transcriptional machinery and signal 
transduction cascade in both directions - by the upregulation and downregulation of 
different sets of related genes. 
Striatin (STRN), which encode a calmodulin binding protein, and cadherin 12， 
type 2(CDH12), which encodes a calcium-dependent cell adhesion molecule, are 
found to be downregulated upon the SARS-CoV nucleocapsid expression. This 
suggests that the SARS-CoV nucleocapsid would also interfere the normal cellular 
, ac t iv i t ies by downregulating certain calcium ion-related biological processes in the 
host. 
Gene transcripts involved in other cellular metabolism processes are also 
downregulated in response to the expression of SARS-CoV nucleocapsid. For 
example, a GTP-binding protein, the guanylate binding protein 1 (GBPl), and an 
ATPase, the ATPase, H+ transporting, lysosomal VI subunit A, are downregulated. It 
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is believed that the SARS-CoV has developed a number of novel functions to take 
over the basal cellular machinery in the host by downregulating various metabolic 
processes through the action of the SARS-CoV nucleocapsid. The reasons and 
outcomes of those cellular processes that are affected by the SARS-CoV 
nucleocapsid, however, remain to be studied in the future. 
To verify the data from Affymetrix analysis (Table 5 and 6), semi-quantitative 
RT-PCRs were carried out. A homeobox gene, homeobox A7 (H0XA7), was 
confirmed to be differentially expressed upon SARS-CoV nucleocapsid expression 
with about 3 fold of induction (Figure 19A, lane 2) when compared with the 
pCMV-TagI empty vector-transfected control sample (Figure 19A, lane 1). 
‘ In human, 39 homeoboxes (HOX) genes have been identified so far and they are 
clustered into 13 groups distributed on chromosomes 7 (HOXA), 17 (HOXB), 12 
(HOXC) and 2 (HOXD). Generally, the homeobox protein, which consists of 
hexapeptide, homeodomain and C-terminal acidic domain, functions as transcription 
factor to regulate the expression of other genes. The homeodomain is responsible for 
the recognition and binding on the c/5-regulatory elements of the affected gene to 
f 
regulate its expression. The HOX genes encode DNA-binding transcription factors 
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that have various regulatory functions, such as regulation of gene expression, 
morphogenesis and differentiation spatially and temporally. Since the HOX genes are 
normally required for differentiation of a particular tissue, they play a causal role in 
the development of carcinogenesis of that tissue if expressed at the wrong time, at the 
wrong level, or in wrong context. 
Human H0XA7 gene is a part of the A cluster on chromosome 7. It is 
frequently over-expressed in acute myeloid leukemia and correlated with the 
occurrence of MLL translocations (Afonja et al” 2000, Calvo et al” 2002, Ayton et 
cd., 2003, Quentmeier et al., 2004). Increased H0XA7 expression level was also 
reported in human lung cancer, esophageal squamous cell carcinoma and epithelial 
ovarian cancer (Calvo et al, 2000, Chen and Gu et al., 2005, Naora et cd., 
2001,Cheng et al.’ 2005). A study on the tissue specific expression of the mRNA 
transcript of human H0XA7 showed that it is expressed in most tissues, such as lung, 
liver, skeletal muscle, kidney, pancreas and placenta, but not in brain tissue (Kim and 
Jin et al., 2000). During embryonic morphogenesis, the HOX genes determine 
positional identity along anterior-posterior axes according to the colinearity rules and 
H0XA7 was reported to be involved in the anterior boundary formation in transgenic 
mouse embryos (Kawanishi et al” 2003, Gaunt et al” 2004). During HL-60 
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monocytic differentiation, H0XA7 was reported to be down-regulated and its 
sustained expression would disturb the regulation of cell adhesive and migratory 
abilities on fibronectin during early differentiation (Leroy et al., 2004). This was 
accompanied by the partial blockage of the transcriptional induction of the 
proline-rich tyrosine kinase 2, which encoded a focal adhesive kinase and a tissue 
transglutamine, which encoded a fibronectin coreceptor specifically in monocytes. It 
also played an important role in regulating keratinocyte transglutaminase type 1 
(TGMl) expression. The expression of H0XA7 was demonstrated to be inversely 
related to differentiation-specific transglutminase type 1 (TGMl) expression and 
keratinocyte differentiation. This homeobox protein repressed TGMl expression by 
binding to the regulatory element of TGMl (La Celle et al., 2001). 
The finding of the elevated level of a homeobox gene mRNA transcript 
regarding to the expression of a viral mRNA is novel. The relationship between 
homeobox genes and viral infection is rarely mentioned in the literature. The 
expression of H0XA13 gene was closely related with hepatitis B and C associated 
human hepatocellular carcinoma (HCC) (Huang and Chesnokov et al., 2001). 
Up-regulation of two HOX genes, HOXAl and H0XA5, which encode from the 




Study on host gene transcriptomes upon SARS-CoV infection (Tang and Chan et al, 
2005), though their results had not been confirmed by RT-PCR or Real-time 
PCR .The GeneChip employed by Tang and Chan et al. was the same as ours. The 
co-expression of the H0XA5 and H0XA7 has been often reported in the acute 
leukemia (Quentmeier et al., 2004). During human skin development, H0XA5 and 
H0XA7 showed similar expression patterns and they were detected in the basal cell 
layers of the 10-week fetal epidermis and throughout the epidermis and dermis of 
17-week skin (Stelnicki et al, 7998). Although co-expressions of H0XA5 and 
H0XA7 have been reported in acute leukemia and human skin development, their 
relationships with viral infection has not yet been established. Relationships among 
HOXAl, H0XA5 and H0XA7 are even weaker since there are yet no reports 
regarding to expression patterns and functional relationships among these three 
” homeobox genes on viral infection. 
It is suggested that the elevated H0XA7 gene expression was not an artifact of 
our experiment as HOXAl and H0XA5 were also upregulated in a similar cDNA 
microarray study. In contrast, it implies the virus has evolved with a novel strategy in 
controlling the host cell by interrupting the normal expression levels of HOX genes 
ill the host through the action of the SARS-CoV nucleocapsid. , 
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4.3. RNA interference demonstrated effective gene silencing of SARS-CoV 
nucleocapsid gene 
RNA interference (RNAi), a post-transcriptional gene silencing (PTGS) 
mechanism mediated by small interfering RNA (siRNA), is an evolutionarily 
conserved cellular mechanism to protect the genome against invasion by mobile 
genetic elements such as viruses and transposons. It was first discovered in the 
nematode worm Caenorhabditis elegans when injection of double-stranded RNA 
(dsRNA) into the worm initiated a potent sequence-specific degradation of 
cytoplasmic mRNA containing the same sequence as the dsRNA trigger. The 
phenomena of RNAi was further demonstrated in various studies on several 
eukaryotic organisms such as plants, Drosophila, Planaria, Hydra, Zebrafish, mice 
and mammalian cell lines. 
The SARS-CoV is a good target for RNAi because it is an RNA virus and 
makes use of its viral RNA at various stages of its viral replication. By targeting the 
RNAi machinery towards the viral RNA, the SARS-CoV viral RNA genome can be 
targeted within the host cell before it is transcribed into sg RNA templates for viral 
protein synthesis in early infection. In the late phase of infection, the RNAi can target 
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the newly synthesized viral genomic RNA before it is packed inside the viron and sg 
RNA to block further viral replication. Since the SARS-CoV nucleocapsid protein 
plays an important role in the viral replication and its sequences are highly conserved 
in different strains of SARS-CoV isolated by different research groups, it may be a 
good target to inhibit the SARS-CoV replication by blocking the expression of this 
viral mRNA, and in turn reducing viral protein synthesis. 
To explore the possibility of silencing the SARS-CoV nucleocapsid gene by 
RNAi technique, we cloned the SARS-CoV nucleocapsid gene into a mammalian 
expression vector pCMVTagl and expressed the viral protein in VE6 cells. 4 
candidate target sequences corresponding to SARS-CoV N gene were selected and 
were in vivo transcribed from pSilencer-3.l-ll\ vector to express shRNA that could 
* be recognized and processed by Dicer to generate functional siRNA within the cells. 
These 4 selected regions are fully conserved among all strains of SARS-CoV 
nucleocapsid gene in order to prevent the escape from siRNA pressure. The in vivo 
transcribed recombinant shRNA expression vectors were introduced into VE6 cells 
transfected with SARS-CoV nucleocapsid protein expression vector by 
lipofectamine-plus reagent. Although siRNAs can be acquired through several 
methods, such as chemical synthesis of siRNA, in vitro transcription fiom, PGR 
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cassettes, in vivo expression from viral-based vectors, the shRNA-expression vector 
with the RNA polymerase III promoter, the human HI promoter was adopted in our 
study. There were several reasons for our choice. The pol III promoters can express 
small RNAs that carry structural features of siRNA and are used most frequently in 
many RNAi research studies because of economic reasons. In vivo transcription from 
shRNA expression vector could also avoid the handling of RNA, which is subject to 
degradation easily. 
Semi-quantitative RT-PCRs were performed to examine the mRNA levels of 
SARS-CoV nucleocapsid gene in shRNA co-transfected cells. The data showed that 
GFP-siRNA，N-siRNAl, N-siRNA2, N-siRNA3 and N-siRNA4 reduced the 
accumulation of N gene mRNA (Figure 20A, lane 3, 4，5, and 6) with different 
• magnitudes when compared with samples from transfectants with 
pCMV-TagI -SARS-nucleocapsid protein expression vector alone (Figure 20A, lane 
1). The S-siRNA，which targeted the SARS-CoV Spike gene, was applied as a 
negative control and had only a small inhibitory effect on N mRNA (Figure 20A, 
lane 2). GAPDH mRNA was not affected by any shRNA constructs (Figure 20B). 
The RT-PCR analysis showed that the SARS-CoV nucleocapsid transcription level in 
all N gene-targeting shRNA-expressiiig constructs transfected VE6 cells reduced 
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significantly. Over 80% inhibition of SARS-CoV nucleocapsid transcript was 
observed in cells transfected with N-siRNAl，N-siRNA2 and N-siRNA3 constructs 
(Figure 20A, lane 3,4,5), while the N-siRNA4 construct suppressed the viral 
transcript with approximately 30% (Figure 20A, lane 6). The GFP-siRNA construct 
was generated according to the sequence targeting GFP gene obtained from Ambion 
Inc.. A certain degree in decreasing the SARS-CoV N gene transcript in VE6 cells 
co-transfected with this shRNA expression vector might be possibly explained by its 
off-target effect. 
We also examined the SARS-CoV N protein expression levels in the presence or 
absence of shRNA-expression vectors. Western blot analysis showed that compared 
with the cells transfected with pCMVTagl-N alone, the SARS N protein expression 
‘ was reduced in cells co-transfected with GFP-siRNA, N-siRNAl, N-siRNA2, 
N-siRNA3 and N-siRNA4 (Figure 22A lane 4,5,6,7). 
VE6 cells co-transfected with negative control S-siRNA, showed a small extent 
in the suppression of SARS-CoV nucleocapsid protein (Figure 22A, lane 3) and this 
might be explained by its off-target effect. The degrees of inhibition of the viral 
protein expression by different tested shRNA expression vectors were consistent with 
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the results obtained from RT-PCR analysis in Figure 20. Among the four tested 
shRNAs, N-siRNA3 demonstrated the highest ability with around 90% inhibition 
(Figure 22A，lane 6). The N-siRNAl and N-siRNA2 suppressed the viral protein 
expression level with about 80% reduction (Figure 22A, lane 4&5). The inhibition of 
SARS-CoV N protein by N-siRNA4 was about 30% (Figure 22A, lane 7). As a 
loading control, GAPDH was not affected by any of the shRNA expression vectors 
(Figure 22B). The GFP positive control, GFP-siRNA, demonstrated a high potency 
in suppressing the GFP expression (Figure 22C, lane 3). This indicated that the 
shRNA expression vectors were transfected and transcribed successfully in the 
cultured cells. Data from both RT-PCR and western blotting indicated that the 
siRNAs generated in vivo from shRNA expression vectors silenced SARS-CoV N 
protein expression through blocking the accumulation of SARS-CoV N mRNA. 
The design of a biologically active siRNA seems to be somewhat a hit-or-miss. 
It is difficult to predict the effectiveness of a certain siRNA and is clear from various 
studies that not all siRNA are equally efficient in generating RNAi response. The 
reasons for these differences are currently not well understood, but likely involve 
secondary structure both in the siRNA and the target viral RNA. The position of the 
siRNA viral recognition sequence in the targeting mRNA has a marked impact on the 
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efficiency of gene silencing. The mRNA sequences that are sensitive to 
siRNA-mediated silencing can be relatively insensitive when placed into a highly 
structured region of RNA. This indicates that target mRNA structure could dictate 
the degree to which target sequence is accessible to the siRNA. In addition, the 
binding of viral and cellular protein to the target mRNA may also prevent the 
recognition of the target by the RISC complex. 
We have tried to look for any explanation on the effectiveness of our four tested 
siRNA target sequences, which were proven to be effective in suppressing the 
SARS-CoV nucleocapsid mRNA and protein expression (Table 2), and the 
incapability of another five siRNA target sequences, which were ineffective on the 
inhibition of SARS-CoV nucleocapsid mRNA and protein expression (Appendix 6)， 
•• however, those so-called "rules" on the siRNA design generated by other groups 
(Schwarz et al., 2003, Ui-Tei et al., 2004) were not able to explain the potency of all 
our nine siRNA sequences targeting different regions of he SARS-CoV nucleocapsid 
gene sequence. Thus, we have worked out two guidelines for siRNA design 
according to the GC contents and the nucleotide sequences of our nine siRNAs, 
which targeted the SARS-CoV nucleocapsid gene. 
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The target positions on the SARS-CoV N gene, the sense strand of the target 
sequences and the GC contents of all the nine siRNAs are given in Table 7. These 
nine siRNA target sequences are divided into 3 groups, highly effective, intermediate, 











































































































































































































































































































































































































































































































































































































































































































































































































































































































The N-siRNAl, N-siRNA2 and N-siRNA3 are classified as the "highly 
effective siRNAs". The N-siRNA2 and N-siRNA3 have low GC contents, which are 
about 33.30/0 for both. Although the N-siRNAl has a relatively higher GC content 
(47.6%) when compared with those of N-siRNA2 and N-siRNA3, the N-siRNAl 
was still potent in suppressing the expressions of both the SARS-CoV nucleocapsid 
mRNA and protein. The N-siRNA4 is regarded as the "intermediate siRNA". Its GC 
content is about 38.1% which is a bit higher than the "highly effective siRNA-
N-siRNA2 and N-siRNA3". 
For the five "ineffective siRNAs", 2 out of 5, which are the N-siPNA5 and 
N-siRNA8, have GC contents higher than 40%. Another 2 target sequences out of 5, 
which are the N-siRNA6 and N-siRNA9, have GC contents around 38.1%. Though 
N-siRNA7 has the lowest GC content, about 28.6%, among all the nine tested siRNA 
target sequences, N-siRNA7 was still found to be ineffective in suppressing the 
SARS-CoV nucleocapsid mRNA and protein expressions. 
According to the GC contents of these nine siRNAs, target sequence with a low 
GC content, around 33.3%, is more likely to be a highly effective siRNA as 2 out of 




about 33.3%. Only one siRNA target sequence having a relatively higher GC content 
about 47.6%, the N-siRNAl, was potent in generating RNAi response in the 
SARS-CoV nucleocapsid mRNA and protein expressions. This suggests that siRNA 
target sequence with a lower GC content is more likely to be an effective one. It is 
further supported when the GC contents of the "intermediate" and "ineffective" 
siRNAs are taken into our consideration. The GC contents of N-siRNA4, which is 
regarded as an "intermediate siRNA" and N-siRNA5, N-siRNA6, N-siRNA8 and 
N-siRNA9, which are classified as "ineffective" siRNAs", all range from 38.1% to 
42.9%. Their GC contents are comparatively higher when compared with the "highly 
effective siRNAs". A lower GC content might make the potential siRNA to be more 
effective. However, we notice that the effectiveness of an siRNA does not increase 
with a low GC content. The N-siRNA7 has the lowest GC content, about 28.6%, but 
it is an ineffective siRNA. Taken together, this implies that an optimal GC content is 
required for the design of an effective siRNA. 
It is also noted that target sequences that begin with an A residue at the 5' end of 
the sense strand, which are the N-siRNA2 and N-siRNA3, are more effective in 
suppressing the SARS-CoV nucleocapsid mRNA and protein expressions. The 
siRNA sequences that start with an G/ C residue would usually give intermediate 
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RNAi response, such as the N-siRNA4, or even ineffective RNAi response, such as 
the N-siRNA8 and N-siRNA9. For the siRNAs that begin with the T residue in the 
5'end of the sense strand, however, their RNAi effects vary significantly. The 
effective N-siRNAl and the ineffective N-siRNA5, N-siRNA6 and N-siRNA7 all 
begin with an T residue in the 5' ends of their sense strands. According to these four 
siRNA target sequences (N-siRNAl, N-siRNA5, N-siRNA6, and N-siRNA7), target 
sequence that begins with an T residue is less likely to be an effective siRNA. 
According to our nine target sequences, two guidelines regarding to the design 
of a highly effective siRNA are suggested. Guideline I: the GC content should not be 
higher than 38% and should not be lower than 30%, according to our nine siRNA 
sequences that targeted against the SARS-CoV nucleocapsid gene, the optimal GC 
. content for an effective siRNA should be around 33%. Guideline II: target sequence 
that begins with an A residue at the 5' end of its sense strand has a higher potency in 
generating a highly effective RNAi response to the target gene; while target sequence 
that begins with an G/ C residue at the 5' end of its sense strand is less likely to be an 
effective one. Since these rules cannot explain why N-siRNAl worked, other 
consideration about the secondary structure of the target mRNA might also be 
important in the siRNA design. . 
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A research group in Mainland China has also identified an effective 
21mer-siRNA sequence targeting at the position of 388 nucleotide of the SARS-CoV 
nucleocapsid gene. The target sequence of the sense strand of this 21mer-siRNA is: 
5' -GGC ATC GTA TGG GTT GCA ACT -3’ and the GC content is 52.4% (Zhao et 
al, 2005). This siRNA could reduce the SARS-CoV nucleocapsid mRNA expression 
level to 20% only. According to its sequence and GC content, this effective siRNA 
from Zhao's group, however, did not agree with our guidelines on siRNA design. The 
design for a 21mer-siRNA might be a bit different from that of a 19mer-siRNA and, 
again, other consideration about the secondary structure of the target mRNA might 
be important in the siRNA design. In our RNAi study, three effective, N-siRNAl, 
N-siRNA2 and N-siRNA3, and one intermediate, N-siRNA4，siRNA target 
sequences have been identified. The four siRNA target sequences that we showed in 
- Chapter Three Results, Section 3.4., have not yet been identified by other research 
groups. We are the first group to identify these 4 siRNA target sequences that give 
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Figure 30. The highly effective siRNA target sites on the SARS-CoV 
nucleocapsid mRNA. The highly effective siRNA target sites identified in our study 
are indicated in red color (pos. 79, 734, 1027 and 1066). The effective siRNA target 
sequence identified by the research group in Mainland China is indicated in brown 
color (pos. 388) (Zhao et al, 2005). The target sequences identified in our study have 
not been reported by other research groups. 
Although the precise mechanism of RNAi is not fully understood yet, evidence 
from molecular and genetic research studies of a wide variety of organism have 
suggested a common set of reactions involved in RNAi. In the initiation step of 
RNAi, the introduction of long double-stranded precursor RNA triggers its cleavage 
by the Rnase-III-like enzyme Dicer in an ATP-dependent manner to produce 21-23 
bp siRNAs, which is the hallmark of RNAi. The siRNAs fragments, which contain 3’ 
overhangs of 2-3 nucleotides and 5'-phosphate termini, are then incorporated into a 
multiprotein RNA-inducing silencing complex (RISC), that possesses nuclease and 
helicase activity. The siRNAs that lack a 5，-P are rapidly phosphorylated by an 
endogenous kinase before entering into RISC. In the effector step, the duplex siRNA 
184 
Discussion 
is unwound, and it left the antisense stand to guide the activated RISC to its 
homologous complementary target mRNA transcript by base pairing interactions for 
endonucleolytic cleavage. Fragments of target mRNA will be recognized as being 
aberrant by the cells and then destroyed. This sequence specific degradation of target 
mRNA results in gene silencing and prevents translation form occurring (Stevenson 
et al., 2003, Downward et al, 2004). 
In theory, RNAi could be applied to treat any disease provided that the 
nucleotide sequence of mRNA encoding any protein that is associated with a disease 
is known. Given the gene-specific features of RNAi, scientists believe that it is 
conceivable to explore the use of siRNA in potential therapeutic applications. Among 
the RNAi research studies on therapeutic use, most of them are focused on applying 
• RNAi as an anti-viral agent to combat the pathogenic viruses by disabling their viral 
RNAs. 
To date, numerous studies on RNAi-mediated inhibition of animal and human 
viruses have been reported. These include the RNA viruses, such as hepatitis C virus 
(HCV), Influenza virus (Ge and McManus et al, 2004), respiratory syncytial virus 
(RSV) (Bitko et a!., 2005), semliki forest virus (SFV) (Caplen et al, 2002), flock 
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house vims (FHV) (Li and Li et al., 2002) and dengue virus (Zhang and Singam et 
al, 2004)，and DNA viruses, such as human immunodeficiency virus-1 (HIV-1), 
hepatitis B virus (HBV) and human papilloma virus (HPV) (Jiang et al, 2004). 
Impressive results have been achieved with RNAi against Influenza virus, HCV, 
HIV-1 and HBV by targeting their viral genes. For the case of HIV-1, significant 
inhibition on viral infection was observed when several specific viral genes, 
including Gag, Pol, Vif and the small regulatory proteins tat and Rev, were targeted 
for siRNA-mediated post-transcriptional gene silencing successfully in mammalian 
cell culture (Capodici et al, 2002, Boden et al, 2003，Dave et al, 2004). As 
demonstrated in both cell culture and adult mice model, siRNA was able to stop 
HBV and HCV replication effectively (McCaffrey et al, 2002 and 2003, Giladi et al, 
2003). The siRNA against the Influenza virus nucleocapsid and RNA transcriptase 
also led to inhibition of viral replication and blockage of other viral RNAs 
transcription (Ge and Fillip et al, 2003). 
While most of these studies made use of synthetic siRNA, which relied on harsh 
lipid-based transfection methods for introduction into cells in culture, these methods 
may not be suitable in animals. Their therapeutic potential is hindered by the poor 
intracellular uptake and limited stability within the blood circulation system. A 
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hydrodynamic approach has been developed by infusing a massive amount of 
siRNA-containing saline, which is equivalent to half of the animal's blood volume, 
into mouse's tail vein. Though this method has been proven to protect the small 
animal against hepatitis, it is absolutely not practical on human beings (Sioud et al” 
2003). Thus, efficient methods and vectors for the delivery of siRNA in vivo remains 
a crucial challenge for successful transition form the laboratory to the clinic. A 
number of delivery methods have been developing. 
The introduction of dsRNA longer than 30 bases would initiate interferon 
response rather than RNAi in mammalian cells. Thus, RNA molecules smaller than 
30 bases, which can be generated directly from naked siRNA with chemical 
modifications, DNA-based or viral-based vectors driving small hairpin RNA (shRNA) 
, expression, can only be used to induce RNAi response in mammalian cells. Cationic 
liposome-mediated intravenous siRNA delivery was demonstrated in mice 
successfully without any signs of toxicity. This method may be applicable in humans 
as a therapeutic siRNA since the cationic liposome-mediated drug delivery is now 
currently being investigated in clinical trials on ovarian cancer. A peptide-based gene 
delivery system MPG, which was derived from the fusion peptide domain of HIV-1 
gp41 protein and the NLS of SV 40 large T antigen, showed its ability to form stable 
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non-covalent complexes with siRNA and promoted its delivery in in vitro cell model 
(Simeoni et aL, 2005). Self-assembling cationic polymers with siRNAs conjugated 
with polyethylene glycol (PEG) - peptide ligand that formed sterically stabilized 
nano-sized particles with enhanced blood stability was also developed. Intravenous 
administration of these siRNA nanoplexes targeting vascular endothelial growth 
factor receptor-2 (VEGF-R2) expression into tumor-bearing mice resulted in 
suppression of both tumor angiogenesis and growth rate (Schiffelers et al.’ 2004). 
More recently, intranasal administration of siRNA showed an inhibitory effect on the 
RSV infected mice (Bitko et al., 2005). This suggests a possible delivery method as 
inhaled siRNA to offer a fast, potent and easily administrable antiviral strategy 
against respiratory viral diseases, such as SARS-CoV, in human. 
" The DNA-based vectors driving shRNA expression in mammalian cells can be 
generated through cloning of the sense and antisense strand separated by a short loop 
sequence with a RNA polymerase II or III promoter, such as human U6 and HI, as a 
single transcript. This transcript forms a hairpin structure that is recognized by Dicer 
and process to form functional siRNA within the cells. In spite of the successful 
examples of DNA-based plasmid vectors include the suppression of intracellular 
HBV and HCV viral replication (Ren and Zhou et cd., 2005, Takigawa et al.，2004), 
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the use of DNA-based plasmid vector would be limited by its difficulty to be 
introduced into primary cells. 
This leads to the use of viral-based vectors, which can give a high efficiency of 
gene delivery and long-term expression, to express shRNAs. These include the 
lentiviral, retroviral and adenoviral-based viral vectors. A study on the lentiviral 
delivery of siRNAs targeting the chemokine receptors CXCR4 and CCR5 on primary 
human T lymphocytes and peripheral blood mononuclear cells (PBMC) in vitro 
demonstrated a reduction of the HIV-1 viral entry and thus a decrease in the number 
of infected cells (Anderson et al, 2005). It was also reported that administration of 
siRNA-producing adenoviral-based vector into mice resulted in reduction in tumor 
size (Uchida et al” 2004). The murine retroviral vector expressing siRNA targeting 
against a mutant allele of human K-Ras proto-oncogene was able to alleviate 
tumorigencity in mice (Brummelkamp et al., 2002). As the case of treatment-related 
death was reported from patient receiving adenovirus on clinical trials, the safety 
issues and cytotoxicity of viral-based vectors are the main concerns regarding its use 
on human. Improved viral vectors that could avoid these unwanted side effects are 
required before any RNAi-based clinical trials could be successful. 
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Besides the difficulties in overcoming the delivery problem of siRNA in vivo, 
the specificity of siRNA-induced silencing effect is also a major concern on its 
therapeutic application. In our experiment, the positive control targeting the green 
fluorescent protein demonstrated an off-target effect on the SARS-CoV nucleocapsid 
at both mRNA and protein expression levels with a small magnitude. Studies on 
DNA microarray generating genome-wide expression profile showed the off-target 
effects elicited by siRNAs (Semizarov et al, 2003, Jackson et al, 2003, Scacheri et 
al, 2004). This warrants further investigations on the detailed mechanism of RNAi 
and its extent on off-target gene regulations. Thus, for the development of siRNA 
therapeutics, it has to be ensured that the siRNA targeting any disease-related gene 
does not evoke any clinically meaningful adverse response, which can be toxic or 
even lethal in human. Expression signatures generated through DNA microarray and 
‘ proteomic analysis of siRNA experiment at both mRNA and protein expression 




4.4. SASR-CoV nucleocapsid protein induced the promoter activity of the fgl2 
prothrombinase fibrinogen-like protein!/ fibroleukin gene 
According to the multiple amino acids sequence alignment of SARS-CoV 
nucleocapsid protein to some other coronavirus nucleocapsid members (Figure 10)， 
the nucleocapsid protein of Murine hepatitis virus is found to have the highest amino 
acid sequence homology with that of SARS-CoV with about 33% amino acids 
identity. As molecular mechanism for the tissue fibrosis has been reported for 
infections with the MHV-3 and MHV-A59, the N proteins of the MHVs have been 
demonstrated to induce promoter activity of the fgl2 prothrombinase fibrinogen-like 
protein2/ fibroleukin gene with 6 fold inductions (Ning et al, 1999). The human/g/2 
fibroleukin prothrombinase is a novel immune procoagulant that has the ability to 
cleave prothrombin into thrombin directly and results in fibrin clot formation at the 
site of viral infection (Yuv/araj et.al, 2000). Robust expression c-f the fgl2 mRNA 
and protein were found in hepatic macrophages and endothelia cells in MHV3 
murine hepatitis models (Ning et al, 1999)，the liver tissue isolated from patients 
with fulminant hepatic failure and the liver tissue isolated from patients with marked 
chronic hepatitis B (Marsden et al, 2003). Upon the MHV-3 infection, the 
7g/2-deficient transgenic mice demonstrated a significant reduction in fibrin 
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deposition in the liver. Necrosis in the liver was also reduced and the survival rate of 
these infected mice increased when compared with the wild-type infected mice 
(Marsden et al, 2003). We were interested to know whether the SARS-CoV infection 
could also induce fgl2 prothrombinase expression in human through the action of 
SARS-CoV N protein. So, in this study, we would like to investigate if the N protein 
of SARS-CoV functions in a similar way as that of the N proteins of MHV-3 and 
MHV-A59 by inducing the expression oifgl2 gene at transcriptional level. 
In our experiment, the luciferase reporter assay demonstrated that the 
SARS-CoV N protein transactivated the human fgl2 promoter acti/ity in a 
dose-dependent manner. In the cell types examined, HepG2 and VE6, the fgl2 
promoter activity increased with the amount of N protein expression vectors 
• transfected. The maximum fold inductions offgl2 transactivation by SARS N protein 
were around 1.67 and 2.59 in HepG2 and VE6 respectively (Figures.24 &26 
V 
respectively). These maximum inductions were obtained when 0.10 |j.g N protein 
expression vector was introduced into the cells through transient transfection. 
RT-PCRs also showed that there were increases in the fgl2 mRNA expressions in 
both the pCMV-Tagl-SARS-CoV-N expression vector transfected-HepG2 and VE6 
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cells when compared with the pCMV-TagI empty vector transfected-HepG2 and 
VE6 cells respectively (Figures 27A and Figure 28A respectively). 
Based on our results, it is suggested that the SARS-CoV N protein iray play a 
similar role as that of MHV N protein to activate theyg/2 transcriptional level which, 
in turn, trigger fibrin deposition. As fgl2 prothrombinase could directly convert 
prothrombin to thrombin, which resulted in a fibrin clot at the site of viral infection, 
the pulmonary fibrosis observed in patients who died of SARS may likely be due to 
. '' i 
the upregulation of fgl 2 prothrombinase (Peiris et al, 2003, Antonio et al, 2003). 
Although the mechanism(s) by which the SARS-CoV N protein induces fgl2 
prothrombinase expression is not known, some possible ideas are given here. The 
SARS-CoV N protein may directly act on the 5'-flanking region of fgl2 
. prothrombinase as a transcriptional activator as the SARS-CoV N protein is known 
to bind nucleic acids (Tang and Wu et al, 2005). Though we did not detect any 
fluorescent signal in the nucleus of VE6 cells that were transfected with 
pEGFP-SARS-CoV-N expression vector (Figure 14) and we were not able to confirm 
whether the fluorescent signal in the nucleus of the 
pEGFP-SARS-CoV-N-transfected HepG2 cells was due to the expression of 
EGFP-SARS-CoV N fusion protein (Figure 15), an extremely minute amount of 
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SARS-CoV N protein might be able to enter the nucleus and act on the fgl2 promoter 
directly inside the nucleus in both cell types. However, the amount of SARS-CoV N 
protein, which could enter the nucleus and act on the fgl2 promoter directly, might be 
too small that we could not be able to detect by using green fluorescent protein. 
Alternatively, since the SARS-CoV N protein has been reported to undergo 
phosphorylation at multiple a.a. residues along the SARS-CoV N protein sequence 
(Surjit et al, 2005), minute quantity of SARS-CoV-N in different phosphorylated 
forms might be able .to enter the nucleus and to directly induce the fgl2 gene 
expression by acting on its promoter region as a transcriptional activator. We suggest 
that the quantity of these phosphorylated forms of SASR-CoV-N protein that could 
enter the nucleus might be too little. Thus, we would not detect the presence of these 
phosphorylated forms of SASR-CoV-N protein in HepG2 and VE6 cells in our 
* subcellular localization study. During SARS infection on Vero cells, apoptosis has 
been demonstrated on the viral-infected cells (Ren and Yang et al, 2005) and this led 
to the activation of caspase-3. It was also reported that the SARS-CoV N protein 
could be cleaved by activated caspase-3 into different shorter forms (Ylng et al, 
2004). Taken together, during SARS infection, the SARS-CoV N protein might be 
cleaved into different shorter forms by the activated caspase-3. These shorter forms 
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of SARS-CoV N protein might be able to pass through the nuclear pore and act on 
tht fgl2 promoter directly inside the nucleus. 
Although both the dual luciferase reporter assays and the RT-PCRs have proven 
that the fgl2 prothrombinase gene was upregulated upon the expression of the 
SARS-CoV nucleocapsid protein in VE6 cells, the fgl2 mRNA transcripts was not 
picked up in the cDNA microarray analysis though it is one of the genes represented 
in the GeneChip HG-U133 Plus 2.0. This may be due to the general criterion on the 
data processing in the cDNA microarray analysis- only gene transcript with fold 
induction (or reduction) higher (or lower) than two fold would be included in the 
gene list. Since the fold induction of the fgl2 transcript expression was relatively low, 
with about two-fold induction, as shown in the dual luciferase assays and RT-PCRs, 
* the fold induction of fgl2 gene might be lower than two-fold during the cDNA 
microarray analysis. Thus, the fgl2 was not picked up in the cDNA microarray 
analysis. As there is yet no direct evidence to link between加2 prothrombinase and 
SARS, examinations on the fgl2 activity in tissues of SARS patient might help us to 





The subcellular location study of EGFP tagged SARS-CoV N protein revealed 
an interesting phenomenon with different intracellular compartmentations in two cell 
types- the Green African monkey kidney cells, VE6, and the human hepatocellular 
carcinoma cells, HepG2. While the SARS N protein is localized predominantly in the 
cytoplasm in VE6 cells, this viral protein is translocated to localize in both the 
cytoplasm and the nucleus of HepG2 cells. 
A number of genes belonging to various functional classes showed alternations 
in their mRNA transcript levels in cDNA microarray Affymetrix analysis. A novel 
finding of elevated gene expression level of a homeobox gene, H0XA7, was verified 
* by semi-quantitative RT-PCR to be consistent with the recent literature (Tang and 
Chen et al, 2005), which demonstrated the increase in transcription level of the 
same cluster of HOX genes, HOXAl and H0XA5. Taken together, SARS-CoV may 
evolve with a novel mechanism in controlling the host cell by interrupting the normal 




Three out of the nine siRNA target sequences examined in the RNAi experiment 
demonstrated high inhibitory effect, with over 80% of suppressive effect, on both the 
mRNA and protein expression levels of SARS-CoV N protein in VE6 cells. Before 
proceeding to the further developments of anti-SARS siRNAs, the off-target effect 
and in vivo delivery methods of these siRNAs should be seriously considered. 
The effect of transcriptional activation on the fgl2 prothrombinase gene by 
SARS-CoV N protein is similar to that induced by MHV-3 N protein. This indicates 
that the SARS-CoV N protein retains conserved functions as other CoVs member. 
The MHV-3 N protein induced the expression offgl2 prothrombinase, which directly 
converted prothrombin to thrombin and, in turn, triggered fibrin deposition at the site 
of viral infection. The transactivation o f f g l 2 gene by SARS-CoV N protein may be 
one of the contributing factors for the vascular thrombosis in pulmonary vessels 
reported from the postmortem examination of SARS patients. 
197 ... 
Discussion 
4.6. Future work 
With the establishment of laboratory equipped with Biological Safety Level 3 
facilities for SARS-CoV research, the siRNA target sequences demonstrating high 
inhibitory effect on SARS-CoV N gene expression should be repeated in the viral-
infected cells to examine their ability in suppressing viral replication in the cell 
culture. Meanwhile, the use of viral vector for siRNA delivery should also be 
examined. Expression profiles induced by these siRNA sequences on transcriptomes 
and proteomes levels should be studied to verify any siRNA off-target activities. 
Due to limited time, the differential expression patterns of over 200 genes 
reported with altered mRNA expression levels upon the over-expression of 
SARS-CoV N gene have not been verified by semi-quantitative RT-PCR. 
Confirmations of the expression levels of those 200 genes should be continued to 
reveal more candidate genes, which may be important in the pathogenesis of 





Vector map and multiple cloning site of the cloning vector pEGFP-Cl (reproduced 
from BD Biosciences Clontech, CA, USA). 
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Vector map and multiple cloning site of the cloning vector pCM V-Tag 1 (reproduced 
from Stratagene, CA, USA). 
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Vector map of the shRNA expression vectors ipSilencer 3.1-HI hygro (reproduced 
from Ambion, TX, USA). 
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Vector map and multiple cloning site of the cloning vector pGL3-Basic (reproduced 
from Promega, Madison, USA). 
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Vector map of the internal control vector pRL-CMV (reproduced from Promega, 
Madison, USA). 
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The siRNA target sequences that are not effective in suppressing the expression of 
SARS-CoV nucleocapsid mRNA and protein in VE6 cells. The SARS-CoV 
nucleocapsid gene sequence was scanned for A A dinucleotide sequence. The 3’ 
adjacent 19 nucleotides of each A A dinucleotide were recorded as the potential 
siRNA target sites. The AA dinucleotide sequence was underlined and the starting 
nucleotide in each target sequence (except the AA dinucleotide) was bold. The GC 
content of each target sequence is also indicated. 
Given name of the Position in 
shRNA expression SARS-CoV Target sequence (5'-> 3’） GC 
vector N gene sequence (sense strand) Content 
N-siRNA5 222 AA TCA ACA CCA ATA GTG GTC C 42.9% 
N-siRNA6 451 AATCC TAATAA CAATGC TGC C 38.1% 
N-siRNA7 580 AA TTC AAG AAA TTC AAC TCC T 28.6% 
N-siRNA8 685 AA CCA GCT TGA GAG CAA AGT T 42.9% 
‘ N-siRNA9 869 赫 GAC CTA ATC AGA CAA GGA A 38.1% 
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The siRNA target sequences that are not effective in suppressing the expression of 
SARS-CoV nucleocapsid mRNA in VE6 cells (given in Appendix 6). 
Semi-quantitative RT-PCRs showed there were no inhibitory effects on the mRNA 
expression levels of SARS-CoV nucleocapsid gene transfected with each of the five 
tested shRNA expression vectors. (A) VE6 cells were transfected with 
pCMVTagl-SARS-N only (lane 1)，pCMVTagl-SARS-N plus N-siRNA5 (lane 2), 
pCMVTagl-SARS-N plus N-siRNA6 (lane 3), pCMVTagl-SARS-N plus 
N-siRNA7 (lane 4), pCMVTagl-SARS-N plus N-siRNA8 (lane 5)， 
pCMVTagl-SARS-N plus N-siRNA9 (lane 6). (B) The cDNA templates were 
normalized with'the housekeeping gene GAPDH. The band intensity was measured 
by gel-dot densitometry. These experiments were repeated five times and the results 
shown here are from a single experiment representative of similar experiments. 
( _ 
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The siRNA target sequences that are not effective in suppressing the expression of 
SARS-CoV nucleocapsid protein in VE6 cells (given in Appendix 6). Western 
blottings showed there were no inhibitory effects on the protein expression levels of 
SARS-CoV nucleocapsid gene transfected with each of the five tested shRNA 
expression vectors. (A) VE6 cells were transfected with pCMVTagl-SARS-N only 
(lane 1)，pCMVTagl-SARS-N plus N-siRNA5 (lane 2)，pCMVTagl-SARS-N plus 
N-siRNA6 (lane 3), pCMVTagl-SARS-N plus N-siRNA7 (lane 4)， 
pCMVTagl-SARS-N plus N-siRNA8 (lane 5), pCMVTagl-SARS-N plus 
N-siRNA9 (lane 6). (B) The cDNA templates were normalized with the 
housekeeping gene GAPDH. The band intensity was measured by gel-dot 
densitometry. These experiments were repeated five times and the results shown 
here are from a single experiment representative of similar experiments. 
m 
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